Progress towards the total synthesis of Herquline A and B by Yang, He
 
 
PROGRESS TOWARDS THE TOTAL SYNTHESIS OF 




A thesis submitted to the University of Birmingham for the degree of  
DOCTOR OF PHILOSOPHY 
 
 
School of Chemistry 
















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 






Herquline A and B were isolated from the fungal strain Penicillium herquei Fg-372 and have 
been shown to exhibit potent platelet aggregation inhibitory activities. The unusual and 
strained structure of herquline A makes it a highly attractive and challenging synthetic target. 
Herquline B is conceived to be an analogue of herquline A, even though its absolute structure 
has not been elucidated.  
A biomimetic approach was initially investigated in Chapter 2, featuring an intramolecular 
direct oxidative phenol coupling strategy. While extensive experimentation failed to afford 
the desired coupling products, an advanced piperazine intermediate possessing a similar fused 
tricyclic ring system to that in herquline A was accessed via an intramolecular aza-Michael 
addition reaction.  
Chapter 3 describes the transition metal-mediated intramolecular aryl coupling strategy. Small 
amounts of biaryl coupling products were fashioned via a Pd-catalysed Suzuki-Miyaura 
coupling protocol. The conformational analysis of diketopiperazines and piperazines is also 
introduced. 
The intramolecular oxidative coupling of enolates or enol silanes approach is presented in 
Chapter 4. While the intramolecular coupling at the piperazine stage was found to be 
challenging, trace coupling product with a 1,4-dicarbonyl moiety was detected by mass 
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CHAPTER 1 INTRODUCTION TO HERQULINE A AND B 
 
1.1 The Herqulines: Isolation and Structure Elucidation   
Herquline A (1) was isolated from the culture broth of Penicillium herquei Fg-372 by Ōmura 
and co-workers in 1979.1 The terrestrial fungal strain, Fg-372 was obtained from a soil sample 
collected at Saitama Prefecture, Japan and was identified as Penicillium herquei according to 
its growth characteristics. Later on herquline A was also isolated from the marine-derived 
fungus Penicillium species separated from the Okinawan bivalve Mytilus coruscus.2 This 
natural product was purified by solvent extraction and silica gel chromatography and the 
molecular formula was determined as C19H26N2O2 on the basis of elemental analysis and high 
resolution mass spectrometry. In 1980, Ōmura and co-workers reported the X-ray crystal 
structure of this alkaloid, which unambiguously determined its absolute structure (Figure 
1.1).3 
           
Figure 1.1: Herquline A and its X-ray crystal structure (Reproduced using data requested from the Cambridge 
Crystallographic Data Centre). 
 
Herquline A is a piperazine derivative possessing a novel structural skeleton. The structure 




tricyclic system consisting of piperazine, pyrrolidine and cyclohexanone functionalities. The 
two ketone rings are tethered together at the α-positions of their carbonyl groups to form a 
nine-membered ring. As exemplified by its crystal structure, the piperazine ring adopts a boat-
like conformation and the cyclohexenone ring is distorted and forced to bend towards the 
tricycle to render herquline A a very strained molecule. Addressing these intriguing and 
unprecedented structural features of this natural product is without doubt a real challenge in 
total synthesis. 
In 1995, the Ōmura research group reported the isolation of another nitrogen-containing 
natural product, named herquline B (2), from the same fungal strain Fg-372.4 Herquline B was 
shown to have the same molecular formula to that of herquline A by mass spectrometry and 
its structure was elucidated based on NMR spectral analysis (Figure 1.2).  
          
Figure 1.2: Structure comparison between herquline A and B. 
 
Different from herquline A as a pentacycle, an extra double bond is present between C8 and 
C9 in herquline B with the absence of a pyrrolidine ring. Although it has the same structural 
constitution as herquline A, the absolute structure of herquline B has not been confirmed, 
since the stereochemistry at C3, C6, C10 and C17 remains unassigned. Considering the fact that 
both herquline A and B were isolated from the same origin and were shown to bear a high 
degree of structural homology, they possibly share the same configuration at some of the 




precursor of the two natural products. Therefore, it seems reasonable to deduce that herquline 
B has the same stereochemistry to herquline A at C3 and C6 positions, which derives from the 
chirality of L-tyrosine, leaving the configuration at C10 and C17 positions waiting for further 
confirmation. 
 
1.2 Biological Activity: New Platelet Aggregation Inhibitors 
During the isolation process conducted by Ōmura and co-workers, antimicrobial activities of 
herquline A and B were assayed using several organisms. However, neither of them was 
active against the tested organisms at 1 mg/mL concentration.1,4 
Ōmura and co-workers also reported the platelet aggregation inhibitory properties of 
herquline A and B. According to their preliminary biological data, herquline A showed weak 
inhibitory activity (IC50 values of 240 and 180 μM respectively) against platelet aggregation 
induced by PAF (platelet activating factor) and ADP (adenosine diphosphate) using the 
platelet rich plasma (PRP) from rabbit blood. Surprisingly, with only a little change in 
structure, herquline B exhibited more potent inhibition against PAF and ADP induced platelet 
aggregation, with IC50 values of 5.0 and 1.6 µM, respectively.  
It is known that blood platelets are small anuclear cells and play one of the most important 
roles in physiological haemostatic process. Under normal conditions, platelets circulate in the 
blood freely without adhering to each other. Upon vessel wall injury, platelets can then 
interact with subendothelial adhesive proteins, leading to platelet adhesion and activation.5,6 
Platelet activation includes several rapid positive feedback loops such as release of the 




activation signals for platelet aggregation and lead to haemostatic plug formation and 
subsequent arrest of bleeding. In contrast to normal platelet response, platelet hyperactivity 
can result in arterial thrombosis.7  
PAF is an endogenous synthesised phospholipid product with the name of 1-alkyl-2-acetyl-
sn-glycero-3-phosphocholine (Figure 1.3). It is a biologically active mediator responsible for 
many physiological functions including platelet aggregation. A variety of natural products and 
synthetic entities with PAF inhibitory activities have been reported.8 
 
Figure 1.3: Structure of PAF (3). 
 
ADP is an important mediator of haemostasis and thrombosis. Although it is regarded as a 
weak agonist of circulating blood platelets, ADP plays a vital role in platelet activation 
induced by other activators (such as thrombin and collagen) which promote ADP release from 
intraplatelet storage pools.9 This results in a positive feedback that enhances platelet 
aggregation and proliferation of platelet plug. Additionally, ADP acts synergistically with 
other platelet agonists.10 
Two purinergic P2Y receptors, designated P2Y1 and P2Y12 have been reported to be 
responsible for the effect of ADP on platelets.11,12 Upon activated by ADP, the Gq-coupled 
P2Y1 receptor mediates the first, reversible phase of platelet aggregation by changing platelet 
shape and initiating platelet response to ADP. The other receptor, Gi-coupled P2Y12 can 
enhance the activating signal and platelet secretion to amplify the platelet aggregation. Both 
of these two receptors belong to the most prominent clinical drug targets for inhibition of 




bundle architecture. Figure 1.4 (A) shows the structure of the complex between P2Y1 receptor 
and BPTU (4), a urea derivative acting as the P2Y1 receptor antagonist.
13  
                     
            
 
Figure 1.4: (A) Structure of the P2Y1 receptor and BPTU complex. (B) Top view of the extracellular side of 
P2Y1 receptor. (C) Structure of BPTU (4), a P2Y1 receptor antagonist. (Reproduced from Nature).13 
 
While the mode of inhibitory action of the herqulines is still not clear, Ōmura and co-workers 
postulated that it could be related to subcellular reaction concerning their non-selective 
inhibition against PAF- and ADP-induced aggregation.4 Due to the prominent activities, the 
herquline alkaloids and their analogues might have great potential for the treatment of 
diseases related to platelet aggregation and thrombosis, such as stroke, myocardial infarction 
and pulmonary embolism.  
Apart from antimicrobial and platelet aggregation inhibitory activities, no other biological 
properties of herquline A and B have been investigated and reported. While more material of 






372 for further biological study, chemical synthesis of these two natural products will no 
doubt provide an avenue for adequate material supplies and procure a chance to diversify the 
molecular architectures of herquline derivatives. 
 
1.3 Proposed Biosynthesis of the Herquline Alkaloids 
During the course of screening herquline-producing media, Ōmura and co-workers found that 
the production of herquline A was enhanced when tyrosine was added to the culture broth.4 
Though no further biosynthesis study has been conducted since then, it seems conceivable to 
suggest tyrosine to be the biosynthetic precursor of the herqulines based on this clue. 
Actually after close scrutiny, it is clear that the chirality within the piperazine moiety of 
herquline A matches that in the naturally occurring amino acid, L-tyrosine. The 
cyclohexenone or cyclohexanone ring can derive from the phenol group of tyrosine. With this 
hypothesis, a possible route for the biogenesis of the herquline alkaloids was proposed, as 
shown in Scheme 1.1. 
Diketopiperazine 6 is considered to be initially assembled from two molecules of L-tyrosine 
through cyclodipeptide formation process. After selective methylation and reduction, 
piperazine intermediate 7 could be produced. At this stage, an intramolecular oxidative phenol 
coupling process is conceived to take place to afford the coupling product bis-phenol 8. Since 
dearomatisation is necessary for further functionalisation, the keto-tautomer 9 might be 
involved in the biosynthesis to allow an aza-Michael addition to occur, forming the 





Scheme 1.1: Postulated biosynthesis of the herqulines. 
 
Herquline B (2) could arise from either the selective reduction of keto-tautomer 9, or an E2-
type elimination of herquline A. 
It is still not clear at which oxidation state (either diketopiperazine or piperazine) the phenol 
coupling reaction occurs, but one could argue that once the coupling product (either bis-
phenol 8 or bis-ketone 9) formed in the first place, with the assistance of certain enzymes, the 
addition of the amino group within the piperazine ring to the conjugated dienone in 9 would 




1.4 Previous Synthesis Towards the Herqulines and Relevant Structures  
1.4.1 Synthetic Studies Towards the Herqulines 
Even though the structures of herqulines have been identified for a long time, no total 
synthesis has been published so far. Synthetic efforts towards these two natural products have 
been made from several research groups worldwide, with research results mainly being 
unveiled in PhD theses. 
In 1997, Kim disclosed studies towards the synthesis of herquline A.14 The retrosynthesis was 
based on an epoxide opening reaction of 10 as a key step to form the C–C bond within the 
1,4-dicarbonyl moiety (Scheme 1.2). During their synthesis, the assembly of acid 11 and 
amine 12 was not successful with various coupling reagents and the synthetic work was not 
carried on following their synthetic plan.   
 
Scheme 1.2: Kim's retrosynthetic analysis of herquline A.14 
 
Hart from the University of Leeds focused on the formation and reduction of dityrosine 
derivatives, which were considered to be the precursors of the herqulines according to their 
retrosynthetic analysis (Scheme 1.3).15* 
*During the course of our project, an electronic copy of the thesis digitised from paper original was obtained 





Scheme 1.3: Hart's retrosynthetic analysis of the herqulines.15 
 
For the formation of dityrosine products such as 16 (Scheme 1.4), while direct oxidative 
phenol coupling or transition metal-catalysed Ullmann coupling methods did not give any 
promising results, the homo-coupling of tyrosine derivative 15 proceeded in moderate yield 
under Bowman coupling conditions.  
 
Scheme 1.4: Hart's synthetic efforts towards the herqulines.15 
 
When the fully protected dityrosine 17 was subjected to Birch reduction conditions, the 
partially reduced product 18 was the main one in all cases, even though no yield was 
mentioned in the thesis. Since the two aromatic rings within 17 could not be reduced 




During the course of our research project, the synthetic efforts from Stawski within the 
Trauner research group were disclosed in 2012, focusing on the intramolecular coupling of 
bis-ketone 19, in order to obtain piperazine derivative 20 for further operations (Scheme 
1.5).16  
 
Scheme 1.5: Synthetic efforts from Stawski in 2012.16 
 
Several metal-catalysed coupling conditions (Ni, Cu and Pd) were screened without 
generating the desired coupling product. Some of the reactions only gave dimers or trimers 
that derived from 19. 
 
1.4.2 Progress in the Synthesis of Relevant Structures 
Piperazinomycin (21) is a piperazine-possessing natural product which shares structural 
resemblance with herquline A and B (Figure 1.5). It was isolated as a minor metabolite from 
Streptoverticillium olivoreticuli subsp. Neoenacticus and has been found to exhibit inhibitory 
activity against fungi and yeasts.17,18  
 




This natural product bears a 14-membered ring system that is composed of a piperazine 
moiety and a diaryl ether linkage. Similar to herqulines, it has been presumed to arise from L-
tyrosine in Nature. Several total syntheses of this piperazine natural product have been 
reported, most of which selected the optically pure amino acid, L-tyrosine or its derivatives as 
starting materials.19-21 
The synthetic work from the Boger research group is depicted in Scheme 1.6.19 Firstly, two 
molecules of amino acid derivatives were coupled to form a dipeptide, which cyclised to give 
DKP derivative 23. After an intramolecular Ullmann reaction, the 14-membered diaryl ether 
derivative 24 was provided. Reduction of the DKP moiety with borane-THF complex 
followed by demethylation completed the total synthesis. 
 
Scheme 1.6: Boger's total synthesis of piperazinomycin.19 
 
Sundararajan and co-workers reported a formal synthesis of piperazinomycin in 2009 
featuring a copper-mediated intramolecular O-arylation reaction between the arylboronic acid 
unit and the phenol moiety in 26 to form the macrocyclic biaryl ether 24 (Scheme 1.7).20 With 
diketopiperazine 24 in hand, the formal synthesis finally afforded the natural product after 





Scheme 1.7: Formal synthesis of piperazinomycin by Sundararajan and co-workers.20 
 
In Yamamura's total synthesis of piperazinomycin, a thallium trinitrate-promoted oxidative 
phenol coupling method was employed, followed by reduction with zinc to afford the key 
intermediate 28 in 19% yield (Scheme 1.8).21 Although the material return for this reaction 
was not efficient, the coupling product 28 was subjected to the next manipulation and the final 
product was synthesised after seven further steps.   
 
Scheme 1.8: Tl-mediated oxidative coupling in Yamamura's total synthesis of piperazinomycin.21 
 
Even though the herqulines and piperazinomycin could all be traced back to tyrosine 
biosynthetically, the structural difference between these two types of alkaloids is that the 
phenol rings in piperazinomycin are not reduced to the cyclohexanone and cyclohexenone 
which exist in the former. In addition, the two aryl rings in piperazinomycin are tethered 
together by an ether linkage, while the cyclohexanone and cyclohexenone rings in herquline 
A are connected via a C–C bond. Nevertheless, the accomplishment of the cyclisation to 
generate the diaryl ether linkage within piperazinomycin might provide an instructive strategy 




Besides the intramolecular diaryl ether synthesis, efforts have also been made in C–C bond 
formation to generate macrocyclic biaryl linkages. Some of the products also bear close 
structural similarity to herqulines. 
In 2003, Atsumi and Noriyoshi reported the synthesis of cyclic biaryl product 30 through a 
Ni-catalysed aryl iodide coupling reaction (Scheme 1.9).22 Treating bis(carboximidate) 29 
with nickel complex, the intramolecular coupling process proceeded smoothly to afford biaryl 
30 in 82% yield, with the formation of a new C–C bond. 
 
Scheme 1.9: Ni-catalysed intramolecular aryl iodide coupling.22 
 
Another relevant work is the total synthesis of mycocyclosin (35), published by the Hutton 
research group in 2012 (Scheme 1.10).23 Mycocyclosin is a diketopiperazine derivative 
produced by Mycobacterium tuberculosis as a secondary metabolite.24,25 Starting from 
tyrosine derivative 31, diketopiperazine intermediate 32 was initially synthesised. The 
cyclisation was performed with a Pd-catalysed domino Suzuki-Miyaura coupling method to 
afford 34 in moderate yield. The final product 35 was obtained after benzyl group cleavage 
with trifluoroacetic acid (TFA) and pentamethylbenzene. According to the crystal structure of 
34, it was confirmed that this cyclised product is a highly strained molecule with a 





Scheme 1.10: Hutton's total synthesis of mycocyclosin.23 
 
There has been no evidence to show the biosynthetic relationship between mycocyclosin and 
herqulines, since they were isolated from different sources. However, these natural products 
are all considered to originate from tyrosine in Nature and from a chemical synthesis 










CHAPTER 2 STUDIES ON DIRECT OXIDATIVE PHENOL 
COUPLING – A BIOMIMETIC APPROACH 
 
2.1 Initial Considerations and Retrosynthetic Analysis 
Attracted by the combination of the novel structural features of the herqulines and their 
promising biological activities, we decided to take up the challenge to explore the total 
synthesis of herquline A and B. Before embarking on the retrosynthesis of the two natural 
products with logical disconnections, it was valuable to have a close analysis of the putative 
biosynthesis, which might suggest a potentially efficient synthetic avenue.  
 
Scheme 2.1: Plausible biosynthetic pathway leading to the formation of the pyrrolidine ring in herquline A. 
 
As depicted in Scheme 2.1, the formation of the pyrrolidine ring was conceived to proceed 
after the generation of the 1,4-dicarbonyl moiety in the organism. Since the two ketone rings 
were tethered together within intermediate 9, rendering the secondary amine and the adjacent 
dienone moiety in close proximity, the intramolecular aza-Michael addition was indeed 
facilitated at this stage. Presumably, within an enzymatic environment, this transformation 
would be a regio- and stereoselective one to form the 5-membered pyrrolidine ring in the final 




While Nature can find a way to convert 8 to herquline A precisely, from a synthetic point of 
view, reductive or oxidative dearomatisation of the biaryl unit within 36 would give an 
advanced intermediate, which could be further manipulated towards the herqulines (Scheme 
2.2). The dearomatisation transformations could be a Birch reduction of the phenol ether 
moieties followed by hydrolysis of the resultant cyclohexadiene to enone functionality, or 
oxidative conversion of phenol to enone derivative, which would facilitate a subsequent 
intramolecular aza-Michael addition. 
                                                                                                               
Scheme 2.2: Retrosynthetic analysis of the herqulines. 
 
Even though the outcome of the proposed dearomatisation remained to be negotiated during 




synthesis more manageable and might provide a quick access to the core skeleton of the 
herqulines. 
For the synthesis of biaryl structure 36, Nature's oxidative phenolic coupling strategy seems to 
be appealing and inspirational. Actually, a variety of methods have been developed to effect 
phenol oxidative coupling in the laboratory. Herein we envisioned an intramolecular version 
of this transformation on piperazine 37 to afford 36. Piperazine substrate 37 would be 
furnished from the reduction of diketopiperazine 38, which could be assembled from two 
molecules of tyrosine derivatives. 
According to the above analysis, the primary goal was the synthesis of the cyclised piperazine 
derivatives, such as 36, starting from tyrosine or tyrosine derivatives.  
Before introducing our attempts in this biomimetic approach, it is valuable to have an 
overview of phenol oxidative coupling processes that happen in Nature and that have been 
developed in the laboratory. 
 
2.2 Introduction to Phenolic Oxidative Coupling 
2.2.1 Oxidative Phenol Coupling in Nature 
It is known that oxidative phenol coupling is an essential transformation during the 
biosynthesis of a large number of biarylic or related natural products. Biosynthetic pathways 
of several natural products have been investigated and some studies also identified the 
enzymes involved in the phenol coupling steps. A famous example of this kind is the 




antibiotics that can inhibit the biosynthesis of bacterial peptidoglycan. As exemplified in 
Figure 2.1, there are two diaryl ether linkages and one biaryl moiety within the molecule of 
vancomycin (40) or balhimycin (41). 
 
Figure 2.1: Structures of vancomycin and balhimycin. 
 
It has been reported that these linkages are formed in three separate oxidative cross-linking 
steps, catalysed by different cytochrome P450 enzymes.26-28 Presumably, the C-O-D system is 
produced as the first phenol coupling process, catalysed by oxygenase OxyB, followed by 
OxyA mediated carbon-oxygen coupling to generate the D-O-E linkage. The biaryl unit is 
synthesised in the last oxidative phenol coupling reaction, which is a carbon-carbon coupling 
transformation catalysed by OxyC enzyme. For the last phenol coupling reaction, a biradical 
mechanism has been suggested, oxidised by Cys4Fe2S2 ferredoxin (Scheme 2.3). It is not 
known yet whether these cross-coupling transformations occur on a free heptapeptide 




bis-aryl linkages is very efficient and precise, with all these units being generated 
atroposelectively. 
 
Scheme 2.3: Oxidative phenol coupling reaction in the biosynthesis of the vancomycin-type glycopeptide 
antiobiotics.27 
 
In isoquinoline alkaloid biosynthesis, several oxidative phenol coupling reactions involving 
cytochrome P450 enzymes have been reported. As delineated in Scheme 2.4, (S)-reticuline 
(44) is an alkaloid isolated from the Japanese goldthread Coptis japonica and is proposed to 
derive from L-tyrosine.29  
                                                                                                            





Within the plant, (S)-reticuline can be converted to (S)-corytuberine (45) via the CYP80G2 (a 
P450 enzyme) catalysed oxidative phenol coupling reaction. After a methylation process, 
another naturally occurring entity, (S)-magnoflorine (46) can be synthesised from (S)-
corytuberine. 
Interestingly, (R)-reticuline (47) is considered to be the biosynthetic precursor for morphine 
(49).29,30 Catalysed by salutaridine synthase, a P450-dependent monooxygenase, (R)-reticuline 
undergoes an ortho-para oxidative phenol coupling to give salutaridine (48) which is further 
functionalised to afford morphine (49) (Scheme 2.5). 
 
Scheme 2.5: Key step in the biosynthesis of morphine.29 
 
Another example of oxidative phenol coupling in Nature is the biosynthesis of the previously 
introduced mycocyclosin (35), a diketopiperazine natural product produced by 
Mycobacterium tuberculosis. It is believed that this secondary metabolite derives from 
cyclo(L-Tyr-L-Tyr) which is formed from two molecules of tyrosyl-tRNA (50) catalysed by 
rv2275, a cyclodityrosine synthetase (Scheme 2.6).24,25 Subsequent oxidative phenol coupling 
is catalysed by the cytochrome P450 enzyme rv2276 (also called CYP121).25 Recently, it has 
been shown that the gene encoding the P450 enzyme (CYP121) is essential for the viability of 
M. tuberculosis,31 which indicates that this enzyme might be a potential target for M. 





Scheme 2.6: Biosynthetic sequence for mycocyclosin.24,25 
 
Based on the crystal structure of cyclodityrosine-bound CYP121 obtained by Belin and co-
workers (Figure 2.2),25 the diketopiperazine ring adopts a flattened-boat conformation with a 
dihedral angle of 15° between the two peptide bonds.  One tyrosine side chain points between 
helices F and G and the other tyrosine side chain faces the DKP ring and approaches the iron.  
 
Figure 2.2: Structure of cyclodityrosine-bound CYP121 (the heme in cyan, the iron in orange, and the 
cyclodityrosine in yellow with nitrogen atoms in blue and oxygen atoms in red, reproduced from PNAS).25 
 
This conformation does not seem to allow a sufficient proximity of the two tyrosyl groups for 
the C–C coupling reaction. Belin and co-workers explained that the two tyrosyl side chains 




filled pocket around the molecule. These movements would guarantee the two tyrosyl side 
chains are sufficiently close together and in appropriate orientation to form the biaryl linkage.  
  
2.2.2 Oxidative Phenol Coupling in Organic Synthesis 
Complementary to Nature's enzymatic synthesis of bis-aryl products, the construction of 
bioactive cyclic biaryl molecules also represents a fascinating and challenging goal in organic 
synthesis.  
 
Figure 2.3: Examples of cyclic biaryl natural products. 
 
A wide range of biarylic natural products, such as haouamine A (51) and B (52) and the 
Lythraceae family alkaloids vertine (53), lythrine (54) and decinine (55) (Figure 2.3), have 
attracted significant synthetic interest.32-36 In some of the studies, intramolecular oxidative 
phenol couplings have been tested or even employed as the key steps during the syntheses. A 





Vanadium Oxidants as the Coupling Agents 
Vanadium species belong to the most common oxidants for oxidative phenol coupling. The 
earliest example can be traced back to the oxidative coupling of simple phenol substrates 
reported by Carrick and co-workers in 1968.37 It was found that dimeric products were 
obtained through a C–C coupling reaction upon treating simple phenols with VCl4. Using 
unsubstituted phenol as the substrate, three biphenols were isolated, favouring the para-para 
coupling product 57 (Scheme 2.7).  
 
Scheme 2.7: VCl4-promoted phenol coupling.37 
 
Although the mechanism has not been completely elucidated, Carrick and co-workers pointed 
out that the hydroxy group might play an important role during the course of the reaction by 
coordinating to the metal center to form a complex. Shift of electrons occurred within the 
complex to fashion a subsequent coupling reaction. 
Remarkable success has been achieved in alkaloid syntheses. Dienone 61, a synthetic 
precursor of the amaryllidaceae alkaloid (±)-oxocrinine (62), was synthesised by treating 
mono-phenolic amide 60 with VOF3 in dichloromethane in the presence of trifluoroacetic acid 
and trifluoroacetic anhydride (Scheme 2.8).38 In one step, linear amide 60 was converted to a 
compact and rigid structure, which demonstrated that oxidative phenolic coupling is an 





Scheme 2.8: Intramolecular oxidative coupling with VOF3.38 
 
Another application of vanadium-mediated oxidative coupling towards alkaloid natural 
products is exemplified in the total synthesis of (±)-decinine (55), published by Yang and co-
workers in 2012.36 After attempting the VOF3-promoted oxidative coupling with several 
different substrates, they finally managed to construct the 12-membered ring of decinine from 
p-nitrobenzyl (PNB) protected phenol ether 63 (Scheme 2.9). The cyclised product 64 was 
delivered in 32% yield and converted to (±)-decinine (55) after removal of the PNB group. 
 
Scheme 2.9: Key steps in the total synthesis of decinine.36 
 
In Evans' synthesis of vancomycin aglycon, a biomimetic approach towards the macrocyclic 
subunit containing a biaryl moiety was employed.39,40 Tripeptide 65 was subjected to VOF3-
mediated oxidative coupling conditions followed by reductive quench with NaBH(OAc)3 to 
give cyclic product 66 in 65% yield (Scheme 2.10). Although the unnatural R atropisomer 
was obtained predominately (d.r. > 95:5), this atropisomerism issue was corrected completely 





Scheme 2.10: VOF3-mediated oxidative coupling in Evans' synthesis of vancomycin aglycon.39,40 
 
It is noted that the addition of a reducing agent, either NaBH(OAc)3 or zinc, is necessary to 
quench the radical cation derived from the biaryl linkage in the product, which is prone to 
nucleophilic attack. 
 
Hypervalent Iodine Induced Oxidative Phenol Coupling 
Organic hypervalent iodine derivatives have been used routinely for various oxidative 
transformations and are classified as environmentally friendly oxidants because of their lower 
toxicity than heavy metal-containing reagents. It has been shown that oxidation of phenolic 
substrates in less or non-nucleophilic solvents (e.g. MeCN, CF3CH2OH and DCM) can 
promote coupling reactions to proceed and lead to cyclisation if the reactions occur 
intramolecularly. PIDA (phenyliodine diacetate) and PIFA (phenyliodine bis(trifluoroacetate)) 
are two of the most popular reagents employed for these transformations. 
As shown in Scheme 2.11, treating amide 67 with PIFA in trifluoroethanol at low temperature, 
cyclisation took place to afford dienone 68, a key intermediate in Kita's total synthesis of (+)-




                                                                                                                
Scheme 2.11: PIFA promoted intramolecular coupling.41 
 
In general, the mechanism for hypervalent iodine-mediated phenol coupling transformations 
involves the reaction between phenolic oxygen and the iodine centre of the oxidant, a process 
of exchanging one ligand on iodine(III) with a nucleophile (such as phenol or phenoxide 
anion) through an addition-elimination sequence (Scheme 2.12).42 After ligand exchange, the 
generated intermediate 71 is prone to nucleophilic attack by either an electron-rich aromatic 
ring or other nucleophile, to give cross-conjugated cyclohexadienone 72. Therefore, the 
phenolic hydroxy group has an important role in the coupling process. 
 
Scheme 2.12: Postulated mechanism of hypervalent iodine induced transformations of phenols.42 
 
Scheme 2.13 exemplified an intramolecular cross-coupling between a phenol and an indole 
moiety which belonged to one of the most efficient steps in the total synthesis of (-)-




PhI(OAc)2 oxidation conditions, the desired aminal 74 was isolated as the main product, 
alongside its diastereoisomer 75 and the epimeric spirodienones 76. The 
dihydrobenzofuro[2,3-b]indole subunit within 74 is supposed to form from 73 through a 
cyclohexadienone-linked indoleninium species 78. 
 
Scheme 2.13: PhI(OAc)2-mediated cyclisation in Harran's total synthesis of (-)-diazonamide A.43 
 
Different from the oxidative coupling of phenol derivatives, the number of reactions with 
phenol ethers as the coupling substrates is limited, largely due to the preferred formation of 




oxidative coupling of phenol ethers can occur in certain circumstances, especially with 
electron-rich ones, such as the example shown in Scheme 2.14. Treating the simple phenol 
ether 79 with PIFA in the presence of BF3·Et2O in DCM gave 80 with a tricyclic [6-7-6] ring 
system in high yield.44  
 
Scheme 2.14: Oxidative coupling of phenol ethers.44 
 
Mechanistically, without a hydroxy functionality, the coupling pathway might involve the 
reaction between hypervalent iodine reagent and phenol ether substrate to generate a cation 
radical intermediate via a single electron transfer process, which has been studied by UV-
visible and ESR (electron spin resonance) spectroscopic methods.45,46 Subsequent 
nucleophilic attack of another phenol ether on the cation radical, or the coupling reaction 
between two radical intermediates would furnish the biaryl product. Thus it seems reasonable 
to infer that the more electron-rich aromatic ring tends to react with the oxidant more easily 
because of the lower oxidation potential. 
 
Other Oxidants Used in Phenolic Coupling Reactions 
Dimerisations of phenol derivatives promoted by iron(III) species have been investigated 
extensively. Presumably the radical cation of the corresponding phenol substrate is involved 
during the coupling process. Among all the iron(III) oxidants, iron(III) chloride is a mild and 




As demonstrated in Scheme 2.15, tetrahydroquinoline 81 was used as the substrate in an 
FeCl3-promoted intramolecular coupling reaction during the synthesis of alkaloid (±)-
kreysigine (82).48 After a reductive work-up with methanol, the natural product was obtained 
directly in 71% yield, with concomitant cleavage of the benzyl protecting group.  
 
Scheme 2.15: FeCl3-mediated intramolecular coupling in the synthesis of (±)-kreysigine (82).48 
 
Another example of intramolecular oxidative aryl aryl coupling was reported by Tobinaga and 
Kotani.49 They treated bis-phenolic substrate 83 with [Fe(DMF)3Cl2][FeCl4], a complex 
prepared from ferric chloride and DMF (Scheme 2.16). Dienone product 84 was delivered in 
67% yield. It was stated that the use of this specific iron complex as the oxidant improved the 
reaction yield and also avoided the formation of polymeric compounds. 
 
Scheme 2.16: Intramolecular oxidative phenol coupling with Fe(III) complex.49 
 
The utility of lead(IV) and silver(I) oxidants has been revealed in the synthesis of dimeric 




Such an example can be found in the synthesis of the antiviral natural product michellamine A 
(87), reported by Bringmann and co-workers (Scheme 2.17).50  
 
Scheme 2.17: Oxidative dimerisation with Pb(IV).50 
 
Treatment of isoquinoline alkaloid korupensamine A (85), the natural monomer of 
michellamine A, with lead tetraacetate in the presence of BF3·Et2O led to diphenoquinone 86. 
It was noteworthy that this intermediate was readily converted to the final product 87 during 
the purification process under incandescent light with MeOH as the reducing reagent. This 
essentially one-step homo-coupling reaction is the first non-enzymatic direct synthesis of 
michellamine A, without losing any axial chirality. It has been reported that similar 




Beyond the above mentioned agents, the oxidative coupling of phenol derivatives can also be 
effected in some cases by Cu(II)-amine complexes,52 Mo(V) and Tl(III) salts,53,54 or with 
different approaches including anodic oxidation and enzymatic conditions.55,56 These methods 
were not essentially explored in our project. 
 
2.3 Efforts on Intramolecular Oxidative Coupling of Piperazine Substrates 
2.3.1 Initial Forward Synthesis Towards Piperazine Intermediates 
Based on the retrosynthetic plan, our initial goal in the biomimetic approach towards the 
herqulines was the synthesis of biaryl structure 36 through the intramolecular direct oxidative 





For the synthesis of diketopiperazine derivative 38, we first explored the dimerisation of 
tyrosine or its derivatives, which was considered to be an appealing approach and could also 




It was reported that thermal dimerisation of phenylalanine methyl ester afforded the 
corresponding 2,5-diketopiperazine in high yield.57 Following the reported procedure, heating 
tyrosine methyl ester 39 in toluene at reflux for 6 h, no reaction occurred (Scheme 2.19). With 
a longer reaction time or O-benzyl-protected tyrosine methyl ester 88 as the substrate, the 





Although the Lewis acid-catalysed or microwave-assisted condensation of free amino acids to 
cyclodipeptides had been reported to be successful,58,59 these conditions always led to 
epimerisation which was deleterious to the efficient synthesis of cis-DKP products in this 
study. We then abandoned this direct cyclisation approach and opted for a stepwise strategy.  
The efforts started from the synthesis of dipeptide 95 following similar procedures reported in 
the literature (Scheme 2.20).60,61 Protection of the amine group of L-tyrosine methyl ester 39 
with (Boc)2O in the presence of Et3N in DCM afforded the Boc-protected substrate 90 in 87% 
yield. Methylation of the phenol group was accomplished by treating 90 with MeI and K2CO3. 
With compound 91 in hand, N-methylation was performed using Ag2O and MeI in DMF. 
Removal of the Boc protecting group of 93 with TFA in DCM delivered free amine 94. 




At this stage, amino acid coupling reaction was attempted and dipeptide 95 was successfully 




To carry on the synthesis, dipeptide 95 was treated with TFA in DCM in order to remove the 
Boc protecting group. Surprisingly, diketopiperazine 96, instead of the linear deprotected 
dipeptide, was isolated from the reaction mixture as the only product, which indicated that 
cyclisation occurred during the basic work-up process after Boc deprotection.  
Having reached DKP derivative 96, we then turned our attention to the reduction of 96 to 
piperazine 97 (Scheme 2.21). Several reducing reagents have been reported for the reduction 
of DKPs, including NaBH4/BF3,
62 BH3,
63,64 lithium aluminium hydride,65,66 and 
NaBH4/TiCl4.




system because of the reasonable reaction time and low reaction temperature (0 oC to rt). 
While it was reported that the reduction of phenolic cyclo-dityrosine derivatives with LAH 
was problematic due to the poor solubility of their phenoxide conjugate bases in ethereal 
solvents,63 the reduction of bis-phenol ether 96 proceeded smoothly to give unsymmetrical 




O-Bn-protected piperazine 100 was also synthesised following a similar procedure from O-Bn 
tyrosine derivative 98 which was generated from the benzylation of 90 with benzyl bromide 











Both of these piperazines were protected with either Boc or COCF3 groups for further 




The bis-phenol products 105 and 106 were obtained via the catalytic hydrogenolysis of 102 




Overall, the syntheses of these piperazines are straightforward processes, although several 
phenomena and chemistry issues during the course of the synthesis merit further discussion. 
The N-methylation of tyrosine derivative 91 was initially performed with MeI and NaH. A 
degree of racemisation was observed during this process and was confirmed by the 
subsequent isolation of a small amount of trans-DKP product. According to several studies, 
racemisation has been observed during the methylations of chiral α-alkyl-α-amino acids using 




deduced that the ratio of L-93 to D-93 was about 4:1. The enantiopure 93 was obtained 
exclusively by treating substrate 91 with Ag2O and MeI in DMF. 
The ease of cyclisation of dipeptide 95 to DKP 96 is an interesting phenomenon. Similar 
results have been mentioned in several reports.70,71 It could be attributed to the cis/trans 
conformation equilibrium of the amide bond (Scheme 2.25).  
 
Scheme 2.25: The cis/trans conformation equilibrium of N-methyl amide bond. 
 
It has been reported that N-alkylated amide bond could affect the cis/trans isomerisation and 
drive the equilibrium to a significant extent of the cis form, which tended to cyclise easily.72 
Actually, during the synthesis of symmetrical DKPs which will be introduced in Chapter 3, 
only removal of the Boc protecting group was observed when dipeptide 107 was subjected to 
the same conditions (Scheme 2.26). No further cyclisation took place to afford DKP 89, 
which supports the above explanation. 
Scheme 2.26 
 
When the 1H NMR spectrum of DKP 99 was interpreted, a doublet of doublets signal for one 




The highfield shift with respect to the chemical shift of 2.85 ppm for the other β-proton in 
DKP 99, indicates that one of the two β-protons is significantly shielded. The conformation of 
the DKP structure may play an important role in such a shielding effect. 
Similar magnetic shielding effects for DKPs with a side chain containing an aromatic ring 
have also been observed from several studies.73,74 According to Kopple and Marr's analysis,73 
at ambient temperature cyclic dipeptides adopt a folded conformation, in which one side chain 
lies over the DKP ring while the other side chain orientates away from the peptide ring, as 
exemplified by DKP 99 in our case (Figure 2.4). They proposed that the preference for a 
folded conformation is largely due to the stabilisation from the interaction of two amide 
dipoles with the polarisable π electron system of the aromatic side chain, and this 









Since both DKPs 96 and 99 were isolated as oils, no crystals could be obtained. But based on 
the evidence from the literature, it appears that both of the two DKP derivatives would adopt 
folded conformations in solution at room temperature, with one aromatic residue facing the 
DKP ring and the other in an extended orientation.  
Similar resonance patterns were observed from the 1H NMR spectrum of symmetrical DKP 
89, with chemical shifts at 2.31 ppm and 3.06 ppm for the two chemically inequivalent β-
protons (Figure 2.5).  
 
 
Figure 2.5: Partial 1H NMR spectrum of DKP 89 (300 MHz, CDCl3, 298 K). 
 
However, the shielding effect within 89 was not as distinct as that within unsymmetrical DKP 
96 or 99. On the one hand, the crystal structure of cyclo(L-phenylalanine-L-phenylalanine) 
published by Gdaniec and Liberek revealed that the folded form is adopted by this 
symmetrical DKP.75 On the other hand, considering the interactions between aromatic ring 
and amide bond, Kopple and Marr proposed a likely conformation for symmetrical DKPs in 
solution that each aromatic ring might associate with one amide group to render the two β-




might be possible that symmetrical DKPs have a different conformation in solution from that 
in the solid state, another explanation could be that a fast equilibrium exists between the two 
equivalent folded conformers for symmetrical DKPs at room temperature.76 In contrast, the 
conformation of DKP 99 (or 96) in our case might be locked due to the presence of the NMe 
group which forced the adjacent aromatic residue facing the DKP ring to avoid the potential 
steric clash. 
During the synthesis, we did obtain the crystal structure of DKP 108 (Figure 2.6), a side-




Figure 2.6: X-ray crystal structure of trans-DKP 108. 
 
Even though this compound has a trans-configuration, it provides certain evidence about the 
potential interaction between aromatic rings and amide bonds, since both aromatic residues 







2.3.2 Vanadium(V) Species as Coupling Oxidants 
Model System: Formation of a Dityrosine Derivative 
With several piperazine substrates in hand, the stage was set to investigate the intramolecular 
oxidative coupling, a key step in the biomimetic synthesis of herquline A and B. Before 
attempting this approach with the real system, we performed a model reaction involving 
VOF3-mediated oxidation of N-Cbz-L-tyrosine methyl ester 109 (Scheme 2.27). This 
intermolecular oxidative coupling reaction was first studied by Edwards and co-workers in 
1990.77  
Substrate 109 was initially synthesised by vigorously stirring a mixture of tyrosine methyl 





Under the oxidative coupling conditions, dityrosine derivative 110 was successfully fashioned 





Intramolecular Oxidative Coupling of Piperazine Derivatives 
With the success of reproducing the intermolecular phenol coupling of tyrosine derivative 109, 
our attention was then turned to effecting the oxidative coupling in an intramolecular version. 
If the coupling reaction could occur, we presumed that the ortho-ortho coupling product 
should be the favourable one, rather than the ortho-para one which was predicted to be 
impossibly strained. 
It is worthy of note that a large excess of TFA is usually needed when the substrate possesses 
an amino group, because the formation of the amine salt will reduce the oxidative tendency of 
the corresponding amine functionality.36 Therefore the addition of TFA would play an 
important role in VOF3-mediated phenolic couplings in our case since there is a tertiary amine 
moiety within the piperazine substrate. 
The coupling reaction was initially performed with piperazine 106 (Entry 1, Table 2.1). 
Subjecting this bis-phenol substrate to the specific reaction conditions employed for the 
model reaction, there was still starting material in the reaction mixture after 3 h and no other 
distinct spot was observed by TLC. When the reaction mixture was warmed up slowly and 
maintained at room temperature, starting material was consumed gradually. However, the 
reaction gave no cyclised products detectable by mass spectrometry. According to the mass 
spectrum, peaks for traces of the corresponding dimeric compounds were observed, along 
with some undefined signals which might arise from decomposition of 106.  
In terms of the function of TFAA, it was pointed out by Dhingra and co-workers that a higher 
yield of coupling product was obtained in the presence of TFAA which could assure an 




mediated reactions, the oxidative coupling was also tested in the absence of TFAA (Entry 2, 
Table 2.1), but a similar result was obtained to Entry 1. 
 






R1     R2 
1 (106) H COCF3 VOF3 (2.5 eq.), TFA, TFAA,       
-10 °C to rt 
Decomposition 
2 (106) H COCF3 VOF3 (2.5 eq.), TFA, 0 °C to rt Decomposition 
3 (106) H COCF3 VOF3 (2.5 eq.), TFA, BF3·Et2O, 
0 °C 
106 and partial 
decomposition 
4 (106) H COCF3 VOCl3 (3.0 eq.), -10 °C to rt 106 and partial 
decomposition 
5 (104) Bn COCF3 VOF3 (10.0 eq.), TFA, 0 °C to rt  104 
6 (103) Me COCF3 VOF3 (10.0 eq.), TFA, 0 °C to rt 103 
* All reactions were conducted in anhydrous dichloromethane. 
 
We also tested the conditions with the addition of BF3·Et2O, which were employed in Evans' 
synthesis of a vancomycin segment as introduced in Section 2.2.2. Once again, no related 
cyclised products could be detected by mass spectrometry and part of the starting material 
was recovered (Entry 3, Table 2.1). The reaction of bis-phenol 106 with VOCl3 mainly led to 




Besides using bis-phenol substrate 106, the oxidative coupling reactions were also attempted 
with phenol ether derivatives 104 and 103 (Entry 5 and 6, Table 2.1). Unfortunately, no 
reaction took place at room temperature with VOF3 as the oxidant. When the systems were 
warmed up to reflux in DCM, side reactions occurred in both cases to give inseparable 
mixtures without producing any traces of the desired coupling products. 
Based on our detailed experimentation, it was likely that the piperazine rings or the phenol 
groups within the substrates tended to decompose under the oxidation conditions we explored, 
even though an excess of TFA was added to convert the piperazine moieties into their amine 
salts. In most cases, vanadium oxidants played an undesired role in the decomposition of 
substrates and formation of intermolecular coupling products, other than effecting 
intramolecular phenolic coupling to generate the cyclised products. 
In the cases of phenol ether oxidative coupling, while the poor results observed at high 
temperature (refluxing DCM) might be attributed to the vulnerability of the piperazine ring to 
VOF3, the inertness of the substrate to the oxidants at room temperature could be explained by 
the high oxidation potentials of aromatic rings. As discussed in Section 2.2.2, a cation radical 
generated from the aromatic ring might be involved in phenol ether oxidative coupling 
process. Therefore, the proneness of the phenol ether to oxidation would have a decisive role 
in the success of the coupling transformation. Referring to the literature, in most phenol ether 
coupling reactions, at least one of the two aromatic coupling partners bears two or more 
alkoxy groups besides an alkyl substituent. The existence of electron-donating groups would 
essentially reduce the oxidation potential of the whole aromatic ring. Since only one alkoxy 
group is possessed by each of the aromatic moiety in our substrates, the oxidation potential 





Nevertheless, another possibility should not be ruled out entirely that the expected coupling 
products might be produced in some of the reactions. However, they might decompose in situ 
due to instability as one could imagine that the coupling products would represent a class of 
strained structures. With negative results being obtained from vanadium-mediated cyclisation, 
we then focused on hypervalent iodine species mediated oxidative couplings. 
 
2.3.3 Hypervalent Iodine(III) Reagents as Coupling Oxidants 
Hypervalent iodine agents are another class of versatile but mild oxidants, which have been 
used widely in intramolecular oxidative phenolic coupling reactions. 
In our study, the attempted coupling reactions were carried out in non-nucleophilic solvents 
such as DCM, acetonitrile and 2,2,2-trifluoroethanol, with PIDA or PIFA as the oxidants. For 
bis-phenol substrates, one equivalent of oxidant was initially used, anticipating that one of the 
phenolic hydroxyl groups could coordinate to the positively charged iodine atom of the 
oxidant while the other phenol ring could act as a nucleophile to furnish the coupling product.  
Following a similar procedure to the one employed by Kita and co-workers in Section 2.2.2, 
bis-phenol 105 was treated with PIDA in DCM at -40 oC (Entry 1, Table 2.2). However, no 
reaction was observed. When the reaction solution was warmed up to ambient temperature, 
starting material was still the main component that could be isolated. Subjecting the bis-
phenol substrate to a slightly larger excess of PIDA did not change the situation. The reaction 
performed in MeCN followed a similar pattern (Entry 2, Table 2.2). When the reaction 
mixture was maintained at room temperature, the bis-phenol substrate was consumed slowly 





Table 2.2: Oxidative coupling conditions with PIDA or PIFA. 
Entry 
Substrate 
Coupling conditions Reaction outcome 
R1 R2 
1 (105) H Boc PIDA, DCM, -40 oC to rt 105 
2 (105) H Boc PIDA, MeCN, -40 oC to rt 105 and partial 
decomposition 
3 (105) H Boc PIFA, CF3CH2OH, rt 105 
4 (102) Bn Boc PIFA, CF3CH2OH, rt 102 
5 (102) Bn Boc PIDA, MeCN, rt to 60 oC  Decomposition 
6 (111) Me Me PIFA, CF3CH2OH, rt 111 
7 (101) Me Boc PIDA, BF3·Et2O, DCM,      
-40 oC to rt 
101 at -40 oC; 
Boc cleavage at rt 
8 (103) Me COCF3 PIDA, BF3·Et2O, DCM,      
-40 oC to rt 
103 
 
Treating bis-phenol 105 with PIFA in trifluoroethanol mainly led to recovery of the 
piperazine starting material (Entry 3, Table 2.2). According to the mass spectrum, the 
existence of deprotected product without the Boc protecting group and the dienone products 
which derived from the nucleophilic addition of trifluoroethanol, were also identified. 
The phenol ether substrate suffered similar fates to that of bis-phenol 105. For example, both 
piperazine derivatives 102 and 111 resisted to the oxidation conditions (PIFA in CF3CH2OH) 




ether 102 and PIDA in MeCN was warmed to 60 oC, possibly due to oxidative reactions of the 
tertiary amine or phenol ether moieties (Entry 5, Table 2.2). 
BF3·Et2O has been reported to be an activator of PIDA or PIFA and the combination of the 
oxidant and BF3·Et2O has been employed in several studies for successful phenol ether 
coupling reactions.36-38 This activating effect might arise from the coordination of BF3 to the 
acetoxy or trifluoroacetoxy ligand, rendering the iodine centre more electropositive. 
Disappointingly, no coupling reactions were effected with our piperazine systems. 
Specifically, no transformation occurred with COCF3-protected piperazine 103 (Entry 8, 
Table 2.2). In the case of 101, only removal of the Boc protecting group was observed (Entry 
7, Table 2.2). 
Since there is no general rule that can indicate the optimal oxidant for a specific coupling 
reaction and the success of oxidative phenol or phenol ether couplings reported in the 
literature usually based on extensive screening of different types of oxidising agents, we then 
turned our attention to other oxidative coupling methods.  
 
2.3.4 Oxidative Coupling with Silver(I) Oxide, Fe(III) and Pb(IV) Reagents 
Bis-phenol 106 was used as the substrate for Ag2O-mediated coupling approach. 
Unfortunately, no reaction took place under the employed condition (Entry 1, Table 2.3). On 
the contrary, the phenol coupling reaction with Pb(OAc)4 as the oxidant led to complete 
decomposition of the starting material (Entry 2, Table 2.3).  
FeCl3 was also tested as the oxidant but no transformations were observed at ambient 




decomposition occurred to give an inseparable mixture, from which no new product could be 
defined according to the mass spectra (Entry 3, Table 2.3). In terms of phenol ether coupling, 
piperazine 104 was found to be inert to the FeCl3 oxidation conditions and only starting 
material was recycled (Entry 4, Table 2.3). 
 
Table 2.3: Attempted oxidative coupling conditions. 
Entry & 
Substrate 
Coupling conditions Reaction outcome 
1 (106) Ag2O (10.0 eq.), Et3N, CHCl3, rt 106 
2 (106) Pb(OAc)4 (0.5 eq. to 1.0 eq.), BF3·Et2O, DCM, 0 
oC Decomposition 
3 (106) FeCl3 (2.5 eq.), DCM or MeOH, rt to reflux Decomposition 
4 (104) FeCl3 (2.5 eq. to 5.0 eq.), DMF, rt or DCM, reflux 104 
 
Overall, we were unable to identify any coupling products or related cyclised structures after 
extensive experimentation. To explain this, the mismatch between the oxidation potentials of 
the substrates and the redox potentials of the oxidants might be one reason. However, another 
possibility is worthy of consideration that the direct oxidative coupling reaction could be 
difficult, or even impossible to proceed with piperazine substrates. 
Regarding the biosynthesis of herquline A and B, the unsuccessful outcome of the biomimetic 
oxidative coupling at the piperazine oxidation state raises an interesting question of whether 




other stages, such as the diketopiperazine stage, since the DKP natural product mycocyclosin 
possessing the biphenol linkage has been isolated. 
Actually, during the total synthesis of mycocyclosin by the Hutton research group, the direct 
oxidative coupling of diketopiperazine 6 was firstly attempted using VOF3 as the oxidant.
23 
Without success in generating the natural product 35, only intermolecular coupling reactions 
occurred to give dimeric and trimeric products (Scheme 2.28).  
 
Scheme 2.28: Oxidative phenol coupling reaction attempted by Hutton and co-workers.23 
 
In our project, similar results were obtained from the oxidative coupling of DKP substrates 
(Scheme 2.29). The unsymmetrical bis-phenol 112 was initially afforded via the catalytic 
hydrogenolysis of 99. On treating DKP 112 with VOF3, dimeric products were detected by 
mass spectrometry without the presence of the desired product 113. In the case of phenol 






In addition, dipeptide 116 was also synthesised from the coupling reaction between acid 115 
and amine 39. When this bis-phenol was subjected to the VOF3 oxidation conditions, 
decomposition occurred without any observation of intramolecular phenolic coupling to 




While no success has been achieved in direct intramolecular oxidative couplings, it is 
plausible that under certain enzymatic assistance within the microorganism the piperazine 
substrate could adopt a favourable conformation for the formation of biphenol product.  
Similarly, biphenyl or diphenyl ether linkages possessed by several natural products are 
proposed to derive from direct oxidative phenol coupling processes in Nature, but all the 
biomimetic approaches in the laboratory failed,33,79-81 such as the total synthesis of alkaloid 
haouamine B (52) reported by Trauner and co-workers in 2012.33 The polyphenol 
intermediate 118 was proposed to be a possible biosynthetic precursor of haouamine B and 
could undergo a regio- and stereoselective oxidative phenolic coupling to afford the natural 




by subjecting substrates 119 or 120 to enzymatic conditions, anodic oxidation conditions or 
chemical oxidations with silver salts, hypervalent iodine reagents, vanadium oxyhalides as 
well as copper and iron reagents, but no desired coupling products were identified (Scheme 
2.31 B). A different synthetic route was adopted finally.  
 
Scheme 2.31: (A) Proposed oxidative phenol coupling step in the biosynthesis of haouamine B. (B) Attempted 
biomimetic synthesis by Trauner and co-workers.33 
 
With the biomimetic approach towards herquline A and B being precluded by difficulties in 
the direct oxidative coupling step, we resolved to employ several alternative aryl coupling 








2.4 Tricyclic Ring Formation via an Intramolecular Aza-Michael Addition 
Reaction 
During the exploration of hypervalent iodine reagent-mediated phenol coupling reactions, our 
attention was attracted by an interesting transformation, that is, the oxidative dearomatisation 
of phenols.  
 
Scheme 2.32: PhI(OAc)2-mediated transformations of tyrosine derivative reported by Wipf and co-workers.72,83 
 
It has been shown that phenols can react with hypervalent iodine species, such as PIDA or 
PIFA, to give cyclohexadienones in the presence of nucleophiles. As outlined in Scheme 2.32, 
Wipf and co-workers treated tyrosine derivative 115 with PhI(OAc)2 to obtain spirolactone 
123 with the carboxyl group acting as a nucleophile.72,83 Upon methanolysis, the lactone was 
cleaved and an intramolecular conjugate addition reaction took place to afford 
hydroxyhydroindole 124 in 34% overall yield with 97% ee due to the contamination from 125 
which arose from partial racemisation likely occurring at the lactone stage prior to 
methanolysis. The diastereoselectivity for the formation of bicycle 124 might be due to the 
less steric interaction involved in the transition state of the cyclisation process. 
With bis-phenol piperazine 105 in hand, it was envisioned that oxidation of both phenol 
groups with PhI(OAc)2 in the presence of a nucleophile such as an alcohol or a halide anion, 




system within 127 could then be rationalised by an intramolecular aza-Michael addition of the 
secondary amine to the adjacent dienone moiety upon removal of the Boc protecting group on 
the piperazine ring. It would be interesting to generate this tricycle since it shares a close 
structural resemblance to that in herquline A. 
 
Scheme 2.33: Proposed transformations of bis-phenol 105. 
 
Fascinated by this transformation, we carried out a model reaction with tyrosine methyl ester 
90 (Scheme 2.34). Oxidation with PhI(OAc)2 in anhydrous methanol gave dienone 128 in 61% 
yield under optimised conditions. MeOH acted as the nucleophile in this case and no 
cyclisation was observed without the presence of a base, which was indicated by the presence 
of a doublet signal corresponding to the N–H at 5.21 ppm in the 1H NMR spectrum, with a 
doublet at 6.83 ppm for vinyl protons H-5 and a multiplet at 6.40-6.35 ppm for H-6.  
 
Scheme 2.34: Model reaction with tyrosine derivative. 
 
The reaction was successfully applied to the bis-phenol system (Scheme 2.35). Subjecting 
piperazine derivative 105 to the oxidation conditions with a slight excess of PhI(OAc)2 in 




moderate, possibly due to the side-reactions involving the tertiary amino group, it was 
gratifying to isolate a new product from the reaction mixture after treating piperazine 129 
with TFA in DCM, followed by a basic work-up with NaHCO3 aqueous solution. 
At this stage, it was considered that the intramolecular conjugate addition should occur 
readily upon removal of the Boc protecting group in 129. In terms of the regioselectivity of 
the aza-Michael reaction, it was envisaged that the addition of the secondary amine to the 
adjacent enone moiety to form the pyrrolidine ring within 130 should be the preferential 
pathway. And two diastereoisomers with H9 and the adjacent methoxy group adopting a cis-
configuration should be the most favourable products, because other structures would be too 





The removal of the Boc protecting group was supported by the absence of a peak from t-butyl 
protons in the 1H NMR spectrum. The occurrence of the aza-Michael addition was also 
confirmed by NMR spectroscopy that overall six vinylic protons from enone functionalities 
were identified. According to the mass spectrum, it showed a [M+H]+ peak at m/z 373.2130 
(calculated: 373.2127), indicating a molecular formula C21H28N2O4 for the new entity 




Actually, a small amount of another product was isolated from the reaction mixture. Although 
no NMR experiment was carried out due to the low material quantity, the corresponding mass 
spectrum revealed that this minor component had the same molecular formula to the main 
product and was presumed to be the other diastereoisomer generated from the intramolecular 
cyclisation reaction.  
Since no structure could be found in the literature bearing close similarity to the tricyclic 
system in our product, it was difficult to gain any clue about the stereochemistry at C-4 and 
C-9 positions within piperazine 130 via NMR data comparison. Therefore, one-dimensional 
NOE experiments were performed to assist the assignment of the stereochemistry within 130 
(Figure 2.7).  
When the protons from one methoxy group (with chemical shift of 3.18 ppm) were irradiated, 
only interactions to vinyl protons were observed. We presumed that this methoxy group was 
possessed by the dienone ring. Upon saturation of the protons (H-10) from the other methoxy 
group (with chemical shift of 3.34 ppm), medium strength NOE interactions were observed to 
H9, which indicated a cis-configuration between the methoxy group and H9.  
It seemed not obvious to differentiate between the two diastereoisomers 130a and 130b based 
on NOE experiments since no valuable stereochemical relationship between certain protons 
could be identified within the extended structures. However, one could argue that H-2 within 
130b should be close in space to H-9 or the methoxy group (H-10) and NOE enhancement 








When either H-9 or the protons from the methoxy group (H-10) were irradiated, no NOE was 
observed to H-2. Therefore, it was presumed that 130a was the main isomer that was 












Further global hydrogenation of 130a delivered bis-ketone 131 in 68% yield (Scheme 2.36). 
Piperazine 131 possesses a similar fused tricyclic ring system to that in herquline A. 
 
2.5 Summary 
Inspired by the biosynthesis of the herquline alkaloids, a biomimetic synthetic approach was 




Having accomplished the synthesis of several piperazine intermediates from a tyrosine 
derivative, the intramolecular oxidative phenol or phenol ether coupling was attempted with a 
variety of oxidants including vanadium(V) species, hypervalent iodine reagents, FeCl3, Ag2O 





Further investigation led to the synthesis of an advanced piperazine intermediate possessing a 
fused tricyclic ring system which consisted of piperazine, pyrrolidine and cyclohexanone 




Since the direct oxidative phenol coupling approach encountered difficulties in accessing the 
piperazine coupling products for further transformations towards herquline A and B, an 
alternative transition metal-mediated biaryl coupling strategy was employed and studied in 











CHAPTER 3 TRANSITION METAL-MEDIATED ARYL COUPLING 
APPROACH TOWARD HERQULINE A AND B 
 
Since no success had been achieved in the biomimetic synthesis of herquline A and B, our 
focus was turned to the metal-mediated aryl coupling strategies. The primary consideration 
was based on the assumption that the two aromatic rings could be tethered together by certain 
metal species during the reaction processes. Presumably, this spatial proximity would 
facilitate the desired intramolecular C–C bond formation, which made this approach superior 
to the direct oxidative phenol coupling. Referring back to the literature, two types of efficient 
and well-established aryl coupling methods attracted our attention: the oxidative coupling of 
aryl cuprates and the palladium-catalysed aryl couplings, which are introduced herein. 
 
3.1 Oxidative Coupling of Organocuprates 
3.1.1 Introduction 
The oxidative coupling of the ligands in lithium organocuprates was observed as a common 
side reaction in organocopper chemistry and has been developed as a powerful tool for C–C 
bond formation. 
One of the earliest studies reported by Whitesides and co-workers focused on the oxidative 
coupling of cuprate complexes, such as 133 which was generated from the reaction between 




organolithium reagent (Scheme 3.1).84 They found that similar homo-coupling reactions could 




While statistical ratios of products were usually obtained in terms of the oxidative coupling of 
heteroleptic cuprates, Lipshutz and co-workers revealed a new route to unsymmetrical biaryl 
products via the formation of the corresponding kinetic higher order cyanocuprates.85 
Specifically, by controlling the reaction temperature and the formation mode of the 
organocuprates, high levels of unsymmetrical ligands couplings were achieved. As shown in 





It was noted that the ratio of hetero-coupling product 140 dropped to 50% when the reaction 




at -125 oC, indicative of the equilibrium between 138 and other homoleptic cuprates at higher 
temperature.  
The application of oxidative organocuprate coupling to intramolecular C–C biaryl bond 
formation makes this methodology more attractive. A wide diversity of biaryl-containing 
structures with medium rings has been constructed with this method. 
Scheme 3.3 demonstrated an example reported by Spring and co-workers.86 Biaryl product 
144 with a 10-membered ring was synthesised following a sequence consisting of the direct 
double lithiation of bis-phenol ether 142, intramolecular cuprate formation and subsequent 
oxidative coupling using oxidant 143. This cyclised product was fashioned from simple linear 




An atropdiastereoselective oxidative biarylcuprate coupling was employed by Spring and co-
workers as the key step in their total synthesis of sanguiin H-5 (148),87 a plant polyphenol 
natural product belonging to the ellagitannin class. As shown in Scheme 3.4, the benzyl-
protected biaryl intermediate 147 was afforded in 65% yield after treating iodide 145 with 
isopropylmagnesium chloride, followed by transmetallation with copper(I) bromide dimethyl 
sulfide complex and oxidation with dinitroamide 143. Alternatively, initial metallation could 
be fashioned by treatment of bromide 146 with Rieke zinc. Transmetallation and subsequent 




70% yield. Both reactions gave rise to the specific (S)-atropisomer, which was attributed to 
the structural restraint imposed by the galloylated sugar ring according to Spring and co-
workers' analysis. Hydrogenolytic global deprotection of 147 completed the total synthesis to 
afford the natural product in quantitative yield. The success of the oxidative coupling reaction 





Besides the two-step sequence mentioned above involving aryllithium formation and 
transmetallation for the generation of arylcuprates, another potential route is via the direct 
deprotonative cupration of functionalised aromatics. 
In 2007, Wheatley, Uchiyama and co-workers reported a diversity of chemical 
transformations that could be realised with functionalised phenyl cuprate intermediates, such 
as aryl cuprate 151 which was initially generated from the direct ortho cupration of amide 149 




152 was produced in quantitative yield upon oxidation of cuprate intermediate 151 with 
nitrobenzene, indicating this protocol as a potential aryl coupling method. 
 
Scheme 3.5  
 
It has been reported that the Gilman and the Lipshutz cuprates are two dominant types of 
structures in organocuprate(I) chemistry and that cuprates of the latter type show higher 




The generation of either type of cuprate depends largely on preparation methods and reaction 
conditions. While the Gilman-type cuprates have homodimeric structures, such as 153 in 
Scheme 3.6, heteroaggregate structures are usually exhibited by the Lipshutz-type species in 
the presence of halides or pseudo-halides, as exemplified by 154.90 The higher order 







3.1.2 Synthesis and Conformational Analysis of Piperazine Derivatives 
In order to simplify the NMR spectra of the piperazine substrates and the potential coupling 
products, symmetrical piperazine derivatives were synthesised initially. 
The manipulation followed a similar route to the synthesis of the unsymmetrical piperazines 
(Scheme 3.7). The coupling reaction between acid 92 and amine 155 which was obtained 
from the deprotection of 91 with TFA gave rise to dipeptide 156. After removal of the Boc 
protecting group, the resulting dipeptide intermediate was subjected to a thermal cyclisation 




Reduction using LAH was applied to the newly formed DKP 157. However, the reaction was 
relatively slow at room temperature and a considerable amount of partially reduced 




retardation might be due to solubility issues since this symmetrical DKP which was isolated 
as a solid has a poorer solubility in THF than unsymmetrical DKP 96 with an NMe group. 
When the reaction mixture was warmed up, a degree of isomerisation was observed. 
Therefore the original reduction conditions were adopted to perform the reaction at room 
temperature but with a longer reaction time. 
Piperazine 158 was further protected with Boc or benzenesulfonyl groups to give 159 or 160, 
respectively. The N, N'-dimethylpiperazine derivative 111 was also formed by reductive 





Before moving on to test the intramolecular coupling reactions with several different 
functionalised piperazines, it would be helpful to investigate the conformation of these 
structures, since the arrangement of the two aromatic residues in these piperazine substrates 




It is known that in substituted piperazine or piperidine amides, the substituent at the vicinal 
position to the amide group prefers to reside in the axial position of the corresponding chair 
conformation due to the pseudo allylic strain between the bulky substituent and the essentially 
planar amide functionality. This phenomenon is exemplified by piperazine 102 in our 
synthesis. As demonstrated by the X-ray crystal structure of this piperazine that is shown in 
Figure 3.1, while the piperazine ring still adopts a normal chair conformation, the side chain 
adjacent to the tert-butyl carbamate moiety is forced to present in the axial position due to the 
potential A1,3 strain.  
 
 
Figure 3.1: Crystal structure of 102. 
 
Inspired by this conformational behaviour of piperazine derivatives, it was presumed that the 
presence of two amide groups in our cis-2,5-disubstituted piperazine derivatives would not 
only result in biased orientations of substituents, but could also affect profoundly the 
conformations of piperazine rings. Specifically, if the methyl group within 102 was replaced 




equatorial position due to steric interaction. Instead, a low-energy conformation would be 
adopted by the piperazine ring with rearranged side chain orientations. 
Ideally, a boat-like conformation with both substituents (R1) in pseudo-axial positions would 
be possible, such as the boat form (A), (B) or (C) in Figure 3.2, which was also assumed to be 
beneficial for the intramolecular aryl coupling strategy. Since the two aromatic rings were 
proposed to be joined together by a metal species during the coupling reaction, the two side 
chains (R1) within the boat conformation seemed to be close enough to each other to facilitate 
this process. 
 
Figure 3.2: Possible conformations of bis-sulfonamide, bis-amide and bis-carbamate. 
 
The 1H NMR spectra were analysed in order to obtain sufficient evidence on the conformation 
of these piperazine substrates. In the case of piperazine 160, it revealed that the vicinal 
coupling constants between the ring protons Ha and Hb/Hb' were Jab 4.8 Hz and Jab' 6.0 Hz 
respectively (Figure 3.3 (A)), which indicated that the molecule could not adopt a normal 
chair conformation. Since the cis coupling between Ha and Hb from Form (B) in Figure 3.2 
was considered to be larger than the observed magnitude, piperazine 160 might adopt the boat 
form (A) or (C) in solution. The analysis was subsequently supported by the X-ray crystal 




(C) in which the torsion angle of N–C–C–N is around 50o. The dihedral angles between Ha 
and Hb/Hb' are 69
o and 51o respectively in the solid state, which is in agreement with the 
corresponding coupling constants.  
 
 
Figure 3.3: (A) Vicinal coupling constants between the protons on the piperazine ring of 160 (CDCl3, 400 MHz). 
(B) X-ray crystal structure of 160. 
 
It was noted that the NMR data of 160 showed strong temperature dependence. When the 
NMR experiments were conducted with DMSO-d6 as the solvent, the signals from the two 
diastereotopic geminal protons Hb and Hb' on the piperazine ring coalesced as the temperature 
was raised and emerged accidentally as one set of resonances at 90 oC, indicating a fast 
equilibrium between different conformers. 
In contrast, the coupling constants between protons Ha and Hb/Hb' were observed as Jab' 5.2 Hz 






literature, the N, N'-diacyl-protected cis-2,5-disubstituted piperazines tend to adopt a twist 
boat conformation such as the form (D) in Figure 3.2, which has been confirmed by relevant 
crystal structures.91 For the twist-boat conformation, the published coupling constants 
between Ha and Hb/Hb' from related compounds were around 11 Hz and 7 Hz,
92 which were 
slightly different from those observed for piperazine 161. Potentially the N-trifluoroacetyl-
protected piperazine 161 and the Boc-protected piperazines could exist as equilibrium 
mixtures of different conformers in solution at room temperature, such as form (B) and (D) in 
Figure 3.2. 
 
Figure 3.4: Vicinal coupling constants between the protons on the piperazine ring of 161 (CDCl3, 400 MHz). 
 
Based on the above analysis, a substantial proportion of boat conformers exist in solution for 
bis-amide structures such as 159, 160 and 161, in which the two side chains on the piperazine 




Therefore, structures like 159, 160 and 161 were envisaged to be superior substrates for 
intramolecular aryl coupling reactions compared with 101 and 111, which exist in normal 




3.1.3 Attempted Intramolecular Oxidative Coupling of Diarylcuprates 
As demonstrated in Section 3.1.1, the organocuprate involved in the oxidative coupling could 
be accessed through several different approaches. The method of direct lithiation followed by 
transmetallation seemed to be the most straightforward and reasonable sequence for our 




In addition, it was envisioned that the copper species would serve as a template to tether the 
two aromatic rings together during the transmetallation process to give a cyclic cuprate 162. 
This reduced flexibility of the metal-bridged intermediate should be beneficial for the 
subsequent oxidative coupling reaction.  
Attempts started from the double lithiation of piperazine substrates 159, with methoxy 
functionalities as the directing metalation groups. Since TMEDA is a commonly used additive 
to essentially break down the alkyllithium aggregates, hence increasing their basicity and 
effectively accelerating the reaction rate,93,94 this bidentate ligand was employed in all of our 




Initial treatment of piperazine 159 with n-butyllithium at -20 oC or 0 oC, followed by 
quenching with TMSCl gave no product, with only starting material being recovered (Entry 1 
and 2, Table 3.1). Since the substrate possessed two tert-butyl carbamate moieties which 
could coordinate with butyllithium, we proposed that an excess of lithium base might be 
required. Increasing the amount of lithium base seemed to be beneficial since a small amount 
of piperazine 163 which derived from mono-lithiation was isolated, but the conversion of 159 
was still low (Entry 3, Table 3.1).  
 
Table 3.1 




1 n-BuLi (2.2 eq.), THF,    
-78 oC to -20 oC  
30 min at -78 oC;    
5 h at -20 oC 
159 
2 n-BuLi (2.2 eq.), THF,    
-78 oC to 0 oC 
15 min at -78 oC;    
3 h at 0 oC 
159 
3 n-BuLi (4.0 eq.), THF,    
-78 oC to 0 oC 
15 min at -78 oC;    
3 h at 0 oC 
159 and 163 (12%) 
4 n-BuLi (4.0 eq.), THF,    
-78 oC to rt 
15 min at -78 oC;    
3 h at rt 
159, 163 (15%) and 
164 (9%) 
5 n-BuLi (3.0 eq.), Et2O,    
-78 oC to rt 
15 min at -78 oC;    
2 h at rt 
159, 163 (18%), 
164 (13%) and by-
products 




It was conceived that temperature should be a decisive parameter for this process. Referring to 
previous studies in the literature, direct lithiation of alkyl anisoles with n-butyllithium was 
usually performed at room temperature,86,95 such as the reaction shown in Scheme 3.3 in 
Section 3.1.1. In our case, the double lithiation of bis-anisole derivative 159 should be more 
challenging. 
At this stage, two model reactions were carried out with anisole and 1,2-dimethoxybenzene 
(Scheme 3.10). For both reactions, good results were obtained when the substrates were 
treated with n-butyllithium at room temperature before trapping the aryllithium species with 





Accordingly, conducting the lithiation reaction at room temperature for the piperazine system, 
mainly starting material and mono-silylated product 163 were isolated, accompanied by the 
desired product 164 only as a minor component (Entry 4, Table 3.1). A similar result was 
obtained when the reaction was performed in diethyl ether (Entry 5, Table 3.1). Extending the 
reaction time or increasing the temperature led to side-reactions, giving several irrelevant 




moderate metalation directing group, deprotonation at the benzylic position or side-reactions 
from the Boc-protected piperazine ring might be competing processes during the ortho-
metalation of 159 above room temperature.96 
Without fashioning an efficient double lithiation, we resolved to adopt the lithium-halogen 
exchange strategy, hoping the dilithio species could be generated readily from halogenated 
piperazine substrates. For this alternative protocol, iodinated or brominated piperazines would 
be the ideal substrates. Scrutinising the synthetic sequence, any substrates bearing aryl halide 
functionalities prior to the DKP reduction step would face the risk of losing halogen atoms 
upon treatment with LAH. Therefore, the direct halogenation of piperazine 159 seemed to be 
a potential solution to the synthesis of piperazine substrates for the lithium-halogen exchange 
approach. Fortunately, treating piperazine 159 with iodine and silver triflate in methanol gave 
the desired bis-iodide 169 in 71% yield, accompanied by a small amount of mono-iodinated 
product which could be removed by careful column chromatography (Scheme 3.11).  
Scheme 3.11 
 
With piperazine 169 in hand, the efficacy of lithium-iodine exchange was initially studied. 
The aryllithium species generated under various conditions were trapped with TMSCl for 
further analysis. Extensive experimentation led to the optimal conditions for the current 







Efforts were made to improve the yield of 164 by using TMSOTf as the electrophile or 
warming up the silylation reaction system to room temperature, but a considerable amount of 
by-products were obtained, due to the removal of the Boc protecting group and other side 
reactions. Treating piperazine 169 with n-BuLi at a higher temperature gave a similar result to 
the one shown in Scheme 3.12. Even though increasing the amount of butyllithium (from 2.2 
eq. to 3.0 eq.) resulted in a slightly higher isolation yield of 164, this modification was not 
employed in the subsequent experiments. It appeared that the Li-I exchange process was 
complete under the optimised condition (2.2 eq. of n-BuLi) since no iodine atom presented in 
any of the products isolated from the reaction mixture. Theoretically, two equivalents of 
butyllithium would be the ideal amount of base for double lithium-iodine exchange and be 
beneficial for the subsequent oxidative cuprate coupling process, because excess n-BuLi 
would inevitably compete with the newly generated aryllithium in the cuprate formation step.  
Before progressing towards the intramolecular oxidative cuprate coupling, model reactions 
were conducted with 4-iodoanisole (Scheme 3.13). On treating iodoanisole with n-BuLi, 
followed by transmetallation in the presence of copper(I) bromide dimethyl sulfide complex, 
the generated diaryl cuprate was oxidised with either CuCl2 or nitrobenzene to give 4,4'-







For the piperazine system, a similar procedure for Li-I exchange was used as discussed above. 
In the literature, the conditions for transmetallation varied depending largely on the substrates. 
Therefore, our elaboration commenced from screening the optimal cuprate formation 
conditions as shown in Table 3.2, with nitrobenzene as the oxidant since it gave impressive 
results with the model system. 
Initial treatment of the bis-aryllithium intermediate generated from 169 with copper(I) 
bromide dimethylsulfide at -78 oC under N2, followed by oxidation resulted in complete 
deiodination (Entry 1, Table 3.2), possibly due to the failure of cupration. With a higher 
temperature for transmetallation (-40 oC), the reactions gave two new products which were 
found to be oxygenated products 174 and 175, accompanied by a small amount of deiodinated 
product 159 (Entry 2, Table 3.2). Further increasing the temperature to -20 oC or 0 oC led to a 
lower combined yield of the three products (Entry 3, Table 3.2). It seemed that maintaining 
the transmetallation reaction system at -40 oC was more efficient for the hydroxylation 
process. When CuCN was employed as the Cu(I) source, a comparable result was obtained 





Table 3.2: Cuprate formation (transmetallation) and oxidation conditions. 
Entry           
(& substrate) 




Oxidant Reaction outcome 
1 (169) CuBr·SMe2 -78 
oC, 1 h PhNO2 159 
2 (169) CuBr·SMe2 -78 
oC, 30 min;                
-40 oC, 1 h 
PhNO2 175 (45%), 174 (25%) 
and 159 
3 (169) CuBr·SMe2 -78 
oC, 30 min;                
-20 oC or 0 oC, 30min 
PhNO2 175 (33%), 174 (20%) 
and 159 
4 (169) CuCN -78 oC, 30 min;                
-40 oC, 1 h 
PhNO2 175 (50%), 174 (20%) 
and 159 
5 (169) CuCN -78 oC, 30 min;                
-40 oC, 1 h 
O2 175 (53%), 174 (26%) 
and 159 
6 (169) CuCN -78 oC, 30 min;                
-40 oC, 1 h 
CuCl2 159 
7 (171) CuCN -78 oC, 30 min;                
-40 oC, 1 h 
PhNO2 Hydroxylation and 
deiodination 






The use of molecular oxygen as the oxidant did not essentially change the reaction pattern, 
giving a similar result to the coupling reactions using PhNO2 (Entry 5, Table 3.2). For the 
oxidation reaction using CuCl2, the proto-deiodinated product 159 was predominantly isolated 
(Entry 6, Table 3.2), which was quite different from the result obtained from the model 
reaction.  
This sequence was also attempted with unsymmetrical piperazine 171. Regrettably, 
oxygenation and deiodination were still the dominating processes (Entry 7, Table 3.2). 
Referring to the mass spectra of the oxidative cuprate coupling reactions, some high 
molecular weight products were also detected accompanying the oxygenated piperazines, 
which indicated that intermolecular oxidative coupling took place and certain amounts of 
linear aryl cuprates rather than the bridged ones formed during the reaction processes. 
In terms of the oxygenation process, it seems explainable when molecular oxygen was used as 
the oxidant because hydroxylation has been reported to be a competing process in some cases 
of oxidative coupling of organocuprates to generate phenol by-products.86 However, it is not 
clear whether the oxidative coupling reaction using PhNO2 would follow a similar pathway. It 
seems unlikely that oxygen from the atmosphere could intervene during the coupling process 
since all the reaction were carried out under argon and subsequent experiments using 
degassed solvent gave similar results to those shown in Table 3.2. 
Another possibility also considered was that oxygenated piperazines could be the products 
from the reaction between aryllithium and O2, if the dilithio intermediate failed to react with 
Cu(I) species. Parker and Koziski reported the directed oxygenation of aromatic compounds 








Scheme 3.14: Directed oxygenation of aromatic compounds reported by Parker and Koziski.97 
 
At this stage, another reaction was performed by treating the dilithiopiperazine derived from 
169 with Ph2SiCl2, anticipating that silacycle 181 would be afforded if the piperazine 




However, only deiodination was observed to give piperazine 159 in 63% yield, without any 
detection of cyclised product 181. Although it is not the same type of reaction to the cupration 
of aryllithium species, the failure in generating 181 may indicate that cyclic cuprate was also 




As an alternative approach, the direct ortho cupration strategy was then tested. Bis-aryl 
cuprate 182 was expected to be fashioned after the deprotonative cupration of piperazine 159 




Intermediate 182 in this case was different from the cyclic cuprates in which the two phenol 
ethers were tethered together by copper species. Upon oxidation, the two aryl cuprate moieties 
within 182 were expected to undergo a coupling process to give cyclic product 172.  
Following the procedure reported by Uchiyama and co-workers,88 amidocuprate 150 was 
prepared from the reaction between copper cyanide and LTMP that was generated from the 
deprotonation of 2,2,6,6-tetramethylpiperidine with n-BuLi (Scheme 3.17). Model reactions 







As demonstrated in Scheme 3.18, treatment of 1,2-dimethoxybenzene with 150, followed by 
trapping the resultant arylcuprate with TMSCl gave silylated product 168 in 66% yield. It 
should be noted that warming up the reaction mixture to room temperature during the 
deprotonative cupration step was crucial, since a lower yield was observed when the cupration 
process was carried out at 0 oC. This might be due to the absence of activating (electron-
withdrawing) groups on the aromatic ring compared with the benzamide substrates that were 
employed in Uchiyama’s study as shown in Scheme 3.5 in Section 3.1.1.88 The oxidative 





While the deprotonative cupration could be fashioned with 1,2-dimethoxybenzene using the 
specific amidocuprate 150, the applicability of this method to anisole-type substrates still 
awaited examination. When the same procedure was followed with anisole as the substrate, 
reduced efficiency was observed as product 166 was only isolated in 11% yield, with starting 






Poor yields in the deprotonation of anisole were also mentioned by Mongin and co-workers.98 
In their work, anisole was deprotonated with a similar lithium cuprate base followed by 
quenching with elemental iodine resulting in 20% isolation of 2-iodoanisole. Even though 
2,2'-dimethoxybiphenyl was also isolated as a by-product, possibly derived from the I2 
oxidised cuprate coupling route, the combined yield of all the products was still low. For our 
piperazine system, it was then hoped that the alkylphenol ether within the substrate would 
behave differently from anisole. 
Treatment of piperazine derivative 159 with 150, followed by electrophilic trapping with 
TMSCl gave only 8% of the mono-silylated product 163, leaving unreacted starting material 
as the main component (Scheme 3.20). Oxidation of the cupration system with either 
nitrobenzene or O2 provided no C–C bond formation, but a small amount of the mono-
hydroxylated piperazine 174, with a large quantity of starting material being recovered.  
Scheme 3.20 
 
Even though the cupration conditions were also tested with other piperazine substrates 







Compared with the Li-I exchange and transmetallation protocol, the direct ortho cupration 
seemed to be a less efficient method of generating aryl cuprate intermediate with our system. 
Following thorough experimentation in intramolecular oxidative cuprate coupling, the last 
attempt was made on the oxidative coupling of aryllithium species. It is known that treating 
organolithium intermediates with an appropriate oxidant could lead to coupling products. 
Several studies have demonstrated the practical usefulness of this method in synthesising 
biaryl compounds.99,100 For example, Shair and co-workers employed this transformation at 
the early stage of the total syntheses of several polyketides.99 In their study, FeCl3-mediated 
oxidative dimerisation of aryllithium species generated from the regioselective ortho lithiation 
of 184 afforded biaryl 185 in 76% yield (Scheme 3.21).  
 
Scheme 3.21: Oxidative dimerisation of aryllithium reported by Shair and co-workers.99 
 
Other oxidants were also used for the oxidation of organolithium intermediate, such as the 
synthesis of biaryl 187, which was produced from CuCl2-mediated oxidative coupling of the 
aryllithium derived from bromide 186 (Scheme 3.22).100 
 




Nevertheless, no intramolecular coupling reactions using this method have been reported and 
piperazines 169 and 171 were tested preliminarily. The Li-I exchange should be a 
straightforward process for the generation of the bis-aryllithium intermediates. However, 





Further efforts on this approach were not made since the lack of reactivity towards cyclisation 
might be due to a conformational issue of the piperazine substrates. Even though the side 
chains, specifically the two benzylic methylene groups, were proposed to reside in the 
pseudo-axial positions of the boat conformer of the Boc-protected piperazine 159 or 169, the 
disposition of the two aromatic rings was not obvious concerning the rotation along the 
corresponding C–C bonds. 
 
3.2 Palladium-Catalysed Coupling Reactions 
Palladium-catalysed coupling methodology has gained widespread use for the formation of 
carbon–carbon and carbon–heteroatom bonds. It is also a well-developed and powerful tool to 
effect aryl coupling reactions, both inter- and intramolecularly. Focusing on generating the 
biaryl piperazine sub-target for the synthesis of herquline A and B, two synthetic aspects were 




aryl halide was essentially needed because Pd-catalysed direct C(sp2)–H/C(sp2)–H coupling 
would be extremely difficult since the two aromatic rings were not in close proximity. 
Secondly, equal functionality would be possessed by the two phenol ethers in the piperazine 
substrate because selective functionalisation of the two aromatic moieties would be 
challenging at this stage. Ideally, biaryl piperazine product 36 could be delivered from the 
previously synthesised bis-iodide 188 via a palladium-catalysed intramolecular coupling 




Biaryl formation from two aryl halides can be fashioned with several different Pd-catalysed 
transformations, among which the domino Suzuki-Miyaura and Stille-Kelly couplings have 
been demonstrated to be two productive ones, especially for intramolecular aryl couplings.  
Other methods have also been developed for intermolecular coupling of aryl halides, which 
could also be modified for an intramolecular version. 
 
3.2.1 Introduction to Intramolecular Suzuki-Miyaura and Stille-Kelly Couplings  
Both the Stille and Suzuki couplings are well-established methods that have been used for the 




mainly focused on Pd-catalysed intramolecular coupling reactions that gave cyclic biaryl 
structures. 
In a classic Suzuki coupling reaction, as reported by Takeya and co-workers, dipeptide 189 
bearing a boronic acid and an iodide moiety was converted to the 12-membered ring structure 
190 catalysed by Pd(PPh3)4 (Scheme 3.25).
101 Two indistinguishable atropisomers were 
obtained in 64% combined yield. While the success of this cyclisation reaction demonstrated 
the efficiency of intramolecular Suzuki coupling, it indicated the requirement that both aryl 
halide moiety and its boronic acid (or equivalent functionality) coupling partner should be 




In 2000, Zhu and co-workers developed a domino macrocyclisation procedure for the 
synthesis of cyclic peptides with biaryl linkages, such as tripeptide 192 (Scheme 3.26).102 
Specifically, diiodide 191 was treated with Pd(dppf)Cl2 in the presence of KOAc and diboron 
ester to give the 15-membered cyclophane 192 in moderate yield. The aryl coupling process 
was proposed to consist of two ordered transformations, the Miyaura borylation of 191 and a 
subsequent intramolecular Suzuki coupling. This could be partially proved by controlled 
experiments in which Pd(dppf)Cl2 or Pd(PPh3)4 alone failed to promote the coupling reaction 
and the diboron ester was found to be crucial for the cyclisation. Even though the existence of 




be the key intermediates during the process and could undergo a Suzuki coupling reaction to 




During the course of our studies on the total synthesis of herquline A and B, Hutton and co-
workers reported the total synthesis of mycocyclosin employing this deft Suzuki-Miyaura 




The success of the intramolecular coupling of DKP 32 is particularly instructive, since the 
only difference between 32 and our substrates lies in the oxidation state of the piperazine 
rings. Application of the promising coupling conditions to our piperazine systems would 
provide a general view on the reactivity of these two kinds of structures. 
The intramolecular Stille-Kelly coupling of bis-aryl halides shares a similar concept. Such as 
the cyclisation of bis-bromide 193 catalysed by Pd(PPh3)4 in the presence of hexamethylditin 




intramolecular cyclisation was not productive, the starting material could be recycled and 
cyclic product 194 served successfully as a synthetic precursor of the macrocyclic natural 
product plagiochin D (195). In contrast to the absence of mono-arylboronate intermediates in 
Suzuki-Miyaura coupling reactions, the arylstannane intermediates were isolated from the 




Compared to macrocyclisation, this tandem stannylation-aryl coupling sequence exhibits 
enhanced efficiency in the formation of 5-, 6- and 7-membered rings. Grigg and co-workers 






The bis-aryl iodide 196 was subjected to the Stille-Kelly coupling conditions to give indoline 
197 in 60% yield. Upon oxidation with DDQ, the final natural product was produced from 




The seven-membered lactam 200 could also be fashioned from the intramolecular coupling of 
amide 199 catalysed by Pd(OAc)2 (Scheme 3.30). 
 
3.2.2 Other Palladium-Catalysed Coupling Methods 
Besides the tandem coupling strategies, the Pd-catalysed direct biaryl formation from two aryl 
halides is another appealing method. A variety of palladium catalysts and conditions have 
been reported to effect the Ullmann-type reductive coupling reactions.  
With the catalytic system developed by Lu and co-worker, biaryls could be synthesised in 
moderate to good yields by treating aryl iodides with Pd(OAc)2 and K2CO3 in MeCOEt 
(Scheme 3.31).105 While homo-couplings of aryl iodide proceeded smoothly, they pointed out 
that the reactivity difference between two iodide substrates and their ratios could affect the 






Different from the Pd(II)-catalysed aryl iodide coupling, the Ullmann-type reaction using 
Pd/C as the catalyst also showed high efficiency in the homo-coupling of various aryl halides. 
According to Li and co-workers' study, subjecting aryl halides, especially aryl iodides to the 
conditions involving Pd/C and Zn in aqueous acetone, symmetrical biaryl products were 
afforded in high yields (Scheme 3.32).106 In contrast to the general Pd catalytic cycle, this 
system was found to be air-tolerant since identical results were obtained when the reactions 
were performed under nitrogen, air or oxygen atmosphere. It was proposed that the palladium 
intermediate might be stabilised by coordinating to the carbonyl group of acetone during the 




Lee and co-workers reported another Pd/C catalysed Csp2–Csp2 bond formation method with 




The combination of Pd/C, indium and LiCl in DMF effects the coupling of iodide or bromide 
substrates both inter- and intramolecularly. For example, the seven-membered biaryl product 





3.2.3 Application to the Synthesis of the Herqulines 
With several promising Pd-catalysed coupling methods available, our elaboration commenced 
with the synthesis of the advanced biaryl precursor of herquline A and B. Since most of these 
Pd-catalysed reactions were carried out at relatively high temperature compared with the 
phenol or organocuprate oxidative coupling reactions, it was anticipated that the favourable 
conformer with a suitable aromatic side chain orientation would contribute to a sizable extent 
of the piperazine substrate via conformational equilibrium during the intramolecular coupling 
processes.  
 
Suzuki-Miyaura Coupling Approach 
The conditions adopted by Hutton and co-workers were employed primarily in our attempts. 
Initial treatment of symmetrical piperazine 169 with Pd(dppf)Cl2·CH2Cl2, K2CO3 and diboron 







Instead, dimeric by-products, such as 206, deiodinated material and even trimeric structures 
were detected by mass spectrometry. After careful column chromatography, compound 206 
was isolated. It was noted that further dilution of the reaction mixture failed to change this 
outcome. These preliminary results indicated that intermolecular coupling was a superior 
pathway to the desired intramolecular reaction with the Boc-protected piperazine substrate. In 
addition, proto-deiodination was a competing process during this transformation. 
While the lack of reactivity in terms of piperazine substrate 169 for the coupling reactions 
awaited further investigation, we decided to reproduce the tandem reaction from the literature 
with a DKP substrate in order to confirm that the reaction conditions employed by Hutton and 
co-workers were replicated in our attempts. 
To obtain substrate 211 for the coupling reaction, the direct iodination method failed due to 
the poor solubility of the corresponding symmetrical DKP precursor. Instead, a stepwise route 






The symmetrical DKP 211 was obtained following a similar procedure as we previously 
employed. Gratifyingly, coupling product 212, an analogue of the natural product 
mycocyclosin, was delivered in 39% yield after subjecting 211 to the specific condition as 
outlined in Scheme 3.36. The main by-product was identified as the deiodinated compound. 
The yield was comparable to the one reported by Hutton and co-workers with a benzyl-
protected bis-phenol ether substrate. Therefore, the conditions we adopted were considered to 




With this information, further efforts were made on the intramolecular coupling of piperazines. 
The reactions were performed with several different piperazine substrates and it was pleasing 
to see that some coupling products could be fashioned finally, although in low yields. The 
coupling reactions exhibited substrate-dependent character.  
Specifically, the unsymmetrical N-Me-N-Boc piperazine derivatives 171 and 213 could 
undergo the Pd-catalysed intramolecular couplings to afford small amounts of the cyclised 
biaryl products 173 and 214 respectively (Table 3.3). Even though both reactions provided 
poor yields, the success of this approach confirmed the existence of the coupling structures. 
According to the mass spectra of these reactions, dimeric piperazines were the main by-





Table 3.3: Pd-catalysed intramolecular coupling reactions. 












The coupling of N, N'-dimethyl piperazine 215 gave a similar result to deliver biaryl 
piperazine 216 with C2 symmetry. This was supported by HRMS spectrum which showed a 
[M+H]+ peak at m/z 505.2844 (C34H37N2O2 requires 505.2855). In the 
1H NMR spectrum of 
piperazine 216, a doublet resonance for Ha was observed at 8.20 ppm (Figure 3.7). The 
downfield shift, compared with the chemical shift of 6.49 ppm for the protons Ha in DKP 
coupling product 212, indicated that the Ha protons within 216 might be deshielded due to the 






Figure 3.7: Partial 1H NMR spectrum of piperazine 216 (400 MHz, CDCl3, 298 K). 
 
On the contrary, the signals from protons Hb (NCH3) in 216 were relatively highfield shifted 
to 1.80 ppm with respect to those from the methyl protons in precursor 215 (δ = 2.37 ppm), 
indicating that the Hb protons in structure 216 were slightly shielded by corresponding 
aromatic rings. 
At this stage, efforts had been made to optimise the reaction conditions, since the above 
conditions that gave satisfactory results with DKP substrates might not be suitable for the 




Section 3.2.1, this Pd-catalysed domino coupling reaction was proposed to consist of two 
steps: Miyaura borylation and Suzuki coupling. For the former step, Miyaura and co-workers 
screened various conditions and found that the combination of Pd(dppf)Cl2/KOAc/DMSO 
was the optimal reaction condition for the cross-coupling of diboron ester and haloarenes to 
give arylboronic esters.108 Interestingly, they found that the use of stronger base K2CO3 
instead of KOAc in the borylation reaction could promote further Suzuki reaction between the 
newly generated arylboronic ester and haloarene to produce biaryl by-product, which was a 
highly desired process for our domino coupling sequence. Based on this analysis, it seems the 
conditions employed in our system (Pd(dppf)Cl2/K2CO3/DMSO) were the most promising 
ones. However, the success of KOAc rather than K2CO3 in promoting the intramolecular 
coupling of linear dipeptide 191 in Scheme 3.26 in Section 3.2.1 reported by Zhu made the 
choice of base negotiable. 
The use of KOAc as the base was tested with substrate 171 while other reaction parameters 
remained unchanged, but deiodination was found to be the dominating process and no 
coupling reaction was observed. Therefore, K2CO3 was used in subsequent coupling reactions. 
In terms of reaction temperature, performing the reaction at lower temperature than 80 oC or 
above 110 oC led to a considerable degree of deiodination and other side reactions.  
Since intermolecular coupling reaction occurred under the current conditions with a substrate 
concentration of 0.005-0.01 M, further diluting the reaction mixture was attempted. 
Unfortunately, no improvement was achieved apart from resulting in a longer reaction time. 
The results from the coupling reactions of 171 and 213 indicated that the methyl or benzyl 
groups on the phenol rings caused no reactivity difference. However, the functional groups on 




Table 3.4: Attempted Suzuki-Miyaura couplings with piperazine and DKP substrates. 
Substrate Reaction outcome* 
 





   
 *The same reaction conditions as shown in Scheme 3.36 were employed. 
When bis-carbamate 169, bis-sulfonamide 217 and bis-amide 161 were employed as the 
substrates, only traces of coupling products were detected by mass spectrometry without 
successful isolation of any of the desired compounds due to low quantities. Instead, 
intermolecular coupling products were the main components isolated from the reaction 
mixtures. In the case of unprotected piperazine 218, the secondary amino moieties seemed to 
be detrimental for the aryl coupling process since the system delivered exclusively the 
deiodinated material. 
Attracted by the promising reactivity of DKP substrates, bis-aryl iodide 219 synthesised from 
the direct iodination of the corresponding DKP substrate in our project was subjected to the 




successfully obtained in 52% yield. The higher yield compared with that in the synthesis of 
symmetrical DKP 212 could possibly be attributed to the good solubility of 220, which 
simplified the purification process. 
 
Stille-Kelly and Other Palladium-Catalysed Coupling Approaches 
According to our attempts on Suzuki-Miyaura coupling, reactions with piperazines 171 and 
213 seemed to give promising results. Therefore, these two substrates were employed in the 
studies of Stille-Kelly coupling and direct aryl halide coupling approaches. 
The Stille-Kelly reaction was initially carried out by treating 171 with Pd(PPh3)4 and n-
Bu6Sn2 in refluxing toluene (Entry 1, Table 3.5). However, deiodination took place to give 
compound 101 accompanied by mono-iodide materials according to the mass spectrum. 
Interestingly, the signals corresponding to the arylstannane intermediates were also observed 
from the mass spectrum, which indicated the Pd-catalysed stannylation occurred during the 
process but the coupling reaction was precluded by the undesired deiodination pathway. 
Switching the solvent to DMF, a trace amount of coupling product was detected by mass 
spectrometry, but could not be isolated due to the low quantity (Entry 2, Table 3.5). The main 
products were piperazine 102 and dimeric compounds. The occurrence of intermolecular 
coupling reactions demonstrated that the conditions were effective for aryl coupling, even 
though not in an intramolecular manner.  
Taking into the consideration that the bulky tributyltin group might have a negative effect on 




hexamethyldistannane was tested. However, a similar result was obtained without changing 
the reaction pattern (Entry 3, Table 3.5). 
 
Table 3.5 
Entry Substrate Coupling conditions* Reaction outcome 
1 171 Pd(PPh3)4, n-Bu6Sn2, 
PhMe, 120 oC, 20 h  
Deiodination and 
stannylation 
2 213 Pd(PPh3)4, n-Bu6Sn2, 
DMF, 80 oC, 12 h 
Deiodination and 
intermolecular coupling 
3 171 Pd(PPh3)4, Me6Sn2, 
DMF, 80 oC, 12 h 
Deiodination and 
intermolecular coupling 
4 171 Pd(PPh3)4, n-Bu6Sn2, 
DMF, MW, 80 oC, 1 h 
Partial deiodination 
5 171 Pd(PPh3)2Cl2, n-Bu 6Sn2, 
DMF, 80 oC, 12 h 
Deiodination 
* All reactions were carried out with anhydrous solvents under Ar atmosphere.  
 
Further efforts were made by using microwave irradiation or employing Pd(PPh3)2Cl2 as the 
catalyst (Entry 4 and 5, Table 3.5). Unfortunately, piperazine 101 was the only compound that 
could be isolated from the reaction mixtures. At this stage, it seemed clear that Stille-Kelly 
coupling might not be the suitable method for the cyclisation of our piperazine substrates or 
even DKP derivatives, since the attempted coupling reaction with DKP 211 also failed to give 







The method developed by Li was also examined by treating bis-iodide 171 with Pd(0) and Zn 
in aqueous acetone.106 However, the reaction did not proceed in the same manner as reported 




Bearing in mind the difficulty with intramolecular coupling of piperazines, the Pd-catalysed 
direct coupling of aryl halides was not investigated in detail. Especially these methods are still 
at their infancies and the methodologies have been developed mainly with simple substrates.  
 
3.3 C–C Bond Formation from Organochalcogenides 
In order to improve the yields of the cyclised piperazine products for further manipulations 
towards herquline A and B, another C–C bond formation strategy was studied, that is, the 
extrusion reactions of organochalcogenides. Specifically, it has been reported that 
organotellurides (or organosulfides) could undergo detelluration (or sulfur expulsion) process 
to afford coupling products with the formation of new C–C bonds.109-111 The substrates 




dialkyl and dialkenyl ones. Relevant to our project, mainly the formation of Csp2–Csp2 bonds 
is introduced here. 
3.3.1 Introduction 
The initial disclosure of C–C bond formation from organotellurium intermediates was 
reported by Bergman and co-workers in the 1970s.109 Treatment of diaryltellurium dichloride 
221 with degassed Raney nickel in refluxing bis(2-methoxyethyl) ether afforded 4,4'-




Milder conditions for similar transformations were later disclosed by Uemura and co-
workers.112 They carried out the reactions with PdCl2 (2 eq.) and NaOAc (4 eq.) in refluxing 
acetic acid and obtained homo-coupling products in moderate yields (Scheme 3.40). Even 
though the palladium catalyst was used in superstoichiometric quantities and the reaction 




The conversion of telluride R1–Te–R2 into the coupled product R1–R2 has made this 




C bond formation could be fashioned with several types of tellurides, such as diaryl-, dialkyl- 




Upon treatment with a stoichiometric amount of Pd(OAc)2 and an excess of triethylamine in 
acetonitrile, bis(4-methoxyphenyl)telluride 224 was successfully converted to dianisyl 141 
quantitatively (Scheme 3.41). In the case of ditelluride 225, which was much less reactive 
than 224, the coupling reaction was performed in HMPA and 141 was delivered in 82% yield.  
The reaction with dialkyltelluride, such as 226, also proceeded smoothly to afford 227 in 81% 
yield. Interestingly, no intermolecular coupling was observed when this unsymmetrical 
telluride was employed as the substrate. Barton and co-workers postulated a working 
hypothesis that certain Pd–Te bonding during the process should be responsible for the 
success of these coupling reactions (Scheme 3.42). While this proposed pathway may not be 
necessarily correct and precise, it is very inspirational for further investigation on this 







The use of substoichiometric amounts of palladium catalyst for detelluration has been 
developed initially with dialkenyltellurides and dialkyltellurides. As shown in Scheme 3.43, 
upon treating symmetrical bis(arylethynyl)tellurides 233 with a catalytic amount of Pd(OAc)2, 
triethylamine and AgOAc additive in DMF at room temperature, homo-coupling products 




Uemura and co-workers found that complex products were usually observed during the Pd-




When (Z)-phenyl styryl telluride 235 was subjected to the coupling conditions, the isomeric 
mixture of 1,3-dienes 236 were isolated in high overall yield, with the Z, Z isomer as the main 




formation of dienes, a small amount of stilbene 237 was also identified. This favourable 
formation of dienes 236 (R1–R1 or R2–R2) rather than 237 (R1–R2) from unsymmetrical 
telluride (R1–Te–R2) was in sharp contrast to the observation by Barton and co-workers (R1–
R2 formation). It might be possible that the stoichiometry variations of palladium catalyst had 
an impact on the outcome of the reactions. In addition, the preferential formation of 236 to 
237 indicated that the phenyl moiety might be less labile for this type of reaction than the 
vinyl moiety attached to the same Te atom. Therefore, the transmetallation of Te with Pd 
being more facile at the vinylic carbon than at the aryl carbon might be another explanation 
for the unmatched phenomena. 
Uemura and co-workers also proposed a catalytic cycle of the coupling reaction in their study 
(Figure 3.8). According to this putative mechanism, an organic Te–Pd complex was formed 
initially (stage I) followed by transmetallation (stage II) to give an organopalladium 
intermediate. Upon reacting with another organotellurium species, a diorganopalladium was 








While detellurations could be furnished under mild conditions, the extrusion reactions with 




Hauptmann and co-workers reported in 1958 that biphenyl derivatives could form in high 
yields after treating aromatic thioethers, disulfides or thioesters with Raney nickel at 220 oC 
(Scheme 3.45).111 It was also pointed out that a mixture of products were usually isolated 
when unsymmetrical substrate was used. 
 
3.3.2 Application to the Intramolecular Coupling of Piperazine Substrates 
Even though the extrusion reactions have been studied mainly with simple substrates in the 
literature, this appealing strategy provided reasonable blueprints for the synthesis of our cyclic 
biaryl intermediates for herquline synthesis. Similar to the metal-mediated coupling methods, 
the two aromatic rings were also expected to be linked together via a tellurium or sulfur atom 
in this approach (Scheme 3.46). And the resultant tellurides or sulfides 241 were assumed to 
be isolable entities. At a practical level, the formation of these cyclic tellurides or sulfides 






Our efforts towards the synthesis of organotellurides commenced with several model 
reactions using 4-iodoanisole as the substrate. The efficient protocol reported by Jin and co-
workers was initially tested. It was reported that the reaction of aryl iodide, elemental 
tellurium and KOH in DMSO at high temperature led to symmetrical diaryl telluride in good 
to excellent yields (Scheme 3.47).115 A variety of aryl iodides with either electron-




According to the mechanism that was postulated by Jin and co-workers, the active tellurium 
species was K2Te, which was generated from the disproportionation reaction between Te
0 and 
KOH. For the displacement of iodine by tellurium, a single electron transfer mechanism was 
proposed, which belonged to the SRN1 type reaction (radical-nucleophilic aromatic 
substitution). As exemplified in Scheme 3.48, the electron transfer from Te2- or ArTe- to aryl 
iodide would generate an aryl iodide anion radical which could possibly collapse into an aryl 







Following the same procedure, the telluration reaction did not proceed at all with 4-
iodoanisole in our case (Scheme 3.49). Only starting material was recovered after the reported 




An alternative method for the generation of Te2- is by treating tellurium element with a 
reducing agent such as NaH (Scheme 3.50).116 A variety of symmetrical aromatic tellurides 





Accordingly, another model reaction was performed by adding 4-iodoanisole to the newly 
prepared Na2Te suspension in DMF. Gratifyingly, bis(4-methoxyphenyl)telluride 224 was 







With this symmetrical telluride in hand, the detelluration method developed by Barton and co-
workers was initially tested. Upon exposure of 224 to a stoichiometric amount of Pd(OAc)2 
and two equivalents of triethylamine in acetonitrile, 4,4'-dimethoxybiphenyl 141 was obtained 




Having achieved the biaryl telluride synthesis and the subsequent Pd-catalysed C–C bond 
formation in the model reactions, we then investigated the application of this two-step 
sequence to the piperazine system. The primary task was the synthesis of cyclic piperazine 
intermediate with a Te bridge. Initial subjection of bis-aryl iodide 213 to the telluration 
conditions we adopted in the model reaction did not produce the desired product 244 (Scheme 
3.53). From the reaction mixture only isolated deiodinated material. After close scrutiny of 
the mass spectrum, tellurium type isotope distributions were observed. However, no structures 




The reaction with DKP substrate 219 suffered a similar fate. While the proto-deiodination was 
the dominating process, a degree of isomerisation also took place under the reaction 







It was difficult to draw any conclusions from the failure of the cyclic telluride formation. 
However, based on the mechanism depicted in Scheme 3.48, one could conceive that a 
diradical piperazine intermediate (piperazine with Ar• and ArTe• radical moieties) would 
need to be generated in order to fashion an intramolecular coupling reaction. While the ease 
of generation and the stability of such a diradical species were not clear, the desired reaction 
pathway might be challenging and unfavourable. 
Besides the diaryl telluride synthesis, various methods have been developed towards C–S 
bond formations, which could serve as an alternative approach to the chalcogen atom-bridged 
piperazine target. 
The copper-catalysed sulfuration of aryl iodide developed by Duan and Li employed the 





Under optimised conditions, a wide range of symmetrical diaryl sulfides 247 were synthesised 




Presumably, diaryl sulfide was formed in a stepwise fashion, with a thiophenolate anion as the 
intermediate. 
Due to its experimental simplicity and a high level of functional group toleration, this 
sulfuration method was initially tested with both piperazine 213 and DKP derivative 219 




However, no positive results were obtained after subjecting the two substrates to similar 
reaction conditions as reported. A large degree of deiodination was observed in both cases, 
along with recovery of part of the starting materials. In the case of the attempted cyclisation 
with 219, isomeric products were also obtained due to the basic reaction conditions. 
In contrast to Cu-catalysed C–S bond forming reactions, diaryl sulfides could be synthesised 
at lower temperature. It has been reported that benzene could react with S2Cl2 in the presence 
of AlCl3 to give biphenyl sulfide.
118 This potentially useful reaction might consist of two 
electrophilic aromatic substitution steps. Before applying this method to the piperazine system, 




4-chloroanisole to S2Cl2 and AlCl3 in dichloromethane, it was pleasing to see the formation of 




Fascinated by the palladium-catalysed detelluration of diaryl tellurides, the extrusion of the 
sulfur atom within 251 was also attempted with the combination of Pd(OAc)2 and 
triethylamine. However, no reaction occurred in this case. This inertness might be due to the 
strong C–S bond compared with the C–Te bond. It was then hoped that the alternative Raney 
nickel-mediated conversion of diaryl sulfide to biaryl product would be an efficient 
transformation to form the desired C–C bond. 
The intramolecular sulfuration was explored first with DKP substrates (Scheme 3.58). When 
96 was treated with S2Cl2 and AlCl3, mainly starting material was recovered with dimeric 
products being detected by mass spectrometry. Further diluting the reaction mixture did not 
essentially change the outcome. For the reaction with bis-phenol 112 as the substrate, no 







Effort has also been made on the synthesis of cyclic sulfoxide that was anticipated to be 
converted to sulfide after subsequent deoxygenation.119,120 However, no promising result was 
achieved in this approach (Scheme 3.59). While the employed conditions mainly effected the 
debenzylation of DKP 99, the reaction between bis-phenol 112 and thionyl chloride in the 
presence of AlCl3 gave a mixture of products, without the formation of the desired diaryl 




At this stage, most attempts to the synthesis of biaryl piperazines had been fruitless. Since the 
yields of the piperazine coupling products from the Pd-catalysed Suzuki-Miyaura coupling 
approach were too low, the synthesis was not carried on for further transformations. However, 
the less efficiency of the intramolecular piperazine coupling than the DKP coupling indicated 
a conformational difference between these two classes of substrates, which is analysed below.   
 
3.4 Comparison of the Conformation of DKPs and Piperazines 
Thorough experimentation revealed that the intramolecular coupling of piperazines could be 
accomplished, but the reactions were not as satisfactorily efficient as those with DKP 
substrates. Clues for the different reactivity between these two classes of structures might be 




corresponding coupling products which were considered to be highly strained structures. 
Presumably, the final coupling products should be able to reflect the conformations of the 
intermediates involved in the transition states of the intramolecular coupling processes. 
In terms of DKP compounds, the central diketopiperazine ring is considered to be a semi-rigid 
structure and can exist in either a boat form or an essentially flat conformation (Figure 3.9).121 
Studies have shown that the boat form is the lowest-energy structure, but the energy 
difference between these two forms is small (less than 5 kcal/mol). Therefore the boat and the 
planar conformers can easily exchange with the affect of weak external forces.122  
 
Figure 3.9: Possible conformations of 2,5-diketopiperazines. 
 
It seems plausible that during the Pd-catalysed coupling reaction the DKP ring tends to adopt 
a planar conformation in which the two aromatic rings could rotate along the corresponding 
C–C bonds to render them in close proximity. Favourable side chain orientations would then 
be achieved for the new C–C bond formation. Interestingly, the X-ray crystal structure of 34 
reported by Hutton and co-workers showed that the DKP ring adopts a flattened-boat 
conformation, very close to a planar form (Figure 3.10).23 This feature, accompanied by other 
distortions balanced and minimised the steric constraint within the molecule. 
Without the cyclic amide functionalities, the piperazine ring is not as flat or rigid as the DKP 




           
Figure 3.10: Crystal structure of DKP 34 (Reproduced using data requested from the Cambridge 
Crystallographic Data Centre). 
 
Referring to the Suzuki-Miyaura coupling approach, only the reactions with piperazine 
substrates 171, 213 and 215 successfully produced small amounts of coupling products, other 
than those with 169, 217 and 161 (Figure 3.11), which were initially proposed to be the 
superior substrates for intramolecular aryl coupling according to the conformational analysis 






On the one hand, while all the piperazines 171, 213 and 215 tend to adopt chair conformations 
at room temperature, conformational equilibrium might provide a substantial extent of 
favourable conformers for the intramolecular coupling process under the Pd-catalysed 
reaction conditions. In the cases of 169, 217 and 161, even though the piperazine rings were 
assumed to exist in a large degree of the boat conformers with the methylene groups in the 
pseudo-axial positions, the orientations of the two aromatic rings might be unsuitable for the 
formation of the biaryl linkage. 
On the other hand, one could imagine that the piperazine coupling products 173, 214 and 216 
would represent a class of strained structures, even though no X-ray crystal structures were 
obtained. Referring to the relevant structure of piperazinomycin (21), the piperazine ring 
prefers to exist in a chair form, which was supported by the crystal structure of this natural 
product (Figure 3.12).18  
          
Figure 3.12: Piperazinomycin and its X-ray crystal structure (Reproduced using data requested from the 
Cambridge Crystallographic Data Centre). 
 
While it is unlikely that the piperazine units within 173, 214 and 216 would adopt ordinary 
chair conformations, certain favourable dispositions would be attained by these molecules 




3.5 Attempted Transformations with Biaryl Coupling Products 
As the DKP products 114 and 220 were synthesised in the Pd-catalysed coupling approach, 
they possessed potential synthetic utility and could serve as advanced intermediates for the 
synthesis of herquline A and B. Herein, two transformations were proposed as shown in 
Scheme 3.60: the reduction of the DKP ring to a piperazine moiety and the reductive 




Our efforts started from the oxidation state adjustment of the DKP ring within 220. Treatment 
of this DKP substrate with LAH failed to afford the desired piperazine 257. Instead, 
decomposition occurred and no reduction product was detected by mass spectrometry. 
Reduction of 220 with BH3•THF complex in THF did not proceed at room temperature. When 
the reaction system was heated to reflux, slow decomposition was again observed and no 
isolable entity was delivered from the system. These negative results might reveal that the 
conversion of DKP 220 to a considerably more strained structure 257 was a difficult process. 
Alternatively, the Birch reduction of 114 could be carried out before the reduction of the DKP 
ring. Referring to the literature, while the Birch reduction of simple linear biphenyl substrate 
often led to a mixture of regioisomers,123,124 no precedent Birch reduction of cyclic rigid 




favourable and flexible product since the replacement of the Csp2–Csp2 linkage in 114 with 
the Csp3–Csp3 one would substantially reduce the strain energy within the molecule. The 
attained flexibility was also presumed to be beneficial for subsequent DKP reduction process. 
Initial conduction of the Birch reduction (Na/NH3) in the presence of proton source (EtOH or 
tBuOH) did not provide the desired product 258. Instead, an inseparable mixture of multiple 
reduced products was isolated from the reaction system. Based on NMR and mass spectral 
analysis, it was found that one aromatic ring persisted under the conditions while two double 
bonds from the other phenyl ether moiety were reduced. The obtained intermediates were 
found to be inert to a further Birch reduction. On the contrary, subjection of the symmetrical 
DKP 259 to a similar Birch reduction resulted in complete decomposition without producing 




Decomposition was also observed during the attempt in the cleavage of the Boc protecting 






Since both 173 and the potential deprotected piperazine product 256 were considered to be 
very strained molecules, it was likely that other reaction pathways dominated under acidic 
conditions to release the strain energy. 
 
3.6 Summary 
This Chapter described the investigation on Cu- and Pd-mediated intramolecular aryl coupling 
of piperazines. While the oxidative coupling of organocuprates led to oxygenated piperazine 
products exclusively, small amounts of the desired coupling products were successfully 




Further attempts in optimising the reaction conditions failed to improve the yields. And the 
low efficiency of the coupling reactions was attributed to the unfavourable conformations of 
piperazine substrates. 
In contrast to piperazines, DKP derivatives were found to be superior substrates for Suzuki-
Miyaura coupling reactions. The corresponding coupling products, analogues of the natural 




DKP coupling products were unsuccessful towards the synthesis of the herqulines. The 
conformational analysis of the diketopiperazine and piperazine substrates was also presented. 
The viability of C–C bond formation from organochalcogenides has also been tested. 
Unfortunately, our efforts were limited by the difficulty in constructing cyclic biaryl sulfides 
or tellurides from piperazine substrates. 
At this stage, all our aryl coupling approaches towards herquline A and B appeared to be 
challenging and difficult. A conceptually different strategy featuring the intramolecular 













CHAPTER 4 OXIDATIVE ENOL SILANES OR ENOLATES 
COUPLING APPROACH 
 
4.1 Initial Considerations and Retrosynthetic Analysis of Herquline A 
Our efforts in the aryl coupling approach towards herquline A and B indicated that 
piperazines were not the ideal substrates for intramolecular coupling reactions to give biaryl 
products which were considered to be the key intermediates during the synthesis. This low 
reactivity was attributed to the unfavourable conformation of piperazine substrates and the 




Close scrutiny of the structure of herquline B as shown in Scheme 4.1, one could imagine that 




more flexible than the biaryl piperazines 173, 214 and 216 possessing Csp2–Csp2 biaryl 
linkages. 
In order to perform the intramolecular coupling reaction at the piperazine stage, it seemed 
reasonable that the cyclisation of 260 would be more favourable than the previously 
investigated biaryl couplings, hoping that the flexibility brought from the two Csp3 centers 
within the 1,4-dicarbonyl moiety would compensate for the unfavourable conformation issue 
with the piperazine rings. Similarly, herquline A could derive from the cyclisation of 261 or 
its derivatives.  
Based on the above analysis, a conceptually distinct approach evolved to tackle the 
challenging cyclisation problem, that is, formation of the 1,4-diketone functionality at the 
piperazine stage. For the synthesis of herquline A whose absolute structure has been 
elucidated, success in this new strategy would require addressing its two conspicuous 
structural features: the 1,4-dicarbonyl unit and the stereochemistry within the tricyclic ring 
system. For the former one, various methods have been developed for the construction of 1,4-
diketone motifs.125,126 At a practical level, the oxidative coupling of silyl enol ethers or 
enolates provided a promising route, since no complex functionalisation of the bis-ketone 
precursors was required compared with other methods. For the generation of the asymmetric 
centers within the fused tricyclic ring, while the two stereogenic centers at C-3 and C-6 could 
derive from L-tyrosine starting material, those at C-8 and C-9 were conceived to be generated 
by using a chiral lithium amide base during the synthesis.  
As outlined in Scheme 4.2, the retrosynthesis of herquline A commenced from the 
disconnection of the 1,4-dicarbonyl group, anticipating that herquline A (1) could be 




fused tricyclic system would be constructed prior to the formation of the nine-membered ring. 
This sequence was based on the assumption that the rotational freedom of one enol silane ring 
would be constrained due to the rigidity of the tricyclic ring system, which was quite different 
from the situation with aryl coupling substrates whose two aromatic moieties could both 




Nevertheless, it was difficult to predict at this stage whether this entropic advantage would be 
beneficial or not for the intramolecular coupling to occur, considering the structure of 262. If 
this bis-silyl enol ether could be obtained with the specific stereochemistry at the C-8 and C-9 
positions, which is in accord with that of the natural product, the shape of the molecule, 




ether ring to pose away from the dienone ether coupling partner, which could be partially 
reflected by the X-ray crystal structure of herquline A (Figure 4.1). Even though the dienone 
ether ring of 262 could rotate along the C6–C14 bond to reside toward the tricycle, the 
challenge of generating a highly strained product was a concern. 
         
Figure 4.1: X-ray crystal structure of herquline A (Reproduced using data requested from the Cambridge 
Crystallographic Data Centre). 
 
Another uncertainty with this approach is the diastereoselectivity of the intramolecular 
oxidative coupling of the silyl enol ethers, as a mixture of diastereoisomers may be obtained 
with respect to the stereochemistry within the 1,4-dicarbonyl moiety. Referring to the X-ray 
crystal structure of the natural product in Figure 4.1, it can be found that the alkenyl hydrogen 
H-16 within the cyclohexenone ring poses away from the tricyclic ring system to avoid the 
potential interaction with H-9, while the two hydrogens within the 1,4-diketone unit adopt a 
cis configuration. Therefore, one could imagine that the structure possessed by herquline A 
should be one of the most favourable products with minimal steric energy, if the 
intramolecular enol silane oxidative coupling could be furnished. 
To carry on the retrosynthesis, the conjugated dienol ether derivative 262 was proposed to 
derive from 263 utilising the combination of MeMgBr/FeCl3 (the Kharasch reagent), which 




enone with high regioselectivity.127,128 Intermediate 263 could arise from 264 through a three-
step sequence involving the cleavage of the Boc protecting group, the intramolecular aza-
Michael addition of the deprotected piperazine to the enone moiety and the in situ generation 
of silyl enol ether from the resultant enolate. It was anticipated that this challenging 
transformation could be accomplished thermally by treating bis-enone 264 with TBSOTf and 
2,6-lutidine. The stereochemistry of the aza-Michael addition was expected to be directed by 
the stereogenic center at C-8 position within molecule 264 and a cis configuration would be 
adopted between H-8 and H-9.  
At this stage, it seemed clear that the stereocontrolled installation of the stereogenic center at 
C-8 within piperazine 264 would be crucial for the whole synthesis. Based on the previous 
systematic work on chiral lithium amide bases in the Simpkins group,129,131 it was proposed 
that the asymmetric deprotonation of bis-ketone 266 with a proper chiral base would generate 
the stereogenic centers at C-8 and C-15, rendering bis-enol silane 265 as the intermediate after 




Various chiral lithium amide bases have been developed and used successfully in 
enantioselective deprotonation of prochiral cyclic ketones, especially conformationally locked 




concentrated on methodology development with structurally simple substrates, few reports 
have been published regarding using chiral bases in target-oriented synthesis.132-134  
One example related to this topic is the total syntheses of chlorotetaine, bacilysin and 
anticapsin, a series of structurally similar antifungal natural products.132,133 During the 
synthesis, cyclohexanone 269, which was tethered with a six-membered ring by a methylene 
group, was deprotonated using lithium (S, S)-bis(1-phenylethyl)amide 270 and was 
subsequently converted to silyl enol ether 271 with a de of 80% (Scheme 4.4). In our case, 
even though the configuration at C-15 position of 265 would be lost in subsequent operations, 
it was anticipated that both cyclohexanones within 266 would be converted into the 
corresponding silyl enol ethers in the chiral base step, which increased the challenge of 
synthesis. 
 
Scheme 4.4: Deprotonation of cyclohexanone with chiral lithium amide base. 
 
The previously synthesised bis-phenol 105 could then serve as the precursor of bis-ketone 266. 
In the forward direction, a catalytic hydrogenation of bis-phenol 105 could be employed, 
followed by oxidation of the resultant bis-cyclohexanol to deliver the desired bis-





4.2 Introduction to the Oxidative Coupling of Enol Silanes and Enolates 
4.2.1 1,4-Dicarbonyl Formation via Enol Silane Oxidative Coupling 
Silyl enol ethers are important and versatile enol derivatives and have been employed in 
different types of C–C bond forming transformations, among which the oxidative coupling of 
two silyl enol ethers is a direct and powerful method for the construction of 1,4-dicarbonyl 
motifs. To date, a variety of oxidants have been developed for this coupling method, most of 
which are metallic species, including Ag(I), Mn(III), Ce(IV) and V(V) oxides or salts. 
In 1975, Saegusa and co-workers reported that reactions between less substituted silyl enol 
ethers and Ag2O in DMSO gave 1,4-diketones in high yields (Scheme 4.5).
135 Cyclic or more 
substituted substrates were found to be less reactive toward oxidation with Ag2O. Higher 
temperature was usually needed in these cases and relatively lower yields were obtained, such 




Unsymmetrical 1,4-diketones could be fashioned from the cross-coupling of two different 
silyl enol ethers. In this case, a superstoichiometric quantity of one coupling partner was 
usually used in order to obtain a higher degree of chemoselectivity. As exemplified by the 




delivered as the main product, due to the excess quantity and the low oxidisability of the 




A similar concept was also applied in the cross-coupling between silyl dienol ether and silyl 
enol ether in Ruzziconi and co-workers' studies (Scheme 4.7).137 Since dienol ether was more 
susceptible to oxidation with respect to silyl enol ether, upon treating 282 (1.0 eq.) and 281 




A mechanistic hypothesis has been proposed for oxidative silyl enol ether coupling.136,138 As 
shown in Scheme 4.8, one electron oxidation of silyl enol ether 284 by the oxidant would lead 
to a transient radical cation 287, which could undergo a desilylation process to generate the 
electrophilic radical 288. Cross-coupling was accomplished after the intermolecular addition 
of radical 288 to a second silyl enol ether to form radical adduct 289. After further oxidation 







This methodology was adopted by the Herzon research group in the synthesis of lomaiviticin 




Treatment of monomeric diazo-containing TMS enol ether 291 with Mn(III) 




yield, along with starting material and the undesired bis-epimer. Although the yield of this 
dimerisation was modest, the enol silane oxidative coupling approach was truly impressive to 
construct such molecular complexity.  
 
 
4.2.2 Advances in Oxidative Enolate Coupling 
Oxidative enolate coupling is another method for the convergent synthesis of 1,4-dicarbonyl 
moieties. The enolates generated in situ from the corresponding carbonyl substrates are 
oxidised directly without any separation of the enol intermediates, which is different from the 
silyl enol ether coupling strategy. The earliest studies largely focused on the C–C bond 
formation process with the stereochemical courses being rarely addressed. 
Saegusa and co-workers reported the CuCl2-mediated oxidative coupling of ketone enolates in 
1975.141 Representatively, the coupling of the lithium enolate generated from ketone 293 





Baran and co-workers published their extensive study on the intermolecular hetero-coupling 
of enolates in 2008.142,143 A wide range of 1,4-dicarbonyl compounds were synthesised from 




combining chiral oxazolidinone substrates with appropriate oxidants, synthetically useful 
levels of diastereocontrol could be achieved (Scheme 4.11). For example, treating the lithium 
enolates generated from 295 and 296 with copper(II) 2-ethylhexanoate afforded the cross-
coupled product 299 as a 1.6:1 mixture of diastereomers in 55% yield. According to the 
proposed mechanism, the observed diastereoselectivity was attributed to the Cu(II)-chelated 




The utility of intramolecular enolate coupling in natural product syntheses is more appealing 
and relevant to our project. In this case, a dienolate is usually involved and one example can 
be found in the total synthesis of actinophyllic acid (302) accomplished by Overman and co-
workers (Scheme 4.12).144 After treating racemic keto-malonate 300 with LDA, the Fe(III)-
mediated intramolecular coupling of the malonate and ketone enolates took place to afford the 
tetracyclic ketone rac-301 in 73% yield. It was noteworthy that the cyclisation proceeded 
smoothly without any protection of the indole moiety in 300 and therefore three equivalents 







The racemic ketone 301 was transformed into the indole alkaloid (±)-actinophyllic acid after 
several further operations. Following a similar sequence, the enantioselective synthesis of (-)-
actinophyllic acid was also accomplished.145  
Another application of intramolecular oxidative enolate coupling to natural product synthesis 




The bridged diketopiperazine motif possessed by stephacidin A and B was constructed 
through the oxidative coupling of the corresponding ester and amide enolates derived from 
303 (Scheme 4.13). The successful generation of the bicyclo[2.2.2]diazaoctane core within 
304 demonstrated the oxidative enolate coupling as a powerful method for C–C bond 




4.3 Initial Forward Synthesis 
Based on the retrosynthesis of herquline A, the conversion of bis-phenol 105 to bis-ketone 
266 was initially investigated. It has been reported that the production of cyclohexanones 
could be realised from the direct hydrogenation of phenol substrates. However, during this 
type of selective reduction process, designed catalysts with special supports were usually 
employed, such as the Pd/mpg-C3N4 catalyst (Pd nanoparticles supported on a mesoporous 
graphitic carbon nitride).148 With ordinary and commercially available catalysts, the selective 
catalytic hydrogenation of phenols in the literature usually led to a mixture of cyclohexanones 
and cyclohexanols, even under modified conditions.149,150 Concerned that the contamination 
of bis-ketone 266 with alcohols would be problematic for further operations, a step-wise 




Among the transition-metal catalysts that have been developed, rhodium and platinum derived 
catalysts are found to be effective for the transformation of phenols to cyclohexanols under 
mild conditions, compared with Ni, Ru or Pd catalysts, the reactions with which usually 
require higher temperature and/or pressure.151 In addition, Rh catalysts seem to be superior to 
Pt ones since the production of cyclohexane derivatives were usually observed during the 
hydrogenation of phenols with Pt catalysts, due to partial hydrogenolysis.152,153 Therefore, the 




The reactions were initially carried out with 5% Rh/C (10 wt%) under 1 atm of H2 in 
methanol or ethyl acetate at room temperature. Unfortunately, no hydrogenation was effected. 
When the pressure was increased to 5 atm, a slight degree of conversion (6%) of 105 to 306 
and the half-reduced piperazine intermediates was observed after 3 days. To drive the reaction 
to completion, a higher pressure (12 atm) was employed consequently. However, the reaction 
was still sluggish and only 32% conversion of 105 was achieved after 8 days. The use of 
Rh/Al2O3 as the catalyst was not beneficial for the progress of the reaction. Further increasing 
the catalyst loading to 20-30 wt% and warming up the reaction system (50-60 oC) were only 
slightly effective in accelerating the reaction. Most of our attempted reactions appeared not to 
be efficient in providing the desired bis-alcohol product. Due to the pressure limit on 
hydrogen supply, no hydrogenation was performed at an even higher pressure. 
In order to examine the effectiveness of the hydrogenation conditions we employed, model 
reactions were performed with mono-phenolic substrate 90 (Scheme 4.15). Surprisingly, the 
hydrogenation proceeded smoothly by treating the substrate with Rh/C (20 wt%) in methanol 
at room temperature under a H2 pressure of 10 atm. An increase in temperature in this case 




According to the NMR spectra, two diastereoisomers of the cyclohexanol derivative were 




position of the chair conformer and therefore the two isomers could be differentiated by the 
chemical shifts of the corresponding protons geminal to the secondary hydroxy group. Since 
the chemical shift of the equatorial proton is usually downfield of the axial one and the signal 
for the axial proton tends to be invariably broader, the multiplet at 3.53 ppm was assumed to 
derive from the trans-isomer 307b whose H-7 was proposed to be in the axial position.* The 
proton with a chemical shift of 3.97 ppm was then correlated to the one from the cis-isomer 
307a. Therefore, the ratio of the cis-isomer to the trans-isomer was determined to be around 
1:1. 
Interestingly, when ethyl acetate was used as the solvent, the hydrogenation favoured the cis-
alcohol, with a ratio of 8:1 for the two isomers. A trace amount of by-product arising from the 
hydrogenolytic cleavage of the hydroxy group was also isolated from the reaction system this 
time. 
While the reaction pathway for hydrogenation is still undefined and usually varies with 
different systems, it has been reported that solvent along with substrate structure, catalyst and 
other parameters could affect the stereoselectivity of the reaction.154-156  
The hydrogenation of phenol ether 91 was a more favourable transformation compared to the 
one with phenol 90 (Scheme 4.16). When the reaction was conducted in methanol at room 
temperature, all starting material was completely hydrogenated within 3 days to afford the 
desired product 308 as the major component. 
 
* The designation of cis or trans refers to the spatial location of the hydroxy group relative to the C-3 side chain 







Byproduct 309 was isolated in 17% yield in this case, indicating that the reduction of phenol 
ether tended to result in a larger degree of hydrogenolysis than that of phenol substrate under 
current conditions. 
The success of these model reactions revealed that the adopted conditions were effective and 
suitable for the hydrogenation of phenols. Theoretically, the hydrogenation of bis-phenol 105 
should be complete with sufficient reaction time, even though two phenol groups are present 
in the substrate. However, all our attempts indicated the low efficiency of these conditions. It 
is unlikely that the conformation of the substrate would have a substantially negative effect on 
hydrogenation process since no distinct steric hindrance exists to prevent the phenol moieties 
from being absorbed on the surface of the catalyst. It is possible that the catalyst was 
deactivated by the tertiary amino group within the substrate because amines have been 
reported to be potential catalyst poisons.157 
According to previous studies in the literature, the addition of organic acid to the 
hydrogenation system could prevent the inhibition or reduction of the catalyst activity by 
amino functionality.158,159 This strategy was not attempted with bis-phenol 105 due to the co-
existing acid-sensitive Boc protecting group. Instead, the hydrogenation under acidic 
conditions was conducted with bis-phenol 311, which derived from the demethylation of 







Treatment of bis-phenol 311 with Rh/C or Rh/Al2O3 in 1:8 of acetic acid and MeOH (v/v) 
under 10 atm H2 at room temperature led to a mixture of compounds after 5 days. The fully 
hydrogenated product 312 was isolated in 20% yield, along with starting material and the 
partially reduced intermediates. The products arising from hydrogenolysis process were also 
identified by mass spectrometry. 
Since no improvement was made from this approach, the neutral hydrogenation conditions 
were employed as the standard ones for our system. And the synthesis was carried on with 
this low-efficiency hydrogenation step. 
The oxidation of alcohols 307 to 313 was initially investigated as a model reaction. Under 




When the same oxidation conditions were applied to the bis-alcohol system, the desired bis-
ketone 266 was delivered as the main product, accompanied by starting material and partially 




starting material 306 had similar polarity and could not be separated by column 
chromatography. A larger excess of oxidation reagents was employed in order to drive the 
reaction to completion. However, the product was still contaminated by a small amount of 
alcohol derivatives. The complete conversion of bis-alcohol 306 to bis-ketone product was 
finally realised in 79% yield with Dess-Martin periodinane in the presence of NaHCO3 as an 




With bis-ketone 266 in hand, the double deprotonation was studied. It was envisioned that the 
enolate anions could be trapped subsequently in the form of silyl enol ethers. A first attempt 
was performed by treating substrate 266 with LDA (2.5 eq.) followed by quenching the 
reaction with TMSCl (Entry 1, Table 4.1). The bis-silyl enol ether 314 was isolated in low 
yield, along with starting material and mono-silyl enol ether intermediates. A degree of 
degradation was observed for 314 during the purification process, presumably due to the 
presence of the labile TMS groups. 
Accordingly, the bulkier TBS group was adopted to protect the bis-enolate. Either adding 
TBSCl to the bis-enolate solution or conducting the deprotonation in the presence of TBSCl, 






Entry Deprotonation conditions Quenching method Reaction outcome 
1 LDA (2.5 eq.), -78 oC, 1 h  TMSCl (5.0 eq.),        
-78 oC to 0 oC 
314 (19%), 266 and 
other intermediates 
2 LDA (3.0 eq.), -78 oC, 1 h TBSCl (6.0 eq.),         
-78 oC to 0 oC (or rt) 
315 (11%), 266 and 
other intermediates 
3 317 (3.0 eq.), -78 oC, 1 h TBSOTf (6.0 eq.),         
-78 oC to 0 oC 
315 (44%) and other 
intermediates 
4 317 (4.0 eq.), -78 oC, 1 h TBSOTf (8.0 eq.),         
-78 oC to 0 oC 
315 (48%) 
5 316 (4.0 eq.), -78 oC, 1 h TBSOTf (8.0 eq.),         




Considering that TBSOTf is far more reactive than TBSCl, the bis-enolate was reacted with 
TBSOTf after the deprotonation of 266 with lithium amide chiral base 317 (Entry 3, Table 
4.1). Improvement was made in this case since no starting material remained. Bis-silyl enol 
ether 315 was the main product, accompanied by mono-silyl enol ethers. Presumably, 315a 
was the major diastereoisomer obtained from the asymmetric double enolisation process 
according to previous studies on the deprotonation of cyclohexanones with this specific chiral 




beneficial for improving the yield of 315, as shown in Entry 4 in Table 4.1. The use of chiral 
lithium amide base 316 gave a comparable result to the reaction with 317 (Entry 5, Table 4.1). 
At this stage, it turned out that the hydrogenation and the enol silane synthesis were 
challenging operations with our system since both of the two phenol rings within 105 or 
cyclohexanone moieties in 266 should react during the corresponding transformations. Even 
though the formation of bis-silyl enol ether 315 was confirmed by 1H NMR and mass spectra, 
insufficient material was brought up for the conversion of 315 to the more stable bis-enone 
264 according to the retrosynthesis of herquline A in Section 4.1 and the diastereoselectivity 
of the chiral base step was not determined. 
To solve the material supply issue, another approach was considered. According to the model 
reaction in Scheme 4.15, hydrogenation of tyrosine derivative 90 could readily deliver alcohol 
307, which might serve as the starting material for bis-ketone 266. Even though a mixture of 
diastereomers would be delivered in each of the following transformations due to the 
existence of the isomeric alcohol functionalities, it was anticipated that these stereogenic 
centers were not consequential for the synthesis and all isomers would be converted to the 






Acid 319 was initially synthesised as a mixture of two diastereoisomers after the hydrolysis of 
307 (Scheme 4.20). Deprotection of 307 with TFA in DCM delivered amine 318 in 81% yield. 
Following a similar procedure as we previously employed, the coupling reaction between acid 
319 and amine 318 gave amide 320, which was confirmed by NMR spectroscopy and mass 
spectrometry. Regrettably, the following deprotection and cyclisation steps afforded a 
complex mixture of products. While the formation of DKP 321 was supported by mass 
spectrometry, the yield was very low and the NMR spectra were complex at this stage. This 
route was finally abandoned and the synthetic plan was reconsidered.  
 
4.4 Revised Retrosynthesis 
As an alternative approach, formation of the 1,4-diketone moiety could be fashioned at an 
early stage (Scheme 4.21). The C10–C17 linkage within 322 would be anticipated to facilitate 
the intramolecular aza-Michael addition reaction after the isomerisation of one double bond to 
its conjugated enone form to give herquline A. Potentially, the synthesis of 322 would also 




This advanced bis-ketone structure 322 could derive from the oxidative coupling of the 




325 (Scheme 4.22). It was noteworthy that the intramolecular coupling at the piperazine stage 
in this approach was comparable to the direct oxidative phenol coupling and the transition 
metal-mediated aryl coupling, which appeared to be difficult transformations. However, it 
was envisioned that the formation of diketone 322 should be more favourable since the Csp3–
Csp3 linkage within the 1,4-dicarbonyl group would increase the flexibility of the molecular 
structure, in contrast to the Csp2–Csp2 linkages possessed by biaryl coupling products which 




Noting that although no precedent examples of oxidative coupling between two conjugated 
dienolate derivatives, such as 323 and 324, have been reported, it was anticipated that both of 
the two intermediates could undergo similar oxidative coupling processes to those involving 
simple enolate substrates as introduced in Section 4.2.1 and 4.2.2. Moreover, diketone 322 




intramolecular manner. Only the formation of the two stereogenic centers at C10 and C17 
remained to be negotiated during the synthesis. 
Assuming this sequence to be feasible, the formation of piperazine intermediate 323 or 324 
could be realised from the selective deprotonation of bis-ketone 325 which would derive from 
precursor 326. Instead of using hydrogenation methods to reduce the aromatic rings, it was 
anticipated that the Birch reduction of 326 followed by hydrolysis would gave the bis-ketone 
product.  
 
4.5 Formation of the 1,4-Dicarbonyl Functionality 
Exploration on the envisioned route towards herquline A and B commenced from the Birch 






Bis-diene 327 was successfully afforded after the subjection of 158 to standard Birch 
reduction conditions with sufficient reaction time. It was noticed that this intermediate was 
not stable and tended to rearomatise during the work-up process. The crude product was then 
treated with PhSO2Cl and DIPEA to give the benzenesulfonyl-protected piperazine 328, 
which was hydrolysed readily to bis-ketone 329 upon treatment with oxalic acid. Mono-
ketone 330 and 160 were also isolated from the reaction mixture, possibly due to the 
rearomatisation of the cyclohexadiene moieties during the course of several operations.  
Following a similar procedure, bis-ketones 333 and 334 were also reached from 159 and 101 
respectively (Scheme 4.24). Even though the overall yields for these sequences were 
relatively low, the success in the synthesis of the advanced piperazine intermediates 329, 333 
and 334 provided a chance for the investigation of the intriguing intramolecular oxidative 
enolate or enol silane coupling, a key step for the construction of the 1,4-diketone unit within 




Before moving on, model reactions of oxidative enolate or enol silane coupling were 
performed with simple substrates (Scheme 4.25). With CuCl2 as the oxidant, the oxidative 
coupling of the lithium enolate derived from cyclohexanone 335 delivered predominantly the 




trace amount of 279b. A comparable result was obtained from CAN-mediated oxidative 
coupling of silyl enol ether 336. Since TBS enol ethers were not employed frequently as the 
substrates for oxidative coupling reactions in the literature, this positive outcome revealed that 
the enol silane with a bulkier silyl group than TMS could also serve as a coupling partner in 




The intramolecular oxidative coupling of silyl enol ethers was primarily investigated with the 






Upon treatment of bis-dienone 329 with LHMDS, followed by trapping the bis-dienolate with 
TBSOTf, bis-silyl enol ether 337 was proposed to be the main product since the 
regioselectivity of the enolisation was confirmed with ketone 330 which was converted 




However, the purification of 337 was found to be difficult due to partial regeneration of the 
corresponding ketone intermediates. Subjection of the crude sample of 337 to CAN-mediated 
oxidation in acetonitrile gave no cyclised product. Only isomerised bis-ketones were 
produced according to the 1H NMR spectra and dimeric compounds were also detected by 
mass spectrometry. 
The intramolecular enolate oxidative coupling approach was attempted with several different 
substrates, as shown in Scheme 4.28. Extensive experimentation revealed that the 
intramolecular oxidative coupling was not a favourable process. Specifically, when CuBr2 
was employed as the oxidant, the reaction involving 333 or unsymmetrical piperazine 334 
delivered mainly isomerised bis-ketones and dimeric products, without any detection of the 
coupling products by mass spectrometry. 
In the case of 329, similar reaction pathways were observed. Noteworthily, a trace amount of 
the desired bis-ketone 338 was isolated from the reaction system this time and was further 




603.1597 which matches the molecular formula of product 338 (C30H32N2O6S2Na requires 
603.1600). Even though this new entity was not fully characterised due to the low quantity, it 




To modify the coupling conditions, other oxidants were examined, such as Fe(acac)3 and 
CuCl2. While the reaction with CuCl2 provided a similar result to that with CuBr2, the use of 
Fe(acac)3 as the oxidant was found to be less efficient. Further attempts using LDA or 
NaHMDS as alternative bases in the enolisation step led to no improvement.  
Bis-ketone 266 was also employed as the substrate for the oxidative enolate coupling protocol 
(Scheme 4.29). Upon treating the isomeric enolates derived from 266 with CuBr2, only 






In the cases of the oxidative coupling of bis-silyl enol ethers 315, the regeneration of 266 
proceeded exclusively without giving any traces of coupling products (Scheme 4.30). 
Scheme 4.30 
 
The intramolecular coupling once again turned out to be a pitfall for the total synthesis. 
According to our previous efforts, DKP substrates tended to give better results than the 
corresponding piperazines in the intramolecular aryl coupling reactions. To obtain suitable 
DKP substrates for oxidative enolate or enol silane coupling, the generation of bis-enolate or 
bis-silyl enol ether from a bis-ketone precursor would be problematic due to the epimerisation 
tendency of the DKP moiety under basic conditions. It has been reported that the Birch 
reduction of silyl aryl ethers with bulkier silyl groups could deliver 1,4-dihydroaryl silyl 
ethers in high yields (Scheme 4.31).162  
 
Scheme 4.31: Birch reduction of silyl aryl ethers.162 
 
Potentially, a bis-silyl enol ether substrate could be fashioned from the Birch reduction of 
DKP 347 (Scheme 4.32). Even though the double bonds within 348 were not at the right 
positions for herquline synthesis, the oxidative coupling of 348 would provide valuable 







However, when DKP 347 was subjected to Birch reduction conditions, no desired product 
was obtained and the reaction gave a mixture of irrelevant by-products. 
 
4.6 Summary 
In summary, the oxidative enolate or enol silane coupling approach was explored. Based on 
the retrosynthesis of herquline A, an asymmetric deprotonation of bis-ketone with a chiral 
base was envisioned for the generation of the stereogenic centers within the fused tricyclic 
ring system of herquline A. While the bis-silyl enol ether was successfully fashioned, 
potentially as a mixture of diastereoisomers, the synthesis was not progressed following the 
proposed sequence due to the low efficiency of the hydrogenation step. No success was 
achieved in overcoming this material supply issue. 
For the intramolecular oxidative coupling of bis-dienolates, detailed investigation led to the 
detection of a trace amount of the coupling product with a 1,4-dicarbonyl moiety. It was 






CHAPTER 5 CONCLUSIONS 
This thesis presented the synthetic efforts from several novel approaches towards herquline A 
and B. From a tactical standpoint, the intramolecular coupling strategy was attempted as the 






Inspired by the biosynthesis of the herquline alkaloids, a biomimetic approach was initially 
explored in Chapter 2 (Route 1, Scheme 5.1). Following the successful synthesis of several 
piperazine intermediates, the direct oxidative coupling of phenol or phenol ether substrates 
was examined with different oxidants to mimic Nature's way of constructing biaryl 
intermediate 36 for the synthesis of herquline A and B. However, extensive experimentation 
failed to deliver the cyclised products.  
The advanced intermediate 130a was accessed via an intramolecular aza-Michael addition 
reaction (Scheme 5.2). Even though no further operations were performed on 130a or 131 
towards the herquline natural products, these molecules share close structural resemblance to 




The transition metal-mediated intramolecular aryl coupling strategy was emphasised in 
Chapter 3 (Route 1, Scheme 5.1). Based on conformational analysis, the reactivity of 
piperazine substrates towards intramolecular coupling was rationalised. While the oxidative 
coupling of organocuprates was unsuccessful in generating biaryl linkages, small amounts of 




coupling approach (Scheme 5.3). Due to the low quantities of these coupling products, the 




In contrast to piperazine coupling, the intramolecular Suzuki-Miyaura coupling reactions with 
DKP substrates were more efficient and the corresponding coupling products, several 
analogues of the natural product mycocyclosin, were provided in relatively higher yields. 
However, further transformations on these DKP coupling products towards herquline A and B 
turned out to be unsuccessful. 
An alternative approach was highlighted in Chapter 4, which featured an intramolecular 
oxidative coupling of enolates or enol silanes as the critical steps (Route 2 and 3, Scheme 5.1). 
Based on the retrosynthetic analysis of herquline A, a bis-silyl enol ether was synthesised in 
moderate yield. Due to the low efficiency in material supply, no further investigations were 
undertaken following this route. In terms of the oxidative coupling of the conjugated 
endocyclic dienolates or dienol silanes, trace bis-ketone product formation was successfully 







Overall, the intramolecular coupling of piperazines was conceived to be a highly desired 
process for the total synthesis of herquline A and B in this study. However, our efforts 
indicated that it was challenging and difficult to perform this transformation at the piperazine 
oxidation state. While it seems not obvious to propose an alternative synthetic approach 
towards herquline A and B, other strategy might employ different building blocks other than 
tyrosine derivatives as the starting materials and further deft tactics are awaited to address the 











CHAPTER 6 EXPERIMENTAL 
 
6.1 Materials and Methods 
All glassware was oven-dried before use unless otherwise stated. Anhydrous THF was 
distilled from sodium/benzophenone immediately prior to use, or collected from a PureSolvTM 
solvent purification system. MeOH, MeCN, Et2O and CH2Cl2 were collected from a 
PureSolvTM solvent purification system. All other solvents and reagents were used as received 
from commercial suppliers unless otherwise stated.  
All 1H NMR and 13C NMR experiments were recorded on a Bruker AC300, AVIII300, 
AVIII400, AV400 or DRX500 spectrometer at 298 K unless otherwise stated. 13C NMR 
spectra were recorded using the PENDANT pulse sequence and/or the UDEFT pulse 
sequence from the Bruker standard pulse program library. DEPT 90, DEPT 135 and two-
dimensional (COSY, HSQC or HMBC) NMR spectroscopy were used to assist the 
assignment of signals in the 1H and 13C NMR spectra where appropriate. The resonances of 
the residual solvent peaks of CDCl3 (δH = 7.26 ppm, δC = 77.16 ppm), MeOD-d4 (δH = 3.34 
ppm, δC = 49.86 ppm) or DMSO-d6 (δH = 2.50 ppm, δC = 39.52 ppm) were used as internal 
references. Chemical shifts (δ) are quoted in ppm and coupling constants (J) are quoted in Hz. 
The following abbreviations are used for multiplicity in 1H NMR spectra: s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet), br (broad) or combination of these. 
Reaction progress was monitored by thin layer chromatography (TLC) performed on Merck 
silica gel 60 F254 plates, which were visualised under UV light (254 nm) and with potassium 




silica gel 60 (230-400 mesh, Merck and Co.) and the indicated solvent systems. Infrared 
spectra were recorded on a Perkin-Elmer Spectrum 100 FTIR spectrometer. Wavelengths (ν) 
are reported in cm-1. Optical rotations were recorded as dilute solutions in the indicated 
solvents in a 25 mm glass cell using an Optical Activity PolAAr 2001 automatic polarimeter. 
The concentrations are reported in grams per 100 mL. EI mass spectra were recorded on a VG 
ZabSpec magnetic sector mass spectrometer and ESI mass spectra were recorded on a 
Micromass LCT time-of-flight mass spectrometer by the analytical services at the University 
of Birmingham. Melting points were measured with a Gallenkamp melting point apparatus 
and are uncorrected. The experiments under microwave irradiation were conducted with a 
CEM Discover S-Class microwave reaction station. The high pressure hydrogenation 
reactions were carried out with a Parr series 5500 high pressure compact reactor (100 mL). 
 
6.2 Preparative Procedures for Chapter 2 
Preparation of N-Boc-L-tyrosine methyl ester 90 
 
To a suspension of L-tyrosine methyl ester hydrochloride (3.48 g, 15.1 mmol) in DCM (30 
mL) was added Et3N (4.60 mL, 33.0 mmol) at 0 ºC and the reaction mixture was stirred for 30 
min. A solution of (Boc)2O (3.57 g, 15.9 mmol) in DCM (10 mL) was added to the mixture 
and the reaction system was warmed to rt and stirred for 12 h. Upon completion, the reaction 
mixture was washed with saturated NaHCO3 solution (30 mL) and then brine (20 mL). The 
organic layer was separated, dried over MgSO4 and concentrated under reduced pressure. The 




the eluent to provide compound 90 (3.84 g, 87% yield) as an oil, which solidified as a white 
solid in the fridge. M.p. 100-101 ºC (lit.163 m.p. 101-103 ºC); Rf = 0.40 (EtOAc/petroleum 
ether 1:1); [α]D
18
 = +46.8 (c = 1.0, CHCl3) (lit.
164 [α]D
20 = +41.2, c = 1.0, CHCl3); FTIR (film) 
νmax 3359, 2977, 2932, 1687, 1516, 1223, 1163;  
1H NMR (CDCl3, 300 MHz) δ 6.89 (d, J = 
8.4 Hz, ArH, 2H), 6.66 (d, J = 8.4 Hz, ArH, 2H), 6.28 (br s, OH, 1H), 4.97 (d, J = 8.3 Hz, NH, 
1H), 4.51-4.43 (m, CHNH, 1H), 3.64 (s, COOCH3, 3H), 2.96 (dd, J = 14.0, 6.0 Hz, ArCHaHb, 
1H), 2.89 (dd, J = 14.0, 6.2 Hz, ArCHaHb, 1H), 1.35 (s, COOC(CH3)3, 9H); 
13C NMR (CDCl3, 
100 MHz) δ 171.7 (CO2Me), 154.4 (COO
tBu), 154.3 (Ar), 129.3 (Ar), 126.4 (Ar), 114.5 (Ar), 
79.2 (COOC(CH3)3), 53.6 (CHNH), 51.3 (CO2CH3), 36.6 (ArCH2), 27.3 (COOC(CH3)3).  
The NMR data are in accord with published values.163 
 
Preparation of N-Boc-O-benzyl-L-tyrosine methyl ester 98 
 
To a mixture of compound 90 (3.00 g, 10.2 mmol) and K2CO3 (1.82 g, 13.2 mmol) in acetone 
(25 mL) was added BnBr (1.45 mL, 12.2 mmol). The mixture was heated under reflux for 10 
h and then cooled to rt. The solid was filtered off and washed with acetone (3×6 mL). The 
organic solvent was concentrated under reduced pressure and the crude product was purified 
by column chromatography using 30% ethyl acetate in petroleum ether as the eluent to afford 
compound 98 (3.68 g, 93% yield) as a white solid. M.p. 83-84 ºC (lit.165 m.p. 83-86 ºC); Rf = 
0.35 (EtOAc/petroleum ether 2:1); [α]D
19
 = +53.7 (c = 1.5, CHCl3); FTIR (film) νmax 3374, 
2957, 2928, 2871, 1745, 1713, 1511, 1242, 1225, 696; 1H NMR (CDCl3, 300 MHz) δ 7.50-
7.31 (m, ArH, 5H), 7.06 (d, J = 8.6 Hz, ArH, 2H), 6.93 (d, J = 8.6 Hz, ArH, 2H), 5.06 (s, 




3.08 (dd, J = 13.9, 5.8 Hz, ArCHaHb, 1H), 3.02 (dd, J = 13.9, 6.1 Hz, ArCHaHb, 1H), 1.45 (s, 
COOC(CH3)3, 9H); 
13C NMR (CDCl3, 100 MHz) δ 172.4 (CO2Me), 157.9 (Ar), 155.1 
(COOtBu), 137.0 (Ar), 130.3 (Ar), 128.6 (Ar), 128.3 (Ar), 128.0 (Ar), 127.5 (Ar), 114.9 (Ar), 
79.9 (COOC(CH3)3), 70.0 (PhCH2), 54.5 (CHNH), 52.2 (COOCH3), 37.5 (ArCH2), 28.3 
(COOC(CH3)3). 
The observed data are in accord with published values.165 
 
Preparation of N-Boc-O-methyl-L-tyrosine methyl ester 91 
 
A mixture of Boc-protected tyrosine derivative 90 (3.84 g, 13.0 mmol), K2CO3 (1.97 g, 14.3 
mmol) and MeI (1.20 mL, 19.3 mmol) in DMF (25 mL) was stirred for 12 h at rt. Water (40 
mL) was added to the reaction suspension and the mixture was extracted with DCM (3×30 
mL). The organic layers were combined and washed with brine (3×30 mL). After being dried 
over MgSO4 and filtration, the organic solvent was concentrated under reduced pressure to 
give a colourless oil. The crude product was purified by column chromatography eluting with 
30% ethyl acetate in petroleum ether to afford 91 (3.66 g, 91% yield) as a white solid. M.p. 
55-56 ºC (lit.166 m.p. 52-53 ºC); Rf = 0.55 (EtOAc/petroleum ether 1:1); [α]D
20
 = +55.5 (c = 
1.8, CHCl3) (lit.
167 [α]D
20 = +50.0, c = 1.8, CHCl3); FTIR (film) νmax 3374, 2977, 1745, 1715, 
1513, 1248, 1167; 1H NMR (CDCl3, 300 MHz) δ 7.05 (d, J = 8.4 Hz, ArH, 2H), 6.84 (d, J = 
8.4 Hz, ArH,  2H), 5.00 (d, J = 7.7 Hz, NH, 1H), 4.55 (dd, J = 13.8, 6.0 Hz, CHNH, 1H), 3.79 
(s, ArOCH3, 3H), 3.72 (s, COOCH3, 3H), 3.22-2.82 (m, ArCH2, 2H), 1.43 (s, COOC(CH3)3, 





(Ar), 127.0 (Ar), 113.0 (Ar), 78.8 (COOC(CH3)3), 54.2 (ArOCH3), 53.6 (CHNH), 51.1 
(CO2CH3), 36.5 (CH2Ar), 27.3 (COOC(CH3)3). 
The observed data are in accord with published values.166 
 
Preparation of N-Boc-N, O-dimethyl-L-tyrosine methyl ester 93 
 
Method A: To a solution of compound 91 (2.50 g, 8.08 mmol) in anhydrous DMF (25 mL) at 
0 ºC was added MeI (0.75 mL, 12.10 mmol), followed by a suspension of NaH (60% 
dispersion in mineral oil, 0.34 g, 8.48 mmol) in DMF (3 mL). The mixture was stirred at 0 ºC 
for 1 h and then at rt overnight. Water (20 mL) was slowly added and the resulting mixture 
was extracted with DCM (3×30 mL). The organic layers were combined and washed twice 
with brine (2×15 mL). After being dried over MgSO4 and filtration, the organic solvent was 
concentrated under reduced pressure. The crude product was used in the next step without 
further purification. 
Method B: A mixture of tyrosine derivative 91 (2.50 g, 8.08 mmol), Ag2O (2.80 g, 12.10 
mmol) and MeI (0.75 mL, 12.10 mmol) in anhydrous DMF (20 mL) was stirred at rt for 36 h. 
The reaction system was diluted with ethyl acetate (25 mL) and the resulting mixture was 
filtered through a layer of Celite pad. The solid was washed twice with ethyl acetate (2×15 
mL) and the filtrate was transferred to a separating funnel. The organic phase was washed 
with brine (3×20 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
product was purified by column chromatography eluting with 30% ethyl acetate in petroleum 




(EtOAc/petroleum ether 1:1); [α]D
18
 = -56.9 (c = 1.0, CHCl3); FTIR (film) νmax 2976, 1743, 
1694, 1514, 1248, 1176; 1H NMR (CDCl3, 300 MHz) (major rotamer) δ 7.12 (d, J = 8.4 Hz, 
ArH, 2H), 6.84 (d, J = 8.4 Hz, ArH, 2H), 4.48 (dd, J = 10.7, 4.6 Hz, CHNMe, 1H), 3.79 (s, 
ArOCH3, 3H), 3.76 (s, COOCH3, 3H), 3.22 (dd, J = 14.4, 4.6 Hz, ArCHaHb, 1H), 2.97 (dd, J 
= 14.4, 10.7 Hz, ArCHaHb, 1H), 2.73 (s, NCH3, 3H), 1.36 (s, COOC(CH3)3, 9H); 
13C NMR 
(CDCl3, 100 MHz) (major rotamer) δ 175.5 (CO2Me), 158.4 (Ar), 155.0 (COO
tBu), 129.9 
(Ar), 129.6 (Ar), 113.5 (Ar), 80.1 (COOC(CH3)3), 61.8 (CHNMe), 52.0 (COOCH3), 34.6 
(ArCH2CH), 32.6 (NCH3), 28.3 (COOC(CH3)3). 
The observed data are in accord with published values.168 
 
Preparation of N-Boc-N-methyl-O-benzyl-L-tyrosine methyl ester 349 
 
N-Boc-N-methyl-O-benzyl-L-tyrosine methyl ester 349 was prepared from 98 (1.36 g, 3.53 
mmol) following a similar procedure to that for the synthesis of 93 (Method B) and was 
obtained as a white solid (1.27 g, 3.18 mmol, 90% yield). M.p. 131-132 oC (lit.169 m.p. 130-
134 ºC); Rf = 0.65 (EtOAc/petroleum ether 1:1); [α]D
20
 = -68 (c = 1.2, CHCl3); FTIR (film) 
νmax 3035, 2976, 1742, 1693, 1512, 1223, 1174, 1142; 
1H NMR (CDCl3, 300 MHz) (major 
rotamer) δ 7.46-7.33 (m, ArH, 5H), 7.13 (d, J = 8.4 Hz, ArH, 2H), 6.93 (d, J = 8.4 Hz, ArH, 
2H), 5.05 (s, PhCH2, 2H), 4.50 (dd, J = 10.8, 5.0 Hz, CHNMe, 1H), 3.76 (s, COOCH3, 3H), 
3.26 (dd, J = 14.0, 5.0 Hz, ArCHaHb, 1H), 2.98 (dd, J = 14.0, 10.8 Hz, ArCHaHb, 1H), 2.75 (s, 
NCH3, 3H), 1.37 (s, COOC(CH3)3, 9H); 
13C NMR (CDCl3, 100 MHz) (major rotamer) δ 
171.6 (CO2Me), 157.6 (Ar), 155.8 (COO




127.4 (Ar), 115.0 (Ar), 114.8 (Ar), 80.2 (COOC(CH3)3), 70.1 (PhCH2), 61.8 (CHNMe), 52.1 
(COOCH3), 34.7 (ArCH2CH), 32.6 (NCH3), 28.2 (COOC(CH3)3); HRMS (ESI) calculated for 
C23H30NO5 [M+H]
+ 400.2124, found 400.2120. 
 
Preparation of N, O-dimethyl-L-tyrosine methyl ester 94 
 
To a solution of N-Boc tyrosine derivative 93 (2.40 g, 7.40 mmol) in DCM (20 mL) was 
added TFA (3.0 mL, 39.2 mmol). After stirring for 5 h, saturated NaHCO3 solution (25 mL) 
was slowly added to the reaction solution. The mixture was extracted with DCM (3×30 mL). 
After being dried over MgSO4 and filtration, the organic solvent was concentrated under 
reduced pressure. The crude product was purified by column chromatography using 50% 
ethyl acetate in petroleum ether as the eluent to give tyrosine derivative 94 (1.56 g, 94% yield) 
as a colourless oil. Rf = 0.20 (EtOAc); [α]D
19
 = +25.5 (c = 0.7, CHCl3) (lit.
170 [α]D
23 = +24, c = 
0.65, CHCl3); FTIR (film) νmax 3339, 2950, 2837, 1732, 1512, 1245, 1174, 1033; 
1H NMR 
(CDCl3, 300 MHz) δ 7.09 (d, J = 8.4 Hz, ArH, 2H), 6.84 (d, J = 8.4 Hz, ArH, 2H), 3.79 (s, 
ArOCH3, 3H), 3.68 (s, COOCH3, 3H), 3.43 (t, CHNH, J = 6.6 Hz, 1H), 2.91 (d, J = 6.6 Hz, 
ArCH2, 2H), 2.37 (s, NCH3, 3H); 
13C NMR (CDCl3, 100 MHz) δ 174.7 (COOCH3), 158.5 
(Ar), 130.1 (Ar), 129.1 (Ar), 113.9 (Ar), 64.8 (CHNH), 55.2 (ArOCH3), 51.6 (COOCH3), 
38.5 (ArCH2), 34.7 (NCH3). 






Preparation of N-methyl-O-benzyl-L-tyrosine methyl ester 350 
 
N-methyl-O-Benzyl-L-tyrosine methyl ester 350 was prepared from 349 (1.24 g, 3.10 mmol) 
following a similar procedure to that for the synthesis of 94. Compound 350 was obtained as a 
colourless oil (0.83 g, 2.76 mmol, 89% yield). Rf = 0.25 (EtOAc); [α]D
20
 = +27.5 (c = 1.0, 
CHCl3) (lit.
170 [α]D
23 = +20, c = 1.0, CHCl3); FTIR (film) νmax 3338, 3032, 2949, 2799, 1732, 
1511, 1238, 1016, 736; 1H NMR (CDCl3, 300 MHz) δ 7.49-7.32 (m, ArH, 5H), 7.11 (d, J = 
8.6 Hz, ArH, 2H), 6.92 (d, J = 8.6 Hz, ArH, 2H), 5.06 (s, PhCH2, 2H), 3.69 (s, COOCH3, 3H), 
3.44 (t, J = 6.8 Hz, CHNMe, 1H), 2.92 (d, J = 6.8 Hz, ArCH2, 2H), 2.38 (s, NCH3, 3H); 
13C 
NMR (CDCl3, 100 MHz) δ 174.6 (COOMe), 157.7 (Ar), 137.1 (Ar), 130.1 (Ar), 129.3 (Ar), 
128.6 (Ar), 127.9 (Ar), 127.5 (Ar), 114.9 (Ar), 70.0 (PhCH2), 64.7 (CHNMe), 51.7 
(COOCH3), 38.5 (ArCH2), 34.7 (NCH3). 
The observed data are in accord with published values.170 
 
Preparation of N-Boc-O-methyl tyrosine 92 
 
To a solution of compound 91 (2.97 g, 9.60 mmol) in THF (8 mL), MeOH (8 mL) and H2O (6 
mL) was added lithium hydroxide monohydrate (0.61 g, 14.4 mmol) at 0 oC. The mixture was 
stirred at 0 oC for 1 h and then at rt for 6 h. To the hydrolysis system was added water (15 mL) 
and the pH of the reaction system was adjusted to 4~5 with 5% HCl (aq). The mixture was 




After filtration and concentration, the crude product was purified by column chromatography 
using 50% ethyl acetate in petroleum ether as the eluent to give acid 92 (2.76 g, 97% yield) as 
a colourless oil which solidified in the fridge. M.p. 95-96 ºC (lit.171 m.p. 92-94 ºC); Rf = 0.35 
(EtOAc/petroleum ether 1:2); [α]D
20
 = +39.5 (c = 1.0, EtOH) (lit.
171 [α]D
25 = +42.2, c = 1.0, 
EtOH); FTIR (film) νmax 3322, 2978, 2933, 1714, 1513, 1248, 1164; 
1H NMR (CDCl3, 300 
MHz) (major rotamer) δ 7.12 (d, J = 8.6 Hz, ArH, 2H), 6.86 (d, J = 8.6 Hz, ArH, 2H), 4.96 (d, 
J = 7.8 Hz, NH, 1H), 4.59 (dd, J = 12.6, 7.8 Hz, CHNH, 1H), 3.81 (s, OCH3, 3H), 3.18-3.02 
(m, ArCH2, 2H), 1.44 (s, COOC(CH3)3, 9H); 
13C NMR (CDCl3, 100 MHz) (major rotamer) δ 
176.5 (COOH), 158.7 (Ar), 155.4 (COOtBu), 130.4 (Ar), 127.7 (Ar), 114.1 (Ar), 80.3 
(COOC(CH3)3), 55.2 (OCH3), 54.4 (CHNH), 36.9 (ArCH2), 28.3 (COOC(CH3)3). 
The observed data are in accord with published values.171 
 
Preparation of N-Boc-O-benzyl tyrosine 351 
 
N-Boc-O-benzyl-L-tyrosine 351 was prepared from 98 (1.80 g, 4.67 mmol) following a 
similar procedure to that for the synthesis of 92. Compound 351 was obtained as a white solid 
(1.54 g, 4.15 mmol, 89% yield). M.p. 106-108 ºC (lit.172 m.p. 109-111 ºC); Rf = 0.40 
(EtOAc/petroleum ether 1:2); [α]D
20
 = +17.4 (c = 2.0, CHCl3); FTIR (film) νmax 3429, 3320, 
2979, 2557, 1711, 1511, 1240, 1161, 734; 1H NMR (CDCl3, 300 MHz) (major rotamer) δ 
10.63 (br s, COOH, 1H), 7.48-7.26 (m, ArH, 5H), 7.13 (d, J = 8.4 Hz, ArH, 2H), 6.95 (d, J = 
8.4 Hz, ArH, 2H), 5.06 (s, PhCH2, 2H), 5.07-4.97 (m, NH, 1H), 4.62 (dd, J = 13.1, 5.8 Hz, 




ArCHaHbCH, 1H), 1.46 (s, COOC(CH3)3, 9H); 
13C NMR (CDCl3, 100 MHz) (major rotamer) 
δ 176.7 (COOH), 158.0 (Ar), 155.4 (COOtBu), 137.0 (Ar), 130.5 (Ar), 128.6 (Ar), 128.1 (Ar), 
128.0 (Ar), 127.5 (Ar), 115.0 (Ar), 80.3 (COOC(CH3)3), 70.0 (PhCH2), 54.4 (CHNH), 37.0 
(ArCH2CH), 28.3 (COOC(CH3)3). 
The observed data are in accord with published values.172 
 
Preparation of dipeptide 95 
 
To a solution of acid 92 (0.37 g, 1.25 mmol) in DMF (8 mL) was added HATU (0.52 g, 1.38 
mmol) and the mixture was stirred for 30 min at 0 oC. A solution of amine 94 (0.28 g, 1.25 
mmol) in DMF (5 mL) was added to the reaction solution, followed by DIPEA (0.22 mL, 1.25 
mmol). The resulting mixture was warmed to rt and stirred overnight. To the system was 
added water (20 mL) and the mixture was extracted with DCM (3×20 mL). The organic layers 
were combined and washed with brine (20 mL). After being dried over MgSO4 and filtration, 
the organic solvent was concentrated under reduced pressure. The crude product was purified 
by column chromatography eluting with 25% ethyl acetate in petroleum ether to give 
dipeptide 95 (0.45 g, 71% yield) as a white solid. M.p. 114-116 ºC; Rf = 0.40 (EtOAc/ 
petroleum ether 1:2); [α]D
20
 = -45.2 (c = 1.0, CHCl3); FTIR (film) νmax 3307, 2988, 2956, 
2837, 1735, 1682, 1513, 1243, 1160, 1030; 1H NMR (CDCl3, 300 MHz) (major rotamer) δ 
7.12 (d, J = 8.4 Hz, ArH, 2H), 7.04 (d, J = 8.5 Hz, ArH, 2H), 6.81 (d, J = 8.5 Hz, ArH, 2H), 




NH, 1H), 4.71 (dd, J = 14.0, 9.2 Hz, CHNH, 1H), 3.78 (s, ArOCH3, 3H), 3.77 (s, ArOCH3, 
3H), 3.71 (s, COOCH3, 3H), 3.28 (dd, J = 14.4, 6.0 Hz, CHaHbCHNMe, 1H), 2.92 (dd, J = 
14.4, 9.7 Hz, CHaHbCHNH, 1H), 2.83 (dd, J = 9.2, 4.0 Hz, CHaHbCHNMe, 1H), 2.77 (s, 
NCH3, 3H), 2.46 (dd, J = 14.0, 4.0 Hz, CHaHbCHNH, 1H), 1.40 (s, COOC(CH3)3, 9H); 
13C 
NMR (CDCl3, 100 MHz) δ 172.2 (CONMe), 170.9 (COOMe), 158.5 (Ar), 155.0 (COO
tBu), 
130.6 (Ar), 129.9 (Ar), 128.7 (Ar), 128.4 (Ar), 113.9 (Ar), 113.8 (Ar), 79.6 (COOC(CH3)3), 
58.8 (CHNMe), 55.2 (ArOCH3), 55.1 (ArOCH3), 52.2 (COOCH3), 51.6 (CHNH), 38.3 
(CH2CHNH), 33.8 (CH2CHNMe), 32.6 (NCH3), 28.3 (COOC(CH3)3); HRMS (ESI) 
calculated for C27H36N2O7Na [M+Na]
+ 523.2420, found 523.2426. 
 
Preparation of dipeptide 352 
 
Dipeptide 352 was prepared from acid 351 (0.65 g, 1.75 mmol) and amine 350 (0.52 g, 1.75 
mmol) following a similar procedure to that for the synthesis of 95 and was obtained as a 
colourless oil (0.89 g, 1.36 mmol, 78% yield). Rf = 0.46 (EtOAc:hexane = 1:1); [α]D
20
 = -38.2 
(c = 2.2, CHCl3); FTIR (film) νmax 3425, 3317, 3033, 2979, 2932, 2879, 1740, 1706, 1645, 
1611, 1510, 1238, 1167, 1015, 732, 696; 1H NMR (CDCl3, 400 MHz) (major rotamer) δ 7.46-
7.31 (m, ArH, 10H), 7.18-7.06 (m, ArH, 3H), 6.95-6.84 (m, ArH, 5H), 5.32 (d, J = 8.8 Hz, 
NH, 1H), 5.24-5.15 (m, CHNMe, 1H), 5.04 (s, PhCH2, 2H), 5.03 (s, PhCH2, 2H), 4.79-4.73 
(m, CHNH, 1H), 3.75 (s, OCH3, 3H), 3.30 (dd, J = 14.4, 5.4 Hz, CHaHbCHNMe, 1H), 2.95 




2.58 (dd, J = 13.8, 6.4 Hz, CHaHbCHNH, 1H), 1.43 (s, COOC(CH3)3, 9H); 
13C NMR (CDCl3, 
100 MHz) δ 172.7 (CONMe), 170.9 (COOMe), 157.8 (Ar), 157.7 (Ar), 155.1 (COOtBu), 
137.1 (Ar), 136.9 (Ar), 130.0 (Ar), 129.9 (Ar), 129.1 (Ar), 128.7 (Ar), 128.6 (Ar), 127.9 (Ar), 
127.4 (Ar), 115.0 (Ar), 114.9 (Ar), 114.8 (Ar), 114.7 (Ar), 79.5 (COOC(CH3)3), 70.0 (d, 
PhCH2), 58.9 (CHNMe), 52.3 (OCH3), 51.7 (CHNH), 38.3 (CH2CHNH), 33.8 (CH2CHNMe), 
32.8 (NCH3), 28.3 (COOC(CH3)3); HRMS (ESI) calculated for C39H44N2O7Na [M+Na]
+ 
675.3046, found 675.3048;  
Although compound 352 was mentioned in the literature and confirmed by mass 
spectrometry,173 no further characterisation has been reported. 
 
Preparation of cis-diketopiperazine 96 
 
To a solution of dipeptide 95 (0.54 g, 1.08 mmol) in dry DCM (10 mL) was added TFA (1.0 
mL, 13.1 mmol) and the mixture was stirred overnight. Another portion of DCM (10 mL) was 
added to the system, followed by slow addition of saturated NaHCO3 solution (20 mL). After 
thoroughly stirring, the organic layer was separated and the aqueous layer was extracted twice 
with DCM (2×20 mL). The organic layers were combined, dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography using ethyl acetate as the eluent to afford DKP 96 (0.26 g, 62% yield) as a 
colourless oil. Rf = 0.20 (EtOAc/MeOH 6:1); [α]D
22
 = -47.5 (c = 6.5, CHCl3); FTIR (film) νmax 
3228, 2934, 1681, 1652, 1513, 1248; 1H NMR (CDCl3, 400 MHz) δ 7.11 (d, J = 8.7 Hz, H-5, 




2H), 5.68 (s, NH, 1H), 4.17 (t, J = 3.8 Hz, H-2, 1H), 3.85 (dt, J = 11.5, 2.8 Hz, H-10, 1H), 
3.78 (s, H-8 or H-16, 3H), 3.76 (s, H-16 or H-8, 3H), 3.22 (dd, J = 14.2, 3.8 Hz, H-3a, 1H), 
3.11 (dd, J = 14.2, 3.8 Hz, H-3b, 1H), 3.11 (s, H-17, 3H), 2.91 (dd, J = 13.6, 2.8 Hz, H-11a, 
1H), 0.93 (dd, J = 13.6, 11.5 Hz, H-11b, 1H); 13C NMR (CDCl3, 100 MHz) δ 165.8 (C-1 or 
C-9), 165.5 (C-9 or C-1), 159.3 (C-7), 158.8 (C-15), 131.4 (C-5), 130.1 (C-13), 128.0 (C-4 or 
C-12), 126.8 (C-12 or C-4), 114.4 (C-6 and C-14), 63.2 (C-2), 56.9 (C-10), 55.4 (C-8 or C-16), 
55.3 (C-16 or C-8), 39.8 (C-11), 35.8 (C-3), 33.1 (C-17); HRMS (ESI) calculated for 
C21H24N2O4Na [M+Na]
+ 391.1634, found 391.1649. 
 
The trans-DKP 353 was obtained as a by-product when the methylation of tyrosine derivative 
91 was conducted with Method A (NaH/MeI). M.p. 156-158 ºC; Rf = 0.20 (EtOAc); [α]D
22
 = 
+4.4 (c = 6.5, CHCl3); FTIR (film) νmax 3244, 2934, 1642, 1511, 1246; 
1H NMR (CDCl3, 400 
MHz) δ 7.01 (d, J = 8.6 Hz, H-5 or H-13, 2H), 6.92 (d, J = 8.6 Hz, H-13 or H-5, 2H), 6.83 (d, 
J = 8.6 Hz, H-6 or H-14, 2H), 6.83 (d, J = 8.6 Hz, H-14 or H-6, 2H), 5.44 (br s, NH, 1H), 4.11 
(t, J = 3.9 Hz, H-2, 1H), 3.83 (s, H-8 or H-16, 3H), 3.81 (s, H-16 or H-8, 3H), 3.26 (dd, J = 
14.0, 3.3 Hz, H-11a, 1H), 3.20 (dd, J = 14.1, 3.5 Hz, H-3a, 1H), 3.08 (dd, J = 14.0, 4.4 Hz, H-
3b, 1H), 3.07 (s, H-17, 3H), 2.61 (dd, J = 10.5, 3.3 Hz, H-10, 1H), 2.49 (dd, J = 14.0, 10.5 Hz, 
H-11b, 1H); 13C NMR (CDCl3, 100 MHz) δ 167.6 (C-9), 166.3 (C-1), 159.4 (C-7 or C-15), 
158.9 (C-15 or C-7), 131.0 (C-5), 130.0 (C-13), 127.5 (C-4 or C-12), 126.3 (C-12 or C-4), 
114.5 (C-6 or C-14), 114.2 (C-14 or C-6), 64.1 (C-2), 55.3 (C-8 and C-16), 54.0 (C-10), 37.4 
(C-11), 35.9 (C-3), 32.9 (C-17); HRMS (ESI) calculated for C21H24N2O4Na [M+Na]
+ 




Preparation of cis-diketopiperazine 99 
 
DKP derivative 99 was prepared from dipeptide 352 (0.72 g, 1.10 mmol) following a similar 
procedure to that for the synthesis of 96. Compound 99 was obtained as a colourless oil (0.42 
g, 0.80 mmol, 73% yield). Rf = 0.25 (EtOAc/MeOH 6:1); [α]D
24
 = -63 (c = 5.0, CHCl3); FTIR 
(film) νmax 3213, 2975, 2939, 1679, 1651, 1510, 1234, 1018, 730; 
1H NMR (CDCl3, 300 MHz) 
δ 7.47-7.21 (m, H-10 and H-11 and H-12 and H-22 and H-23 and H-24, 10H), 7.11 (d, J = 8.6 
Hz, H-5, 2H), 7.01 (d, J = 8.6 Hz, H-6, 2H), 6.90 (d, J = 8.6 Hz, H-18, 2H), 6.85 (d, J = 8.6 
Hz, H-17, 2H), 5.56 (d, J = 1.2 Hz, NH, 1H), 5.06 (s, H-8 or H-20, 2H), 5.05 (s, H-20 or H-8, 
2H), 4.19 (t, J = 3.8 Hz, H-2, 1H), 3.83 (m, H-14, 1H), 3.26 (dd, J = 14.2, 3.8 Hz, H-3a, 1H), 
3.13 (s, H-25, 3H), 3.12 (dd, J = 14.2, 3.8 Hz, H-3b, 1H), 2.86 (dd, J = 13.6, 2.8 Hz, H-15a, 
1H), 0.82 (dd, J = 13.6, 11.7 Hz, H-15b, 1H); 13C NMR (CDCl3, 100 MHz) δ 165.7 (C-1 or 
C-13), 165.4 (C-13 or C-1), 158.4 (C-7 or C-19), 158.0 (C-19 or C-7), 136.9 (C-9 or C-21), 
136.7 (C-21 or C-9), 131.5 (C-5), 130.2 (C-17), 128.6 (C-11 or C-23), 128.5 (C-23 or C-11), 
128.3 (C-12 or C-24), 128.0 (C-24 or C-12), 127.9 (C-16), 127.4 (C-10 or C-22), 127.2 (C-22 
or C-10), 127.0 (C-4), 115.5 (C-6), 115.4 (C-18), 70.1 (C-8 or C-20), 70.0 (C-20 or C-8), 63.2 
(C-2), 56.9 (C-14), 39.8 (C-15), 35.7 (C-3), 33.1 (C-25); HRMS (ESI) calculated for 
C33H32N2O4Na [M+Na]





The trans-DKP 108 was obtained as a by-product when the methylation of 98 was conducted 
with Method A (NaH/MeI). M.p. 165-166 ºC; Rf = 0.30 (EtOAc); [α]D
22
 = +3.0 (c = 6.5, 
CHCl3); FTIR (film) νmax 3225, 2930, 1682, 1656, 1510, 1240, 1025; 
1H NMR (CDCl3, 400 
MHz) δ 7.54-7.32 (m, H-10 and H-11 and H-12 and H-22 and H-23 and H-24, 10H), 7.02 (d, 
J = 8.6 Hz, H-5 or H-17, 2H), 6.91 (d, J = 8.6 Hz, H-17 or H-5, 2H), 6.90 (d, J = 8.6 Hz, H-6 
and H-18, 4H), 5.51 (s, NH, 1H), 5.07 (d, J = 4.3 Hz, H-8 or H-20, 2H), 5.05 (s, H-20 or H-8, 
2H), 4.10 (t, J = 3.9 Hz, H-2, 1H), 3.25 (dd, J = 14.2, 3.3 Hz, H-15a, 1H), 3.20 (dd, J = 14.0, 
3.2 Hz, H-3a, 1H), 3.09 (dd, J = 14.0, 4.4 Hz, H-3b, 1H), 3.07 (s, H-25, 3H), 2.65 (dd, J = 
10.4, 3.3 Hz, H-14, 1H), 2.52 (dd, J = 14.2, 10.4 Hz, H-15b, 1H); 13C NMR (CDCl3, 100 
MHz) δ 167.6 (C-13), 166.3 (C-1), 158.6 (C-7 or C-19), 158.1 (C-19 or C-7), 136.9 (C-9 or 
C-21), 136.7 (C-21 or C-9), 131.0 (C-5), 130.1 (C-17), 128.7 (C-11 or C-23), 128.6 (C-23 or 
C-11), 128.1 (C-12 or C-24), 128.0 (C-24 or C-12), 127.8 (C-16), 127.5 (C-10 or C-22), 127.4 
(C-22 or C-10), 126.7 (C-4), 115.5 (C-6 or C-18), 115.1 (C-18 or C-6), 70.1 (C-8 and C-20), 
64.1 (C-2), 54.0 (C-14), 37.5 (C-15), 35.9 (C-3), 32.9 (C-25); HRMS (ESI) calculated for 
C33H32N2O4Na [M+Na]
+ 543.2260, found 543.2249. 
 





At 0 ºC, to a solution of DKP 96 (0.22 g, 0.60 mmol) in anhydrous THF (10 mL) was added 
lithium aluminium hydride solution (1.0 M in THF, 1.80 mL, 1.80 mmol) dropwise. The 
system was maintained at the same temperature for 3 h and then warmed to rt. After being 
stirred for 4 days at rt, the mixture was cooled to 0 ºC and ethyl acetate (10 mL) was added to 
quench the reaction, followed by addition of saturated NaOH aqueous solution (2 mL) and 
THF (15 mL). After being stirred for 15 min, the mixture was filtered and the solid was 
washed thoroughly with DCM (4×10 mL). The filtrate was dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography using ethyl acetate/MeOH (10:1) as the eluent to afford piperazine 97 (0.13 g, 
65% yield) as a white film. Rf = 0.30 (EtOAc/MeOH 3:1); [α]D
24
 = +26.5 (c = 0.65, CHCl3); 
FTIR (film) νmax 3031, 2929, 2835, 2796, 1509, 1241, 1026, 804, 733; 
1H NMR (CDCl3, 400 
MHz) δ 7.16 (d, J = 8.4 Hz, H-5 or H-12, 2H), 7.12 (d, J = 8.4 Hz, H-12 or H-5, 2H), 6.87 (d, 
J = 8.8 Hz, H-6 or H-13, 2H), 6.84 (d, J = 8.4 Hz, H-13 or H-6, 2H), 3.81 (s, H-15 or H-16, 
3H), 3.80 (s, H-16 or H-15, 3H), 3.01 (ddd, J = 14.9, 7.5, 3.6 Hz, H-2, 1H), 2.86-2.84 (m, H-
10, 2H), 2.80-2.77 (dd, J = 11.9, 3.6 Hz, H-8a, 1H), 2.71-2.64 (m, H-3 and H-8b and H-9, 4H), 
2.51-2.46 (dd, J = 11.9, 3.6 Hz, H-1a, 1H), 2.46 (s, H-17, 3H), 2.44-2.41 (dd, J = 11.9, 3.6 Hz, 
H-1b, 1H); 13C NMR (CDCl3, 100 MHz) δ 157.1 (C-7 or C-14), 156.8 (C-14 or C-7), 131.6 
(C-4 or C-11), 130.0 (C-11 or C-4), 129.2 (C-5 or C-12), 129.1 (C-12 or C-5), 112.9 (C-6 or 
C-13), 112.8 (C-13 or C-6), 61.1 (C-9), 55.3 (C-2), 54.7 (C-1), 54.2 (C-15 and C-16), 45.7 (C-
8), 42.1 (C-17), 38.2 (C-3), 27.3 (C-10); HRMS (ESI) calculated for C21H29N2O2 [M+H]
+ 







Reduction of DKP to piperazine 100 
 
Piperazine derivative 100 was prepared from the reduction of 99 (0.36 g, 0.69 mmol) 
following a similar procedure to that for the synthesis of 97. Compound 100 was obtained as a 
white solid (0.23 g, 0.47 mmol, 68% yield). M.p. 129-131 ºC; Rf = 0.35 (EtOAc/MeOH 3:1); 
[α]D
24
 = +16.5 (c = 0.80, CHCl3); FTIR (film) νmax 3031, 2924, 2796, 1509, 1237, 1017, 801; 
1H NMR (CDCl3, 300 MHz) δ 7.40-7.20 (m, PhH, 10H), 7.06 (d, J = 8.6 Hz, H-5 or H-12, 
2H), 7.03 (d, J = 8.6 Hz, H-12 or H-5, 2H), 6.84 (d, J = 8.8 Hz, H-6 or H-13, 2H), 6.81 (d, J = 
8.8 Hz, H-13 or H-6, 2H), 4.96 (s, PhCH2, 2H), 4.94 (s, PhCH2, 2H), 3.02-2.90 (m, H-2, 1H), 
2.80-2.57 (m, H-10 and H-8 and H-3 and H-9, 7H), 2.42-2.36 (m, H-1, 2H), 2.38 (s, NCH3, 
3H); 13C NMR (CDCl3, 100 MHz) δ 157.4 (C-7 or C-14), 157.1 (C-14 or C-7), 137.2 (Ph), 
132.6 (C-4 or C-11), 131.0 (C-11 or C-4), 130.3 (C-5 or C-12), 130.2 (C-12 or C-5), 128.6 
(Ph), 127.9 (Ph), 127.5 (Ph), 114.9 (C-6 or C-13), 114.8 (C-13 or C-6), 70.1 (PhCH2), 61.9 
(C-9), 56.1 (C-2), 55.4 (C-1), 46.4 (C-8), 43.0 (NCH3), 39.0 (C-3), 28.5 (C-10); HRMS (ESI) 
calculated for C33H37N2O2 [M+H]
+ 493.2855, found 493.2863. 
 





To a solution of piperazine derivative 97 (0.51 g, 1.51 mmol) in DCM (8 mL) was added a 
solution of (Boc)2O (0.40 g, 1.81 mmol) in DCM (2 mL), followed by Et3N (0.25 mL, 1.81 
mmol). The mixture was stirred at rt for 10 h. Upon completion, DCM (10 mL) was added 
and the reaction mixture was washed with saturated NaHCO3 (aq) (10 mL). The organic layer 
was dried over MgSO4, filtered and concentrated under reduced pressure. The crude product 
was purified by column chromatography eluting with ethyl acetate/petroleum ether (1:6) to 
afford product 101 (0.51 g, 77% yield) as a white solid. M.p. 118-119 ºC; Rf = 0.60 
(EtOAc/petroleum ether 1:1); [α]D
20
 = -99 (c = 0.4, CHCl3); FTIR (film) νmax 2966, 2927, 
2862, 2792, 1688, 1612, 1511, 1243, 1165, 1035, 820; 1H NMR (CDCl3, 400 MHz) δ 7.15 (d, 
J = 8.5 Hz, H-5 and H-12, 4H), 6.85 (d, J = 8.5 Hz, H-6 and H-13, 4H), 4.15-4.04 (br m, H-2, 
1H), 3.86-3.74 (br m, H-8a, 1H), 3.80 (s, H-19 or H-20, 3H), 3.79 (s, H-20 or H-19, 3H), 3.13 
(dd, J = 13.8, 4.0 Hz, H-10a, 1H), 3.06-2.95 (br m, H-3a, 1H), 2.89-2.67 (m, H-3b and H-8b 
and H-1a, 3H), 2.55-2.47 (m, H-10b, 1H), 2.38 (s, H-15, 3H), 2.26-2.10 (m, H-1b and H-9, 
2H), 1.32 (s, H-18, 9H); 13C NMR (CDCl3, 100 MHz) δ 158.2 (C-7 or C-14), 158.1 (C-14 or 
C-7), 154.4 (C-16), 131.4 (C-4 and C-11), 130.3 (C-5 or C-12), 130.2 (C-12 or C-5), 113.9 
(C-6 or C-13), 113.8 (C-13 or C-6), 79.4 (C-17), 64.2 (C-9), 57.8 (C-1), 55.3 (C-19 and C-20), 
53.7 (C-2), 43.2 (C-15), 43.1 (C-8), 36.9 (C-10), 35.2 (C-3), 28.2 (C-18); HRMS (ESI) 
calculated for C26H37N2O4 [M+H]
+ 441.2753, found 441.2760. 
 





The N-Boc-protected compound 102 was prepared from piperazine 100 (0.35 g, 0.71 mmol) 
following a similar procedure to that for the synthesis of 101 and was obtained as a white 
solid (0.37 g, 0.63 mmol, 88% yield). M.p. 105-106 ºC; Rf = 0.40 (EtOAc/petroleum ether 
1:3); [α]D
20
 = -34 (c = 0.6, CHCl3); FTIR (film) νmax 3032, 2975, 2928, 2860, 2792, 1687, 
1509, 1239, 1166; 1H NMR (CDCl3, 300 MHz) δ 7.51-7.31 (m, ArH, 10H), 7.16 (d, J = 8.6 
Hz, H-5 and H-12, 4H), 6.93 (d, J = 8.6 Hz, H-6 and H-13, 4H), 5.07 (s, H-19 and H-20, 4H), 
4.17-4.04 (br m, H-2, 1H), 3.85-3.81 (br m, H-8a, 1H), 3.14 (dd, J = 13.8, 3.9 Hz, H-10a, 1H), 
3.08-2.94 (br m, H-3a, 1H), 2.92-2.65 (m, H-3b and H-8b and H-1a, 3H), 2.57-2.44 (br m, H-
10b, 1H), 2.38 (s, H-15, 3H), 2.21-2.13 (br m, H-1b and H-9, 2H), 1.33 (s, H-18, 9H); 13C 
NMR (CDCl3, 100 MHz) δ 157.4 (C-7 or C-14), 157.3 (C-14 or C-7), 154.4 (C-16), 137.2 
(Ph), 131.8 (C-4 and C-11), 130.4 (C-5 or C-12), 130.3 (C-12 or C-5), 128.6 (Ph), 127.9 (Ph), 
127.5 (Ph), 114.9 (C-6 and C-13), 79.4 (C-17), 70.1 (C-19 and C-20), 64.1 (C-9), 58.0 (C-1), 
53.7 (C-2), 43.3 (C-15), 43.2 (C-8), 37.0 (C-10), 35.2 (C-3), 28.3 (C-18); HRMS (ESI) 
calculated for C38H45N2O4 [M+H]
+ 593.3379, found 593.3384. 
 
Preparation of piperazine derivative 103 
 
To a solution of piperazine 97 (51 mg, 0.15 mmol) in DCM (5 mL) at 0 ºC was added Et3N 
(25 μL, 0.18 mmol), followed by a solution of trifluoroacetic anhydride (25 μL, 0.18 mmol) in 
DCM (2 mL). The resulting mixture was stirred at room temperature overnight. Upon 
completion, the reaction system was washed with saturated NaHCO3 solution (10 mL). The 




dried over MgSO4, filtered and concentrated under reduced pressure. The crude product was 
purified by column chromatography eluting with 30% EtOAc in petroleum ether to afford 
desired product 103 (55 mg, 84% yield) as a white solid. M.p. 143-144 ºC; Rf = 0.55 
(EtOAc/petroleum ether 1:1); [α]D
20
 = -83 (c = 0.6, CHCl3); FTIR (film) νmax 2959, 2801, 
1689, 1513, 1464, 1249, 1142, 1038, 822; 1H NMR (CDCl3, 300 MHz) δ 7.17 (d, J = 8.6 Hz, 
H-5 or H-12, 2H), 7.13 (d, J = 8.7 Hz, H-12 or H-5, 2H), 6.89 (d, J = 8.6 Hz, H-6 or H-13, 
2H), 6.85 (d, J = 8.7 Hz, H-13 or H-6, 2H), 4.66-4.58 (br m, H-2, 1H), 4.14 (dd, J = 13.4, 2.4 
Hz, H-8a, 1H), 3.83 (s, H-18 or H-19, 3H), 3.82 (s, H-19 or H-18, 3H), 3.49 (d, J = 13.4 Hz, 
H-10a, 1H), 3.23-3.00 (m, H-3a and H-10b, 2H), 2.89-2.64 (m, H-1a and H-3b and H-8b, 3H), 
2.40 (s, H-15, 3H), 2.23-2.18 (m, H-1b and H-9, 2H); 13C NMR (CDCl3, 100 MHz) δ 158.5 
(C-7 or C-14), 158.4 (C-14 or C-7), 155.6 (q, 2JFC = 36 Hz, C-16), 130.3 (C-5 or C-12), 130.0 
(C-12 or C-5), 129.7 (C-4 and C-11), 117.6 (q, 1JFC = 286 Hz, C-17), 114.1 (C-6 or C-13), 
114.0 (C-13 or C-6), 64.4 (C-9), 56.7 (C-1), 55.3 (C-18 and C-19), 52.2 (C-2), 45.3 (C-10), 









N-trifluoroacetyl-protected piperazine derivative 104 was prepared from piperazine 100 (0.35 
g, 0.71 mmol) following a similar procedure to that for the synthesis of 103 and was obtained 
as a white solid (0.31 g, 0.53 mmol, 75% yield). M.p. 146-147 ºC; Rf = 0.50 (EtOAc:hexane = 
1:1); [α]D
20
 = -3.2 (c = 2.5, CHCl3); FTIR (film) νmax 3666, 2972, 2923, 1680, 1512, 1454, 
1247, 1180, 1137, 1041, 813, 729; 1H NMR (CDCl3, 400 MHz) δ 7.52-7.33 (m, PhH, 10H), 
7.19 (d, J = 8.6 Hz, H-5 or H-12, 2H), 7.15 (d, J = 8.6 Hz, H-12 or H-5, 2H), 6.98 (d, J = 8.6 
Hz, H-6 or H-13, 2H), 6.97 (d, J = 8.6 Hz, H-13 or H-6, 2H), 5.11 (s, H-18 or H-19, 2H), 5.07 
(s, H-19 or H-18, 2H), 4.69-4.61 (br m, H-2, 1H), 4.18 (dd, J = 13.4, 2.6 Hz, H-8a, 1H), 3.51 
(d, J = 13.6 Hz, H-10a, 1H), 3.21-3.09 (m, H-3a and H-10b, 3H), 2.93-2.68 (m, H-1a and H-
3b and H-8b, 3H), 2.42 (s, H-15, 3H), 2.26-2.20 (m, H-1b and H-9, 2H); 13C NMR (CDCl3, 
100 MHz) δ 157.8 (C-7 or C-14), 157.7 (C-14 or C-7), 155.2 (q, 2JFC = 35 Hz, C-16), 137.1 
(Ph), 137.0 (Ph), 130.4 (C-5 or C-12), 130.1 (C-12 or C-5), 128.6 (Ph), 128.0 (C-4 and C-11), 
127.9 (Ph), 127.5 (Ph), 117.7 (q, 1JFC = 286 Hz, C-17), 115.2 (C-6 or C-13), 115.0 (C-13 or 
C-6), 70.1 (C-18 and C-19), 64.4 (C-9), 56.7 (C-1), 52.2 (C-2), 45.3 (C-10), 42.8 (C-8 and C-
15), 34.6 (C-3); HRMS (ESI) calculated for C35H36F3N2O3 [M+H]
+ 589.2678, found 589.2681. 
 
Preparation of bis-phenol 106 
 
A mixture of piperazine 104 (0.32 g, 0.54 mmol) and 10% Pd/C catalyst (0.09 g) in ethyl 
acetate (5.0 mL) was stirred under H2 atmosphere (1 atm) for 48 h. Upon completion, the 
reaction was filtered through a layer of Celite pad and the catalyst was washed with MeOH 




chromatography eluting with 40% EtOAc in petroleum ether to afford the desired product 106 
(0.20 g, 89% yield) as a colourless oil. Rf = 0.37 (EA:Hexane = 1:1); [α]D
19
 = +58 (c = 0.2, 
MeOH); FTIR (film) νmax 3389, 2971, 2926, 1675, 1516, 1447, 1211, 1149, 1047, 824; 
1H 
NMR (MeOD-d4, 300 MHz) δ 7.07 (d, J = 8.5 Hz, H-5 or H-12, 2H), 7.04 (d, J = 8.5 Hz, H-
12 or H-5, 2H), 6.77 (d, J = 8.5 Hz, H-6 or H-13, 2H), 6.70 (d, J = 8.5 Hz, H-13 or H-6, 2H), 
4.62-4.55 (m, H-2, 1H), 4.09 (dd, J = 13.4, 2.4 Hz, H-8a, 1H), 3.47 (d, J = 14.2 Hz, H-10a, 
1H), 3.26-3.09 (m, H-3a and H-10b, 2H), 3.04-2.80 (m, H-1a and H-3b and H-8b, 3H), 2.33 
(s, H-15, 3H), 2.26 (dd, J = 12.1, 4.1 Hz, H-1b, 1H), 2.21-2.12 (m, H-9, 1H); 13C NMR 
(MeOD-d4, 100 MHz) δ 157.4 (C-7 or C-14), 157.2 (C-14 or C-7), 155.2 (q, 
2JFC = 36 Hz, C-
16), 131.4 (C-5 or C-12), 131.3 (C-12 or C-5), 129.6 (C-4 and C-11), 117.6 (q, 1JFC = 286 Hz, 
C-17), 116.5 (C-6 or C-13), 116.4 (C-13 or C-6), 66.2 (C-9), 58.1 (C-1), 53.8 (C-2), 46.2 (C-
10), 43.1 (C-8 and C-15), 35.4 (C-3); HRMS (ESI) calculated for C21H23F3N2NaO3 [M+Na]
+ 
431.1558, found 431.1574. 
 
Preparation of bis-phenol 105 
 
Following a similar procedure to that for the synthesis of 106, compound 105 was obtained 
from piperazine 102 (0.26 g, 0.44 mmol) as a white solid (0.16 g, 0.38 mmol, 87% yield). M.p. 
94-95 ºC; Rf = 0.40 (MeOH:EtOAc = 1:10); [α]D
20
 = +76 (c = 0.1, MeOH); FTIR (film) νmax 
3320, 2977, 2927, 2857, 2800, 1658, 1515, 1427, 1241, 1162, 734; 1H NMR (CDCl3, 300 




3.88 (d, J = 11.2 Hz, H-8a, 1H), 3.12 (m, H-10a, 1H), 3.00-2.70 (m, H-1a and H-8b and H-3, 
4H), 2.48 (dd, J = 13.1, 10.0 Hz, H-10b, 1H), 2.39 (s, H-15, 3H), 2.33-2.13 (m, H-1b and H-9, 
2H), 1.27 (s, H-18, 9H); 13C NMR (CDCl3, 100 MHz) δ 154.9 (C-16), 154.7 (C-14 and C-7), 
130.4 (C-5 or C-12), 130.3 (C-12 or C-5), 128.8 (C-4 and C-11), 115.6 (C-6 or C-13), 115.4 
(C-13 or C-6), 80.3 (C-17), 64.4 (C-9), 58.3 (C-1), 53.6 (C-2), 43.3 (C-15), 42.9 (C-8), 36.5 
(C-10), 35.2 (C-3), 28.2 (C-18); HRMS (ESI) calculated for C22H34N2O4Na [M+Na]
+ 
413.2416, found 413.2420. 
 
Synthesis of N-Cbz-L-tyrosine methyl ester 109 
 
At 0 ºC, a solution of Na2CO3 (0.21 g, 1.99 mmol) in water (2 mL) was added to a suspension 
of L-tyrosine methyl ester hydrochloride (0.46 g, 1.99 mmol) in chloroform (10 mL). After 
stirring for 15 min at 0 oC, another solution of Na2CO3 (0.21 g, 1.99 mmol) in water (2 mL) 
was added, followed by benzyl chloroformate (0.30 mL, 1.99 mmol). The mixture was 
warmed up to room temperature and stirred vigorously for 5 h. Upon completion, saturated 
NaHCO3 solution (10 mL) was added and the organic layer was separated after vigorously 
stirring the resulting mixture for 5 min. The aqueous layer was extracted with DCM (3×10 
mL). The combined organic fractions were washed with brine (15 mL), dried over MgSO4 
and concentrated under reduced pressure. The crude product was purified by column 
chromatography eluting with 50% EtOAc in petroleum ether to afford the desired product 109 
(0.51 g, 79% yield) as a colourless oil. Rf = 0.45 (EtOAc/petroleum ether 1:1); [α]D
20
 = +36.6 
(c = 0.5, CHCl3); FTIR (film) νmax 3336, 2954, 1694, 1515, 1215; 




δ 7.34-7.18 (m, ArH, 5H), 6.84 (d, J = 8.3 Hz, ArH, 2H), 6.62 (d, J = 8.3 Hz, ArH, 2H), 5.22 
(m, NH, 1H), 5.04 (s, PhCH2, 2H), 4.59-4.51 (m, CHNH, 1H), 3.65 (s, COOCH3, 3H), 3.08 
(dd, J = 14.0, 5.6 Hz, CHaHbCHNH, 1H), 3.00 (dd, J = 14.0, 6.2 Hz, CHaHbCHNH, 1H); 
13C 
NMR (CDCl3, 100 MHz) δ 172.5 (COOCH3), 156.1 (Ar), 155.4 (CO2CH2Ph), 136.0 (Ar), 
130.4 (Ar), 128.6 (Ar), 128.3 (Ar), 128.1 (Ar), 127.0 (Ar), 115.6 (Ar), 67.2 (PhCH2), 55.1 
(CHNH), 52.5 (OCH3), 37.4 (CH2CHNH). 
The observed data are in accord with published values.174,175 
 
Intermolecular phenol oxidative coupling (Synthesis of dityrosine 110) 
 
At -10 ºC, to a solution of tyrosine derivative 109 (0.15 g, 0.47 mmol) in anhydrous DCM (8 
mL), trifluoroacetic acid (1.90 mL, 24.8 mmol) and trifluoroacetic anhydride (95 μL, 0.67 
mmol) was slowly added a solution of VOF3 (0.15 g, 1.17 mmol) in ethyl acetate (0.75 mL), 
trifluoroacetic acid (0.71 mL, 9.27 mmol) and trifluoroacetic anhydride (35 μL, 0.25 mmol). 
The mixture was stirred at -10 ºC for 3 h and then quenched by adding saturated NaHCO3 
solution (15 mL). The organic layer was separated and the aqueous layer was extracted with 
DCM (2×10 mL). The combined organic fractions were washed with brine (10 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure. The crude product was 
purified by column chromatography eluting with 15% EtOAc in petroleum ether to afford 






 = +24.5 (c = 0.5, CHCl3) (lit.
77 [α]D
28 = +18.6, c = 0.3, CHCl3); FTIR (film) 
νmax 3334, 2954, 1699, 1513, 1498, 1216; 
1H NMR (CDCl3, 400 MHz) δ 7.36-7.25 (m, ArH, 
10H), 7.06 (s, ArH, 2H), 7.01 (d, J = 8.2 Hz, ArH, 2H), 6.91 (d, J = 8.2 Hz, ArH, 2H), 5.38 (d, 
J = 8.5 Hz, NH, 2H), 5.05 (d, J = 12.0 Hz, PhCHaHb, 2H), 5.01 (d, J = 12.0 Hz, PhCHaHb, 
2H), 4.68 (dd, J = 13.0, 7.5 Hz, CHNH, 1H), 3.75 (s, OCH3, 6H), 3.16 (dd, J = 13.8, 4.8 Hz, 
ArCHaHb, 2H), 2.89 (dd, J = 13.8, 7.6 Hz, ArCHaHb, 2H); 
13C NMR (CDCl3, 100 MHz) δ 
172.1 (COOCH3), 155.8 (CO2CH2Ph), 152.8 (Ar), 136.0 (Ar), 131.7 (Ar), 130.9 (Ar), 128.5 
(Ar), 128.2 (Ar), 128.1 (Ar), 123.5 (Ar), 117.0 (Ar), 67.1 (PhCH2), 55.1 (CHNH), 52.5 
(OCH3), 38.1 (ArCH2); HRMS (ESI) calculated for C36H36N2O10Na [M+Na]
+ 679.2268, 
found 679.2264. 
The observed data are in accord with published values.77 
 
Synthesis of N-Cbz-L-tyrosine 115 
 
N-Cbz-L-tyrosine 115 was prepared from 109 (0.31 g, 0.94 mmol) following a similar 
procedure to that for the synthesis of 92. This product was obtained as a colourless oil which 
solidified in the fridge (0.27 g, 0.86 mmol, 92% yield). M.p. 95-96 oC; Rf = 0.25 
(EtOAc/petroleum ether 1:1); [α]D
20
 = +34.0 (c = 1.0, CHCl3); FTIR (film) νmax 3320, 3032, 
2963, 1694, 1515, 1222, 1055; 1H NMR (CDCl3, 400 MHz) (major rotamer) δ 8.93 (br s, 
COOH, 1H), 7.48-7.25 (m, ArH, 5H), 6.96 (d, J = 8.4 Hz, ArH, 2H), 6.70 (d, J = 8.4 Hz, ArH, 
2H), 5.51 (d, J = 8.2 Hz, NH, 1H), 5.11 (s, PhCH2, 2H), 4.66 (dd, J = 13.8, 5.8 Hz, CHNH, 
1H), 3.10 (dd, J = 14.0, 5.2 Hz, ArCHaHbCH, 1H), 3.02 (dd, J = 14.0, 6.0 Hz, ArCHaHbCH, 




(CO2CH2Ph), 136.0 (Ar), 130.5 (Ar), 128.6 (Ar), 128.3 (Ar), 128.1 (Ar), 127.0 (Ar), 115.7 
(Ar), 68.0 (PhCH2), 54.8 (CHNH), 37.0 (CH2CHNH). 
The observed data are in accord with published values.172 
 
Synthesis of dipeptide 116 
 
Dipeptide 116 was prepared from acid 115 (0.25 g, 0.79 mmol) and amine 39 (0.15 g, 0.79 
mmol) following a similar procedure to that for the synthesis of 95. This product was obtained 
as a white solid (0.28 g, 0.57 mmol, 72% yield). M.p. 159-161 oC; Rf = 0.30 (EtOAc); [α]D
20 
= +34.0 (c = 1.0, CHCl3); FTIR (film) νmax 3373, 2943, 1654, 838; 
1H NMR (MeOD-d4, 400 
MHz) δ 7.37-7.22 (m, H-19 and H-20 and H-21, 5H), 7.03 (d, J = 8.4 Hz, H-5 or H-12, 2H), 
7.00 (d, J = 8.4 Hz, H-12 or H-5, 2H), 6.71 (d, J = 8.4 Hz, H-6 or H-13, 2H), 6.69 (d, J = 8.4 
Hz, H-13 or H-6, 2H), 5.08 (d, J = 12.6 Hz, H-17a, 1H), 5.00 (d, J = 12.6 Hz, H-17b, 1H), 
4.60 (dd, J = 7.9, 6.0 Hz, H-9, 1H), 4.33 (dd, J = 9.2, 5.9 Hz, H-2, 1H), 3.66 (s, H-15, 3H), 
3.03 (dd, J = 13.9, 6.0 Hz, H-10a, 1H), 2.97 (dd, J = 14.0, 5.9 Hz, H-3a, 1H), 2.91 (dd, J = 
13.9, 7.9 Hz, H-10b, 1H), 2.71 (dd, J = 14.0, 9.2 Hz, H-3b, 1H); 13C NMR (MeOD-d4, 100 
MHz) δ 174.0 (C-1), 173.2 (C-8), 158.2 (C-16), 157.4 (C-7 or C-14), 157.2 (C-14 or C-7), 
138.2 (C-18), 131.4 (C-5 and C-12), 129.5 (C-20), 129.1 (C-4 or C-11), 128.9 (C-21), 128.6 
(C-19), 128.5 (C-11 or C-4), 116.3 (C-6 or C-13), 116.2 (C-13 or C-6), 67.6 (C-17), 57.9 (C-
2), 55.4 (C-9), 52.7 (C-15), 38.3 (C-3), 37.8 (C-10); HRMS (ESI) calculated for 
C27H28N2O7Na [M+Na]




Preparation of bis-phenol 112 
 
Bis-phenol 112 was prepared from 99 (0.31 g, 0.60 mmol) following a similar procedure to 
that for the synthesis of 106 and was obtained as a colourless crystalline solid (0.19 g, 0.55 
mmol, 93% yield). M.p. 196-199 oC; Rf = 0.20 (EtOAc/MeOH 5:1); [α]D
20
 = -176 (c = 0.8, 
MeOH); FTIR (film) νmax 3248, 2926, 2854, 1682, 1512, 1453, 1247; 
1H NMR (MeOD-d4, 
300 MHz) δ 6.99 (d, J = 8.5 Hz, H-5 or H-12, 2H), 6.88 (d, J = 8.5 Hz, H-12 or H-5, 2H), 
6.81 (d, J = 8.6 Hz, H-6 or H-13, 2H), 6.74 (d, J = 8.6 Hz, H-13 or H-6, 2H), 4.18 (t, J = 4.2 
Hz, H-2, 1H), 3.94 (dd, J = 9.4, 3.6 Hz, H-9, 1H), 3.02 (dd, J = 14.4, 4.2 Hz, H-3a, 1H), 2.98 
(s, H-15, 3H), 2.73 (dd, J = 14.4, 4.2 Hz, H-3b, 1H), 2.65 (dd, J = 13.7, 3.6 Hz, H-10a, 1H), 
1.43 (dd, J = 13.7, 9.4 Hz, H-10b, 1H); 13C NMR (MeOD-d4, 100 MHz) δ 167.3 (C-1 or C-8), 
166.7 (C-8 or C-1), 156.7 (C-7 or C-14), 156.2 (C-14 or C-7), 130.9 (C-5 or C-12), 130.3 (C-
12 or C-5), 126.9 (C-4 or C-11), 126.3 (C-11 or C-4), 115.3 (C-6 or C-13), 115.1 (C-13 or C-
6), 63.3 (C-2), 56.7 (C-9), 39.6 (C-10), 36.0 (C-3), 32.4 (C-15); HRMS (ESI) calculated for 
C19H20N2O4Na [M+Na]
+ 363.1321, found 363.1324. 
 





To a solution of tyrosine derivative 90 (0.21 g, 0.71 mmol) in MeOH (20 mL) at -40 oC was 
added PhI(OAc)2 (0.23 g, 0.71 mmol) and the reaction mixture was stirred at the same 
temperature for 6 h. Upon completion, the mixture was partitioned between brine (20 mL) and 
DCM (30 mL). The organic phase was separated and the aqueous phase was extracted with 
DCM (2×15 mL). The combined organic fractions were washed with brine (20 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure. The crude product was 
purified by flash column chromatography eluting with 50% EtOAc in petroleum ether to 
afford product 128 as a colourless oil (0.14 g, 61% yield). Rf = 0.30 (EtOAc/petroleum ether 
1:1); FTIR (film) νmax 3671, 3352, 2976, 1699, 1394, 1174, 1080; [α]D
20
 = +6 (c = 0.45, 
CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 6.83 (dd, J = 12.0, 1.6 Hz, H-5a and H-5b, 2H), 6.40-
6.35 (m, H-6a and H-6b, 2H), 5.21 (d, J = 7.4 Hz, NH, 1H), 4.52-4.41 (m, H-2, 1H), 3.74 (s, 
H-12, 3H), 3.20 (s, H-8, 3H), 2.29 (dd, J = 14.3, 3.7 Hz, H-3a, 1H), 2.04 (dd, J = 14.3, 8.3 Hz, 
H-3b, 1H), 1.45 (s, H-11, 9H); 13C NMR (CDCl3, 100 MHz) δ 184.7 (C-7), 172.6 (C-1), 154.9 
(C-9), 149.3 (C-5a), 149.2 (C-5b), 131.6 (C-6a), 131.4 (C-6b), 80.3 (C-10), 74.1 (C-4), 53.1 
(C-12), 52.5 (C-8), 50.3 (C-2), 42.6 (C-3), 28.3 (C-11); HRMS (ESI) calculated for 
C16H23NO6Na [M+Na]
+ 348.1423, found 348.1430. 
 
Preparation of piperazine 129 
 
To a solution of bis-phenol 105 (0.51 g, 1.24 mmol) in MeOH (20 mL) at 0 oC was added 




for 12 h. Upon completion, the mixture was partitioned between brine (20 mL) and DCM (30 
mL). The organic phase was separated and the aqueous phase was extracted with DCM (2×15 
mL). The combined organic fractions were washed with brine (20 mL), dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash 
column chromatography eluting with EtOAc to afford the product 129 as a colourless oil 
(0.30 g, 52% yield). Rf = 0.46 (MeOH:EtOAc = 1:4); [α]D
20
 = +184 (c = 0.2, CHCl3); FTIR 
(film) νmax 2975, 2935, 1692, 1671, 1168, 1057; 
1H NMR (CDCl3, 300 MHz) δ 6.94-6.69 (m, 
H-6 and H-15, 4H), 6.54-6.24 (m, H-5 and H-14, 4H), 4.03-3.85 (br m, H-2, 1H), 3.21 (s, H-8 
or H-9, 3H), 3.20 (s, H-9 or H-8, 3H), 3.08-2.57 (m, H-11 and H-12, 3H), 2.37-1.99 (m, H-1 
and H-3 and H-10, 6H), 2.15 (s, H-17, 3H), 1.46 (s, H-20, 9H); 13C NMR (CDCl3, 100 MHz) 
δ 185.1 (C-7 and C-16), 152.2 (C-18), 150.8 (C-5 or C-14), 149.9 (C-14 or C-5), 131.7 (C-6 
or C-15), 131.1 (C-15 or C-6), 79.8 (C-19), 74.5 (C-4 or C-13), 74.3 (C-13 or C-4), 60.9 (C-2 
or C-11), 60.6 (C-11 or C-2), 58.4 (C-1), 53.0 (C-8 and C-9), 43.3 (C-17), 40.9 (C-10), 40.2 




Preparation of piperazine 130a 
 
To a solution of piperazine derivative 129 (47 mg, 0.10 mmol) in DCM (8 mL) was added 
TFA (1.0 mL) and the resultant mixture was stirred at rt for 6 h. The reaction solution was 
then diluted with DCM (20 mL) and saturated NaHCO3 solution (25 mL) was added dropwise 




separated and the aqueous phase was extracted with DCM (3×15 mL). The combined organic 
fractions were washed with brine (20 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. The crude product was purified by flash column chromatography eluting 
with 15% MeOH in EtOAc to afford the cyclised product 130a as a colourless oil (23 mg, 62% 
yield). Rf = 0.35 (MeOH:EtOAc = 1:2); [α]D
24
 = +45 (c = 0.7, MeOH); FTIR (film) νmax 2927, 
2854, 2823, 1688, 1670, 1090; 1H NMR (CDCl3, 300 MHz) δ 6.80 (dd, J = 10.1, 3.1 Hz, H-14 
or H-18, 1H), 6.67 (dd, J = 9.9, 2.9 Hz, H-18 or H-14, 1H), 6.61 (dd, J = 10.3, 1.9 Hz, H-5, 
1H), 6.44-6.34 (m, H-15 and H-17, 2H), 6.03 (d, J = 10.3 Hz, H-6, 1H), 3.34 (s, H-21, 3H), 
3.18 (s, H-20, 3H), 2.87-2.84 (m, H-9, 1H), 2.82 (dd, J = 10.7, 2.1 Hz, H-10a, 1H), 2.68 (dd, J 
= 9.2, 5.5 Hz, H-11, 1H), 2.64-2.58 (m, H-8 and H-1a, 3H), 2.58-2.53 (m, H-2, 1H), 2.28 (s, 
H-19, 3H), 2.22 (d, J = 10.7 Hz, H-10b, 1H), 2.12-2.01 (m, H-1b and H-3a and H-12a, 3H), 
1.72 (d, J = 14.0 Hz, H-12b, 1H), 1.47 (dd, J = 13.3, 10.3 Hz, H-3b, 1H); 13C NMR (CDCl3, 
100 MHz) δ 197.2 (C-7), 185.4 (C-16), 151.1 (C-14 and C-18), 148.8 (C-5), 131.4 (C-15 and 
C-17), 128.2 (C-6), 79.5 (C-4), 75.3 (C-13), 65.3 (C-9), 59.6 (C-2), 54.1 (C-11), 53.3 (C-1), 
53.1 (C-10), 52.9 (C-20), 52.5 (C-21), 42.1 (C-19), 42.1 (C-3), 37.8 (C-8), 33.3 (C-12); 
HRMS (ESI) calculated for C21H29N2O4 [M+H]
+ 373.2127, found 373.2130. 
 
Hydrogenation of 130a to piperazine 131 
 
A mixture of piperazine derivative 130a (53 mg, 0.14 mmol) and 10% Pd/C (10 mg) in THF 
(10 mL) was stirred under an atmosphere of H2 for 10 h. Upon completion, the reaction was 




filtrate was concentrated under reduced pressure and the crude product was purified by flash 
column chromatography eluting with 20% MeOH in EtOAc to afford the reduced product 131 
as a colourless oil (32 mg, 68% yield). Rf = 0.30 (MeOH:EtOAc = 1:2); [α]D
20
 = -108 (c = 0.2, 
CHCl3); FTIR (film) νmax 2944, 2828, 1714, 1456, 1224, 1067; 
1H NMR (CDCl3, 300 MHz) δ 
3.29 (s, OCH3, 3H), 3.28 (s, OCH3, 3H), 2.93 (d, J = 6.3 Hz, 1H), 2.75-2.65 (m, 3H), 2.63-
2.50 (m, 4H), 2.46 (dd, J = 15.4, 3.1 Hz, 1H), 2.38 (s, NCH3, 3H), 2.32-2.01 (m, 10H), 1.87-
1.59 (m, 2H), 1.46-1.31 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 211.7 (C=O), 211.0 (C=O), 
82.2 (COCH3), 73.9 (COCH3), 67.5 (CH), 59.0 (CH), 54.0 (CH), 53.4 (CH2), 53.0 (CH2), 50.3 
(OCH3), 49.4 (OCH3), 42.3 (NCH3), 40.0 (CH2), 36.8 (CH2), 36.7 (CH2), 36.3 (CH2), 34.0 
(CH2), 33.9 (CH2), 33.5 (CH2), 30.2 (CH2); HRMS (ESI) calculated for C21H35N2O4 [M+H]
+ 
379.2597, found 379.2606. 
 
6.3 Preparative Procedures for Chapter 3 
Preparation of O-methyl-L-tyrosine methyl ester 155 
 
O-methyl-L-tyrosine methyl ester 155 was prepared from 91 (1.18 g, 4.00 mmol) following a 
similar procedure to that for the synthesis of 94. Compound 155 was obtained as a colourless 
oil (0.74 g, 3.80 mmol, 95% yield). Rf = 0.15 (EA); [α]D
20
 = +23.2 (c = 1.0, MeOH); FTIR 
(film) νmax 3379, 2999, 2952, 2837, 1733, 1511, 1244, 1175, 1032, 818; 
1H NMR (CDCl3, 400 
MHz) δ 7.11 (d, J = 8.7 Hz, ArH, 2H), 6.85 (d, J = 8.7 Hz, ArH, 2H), 3.79 (s, ArOCH3, 3H), 
3.72 (s, COOCH3, 3H), 3.70 (dd, J = 7.7, 5.2 Hz, CHNH2, 1H), 3.03 (dd, J = 13.6, 5.2 Hz, 





(CDCl3, 100 MHz) δ 175.6 (COOMe), 158.5(Ar), 130.2 (Ar), 129.1 (Ar), 113.9 (Ar), 55.9 
(CHNH), 55.2 (ArOCH3), 51.9 (COOCH3), 40.2 (ArCH2). 
The observed data are in accord with published values.176 
 
Preparation of dipeptide 156 
 
Dipeptide 156 was prepared from acid 92 (0.93 g, 3.15 mmol) and amine 155 (0.61 g, 3.15 
mmol) following a similar procedure to that for the synthesis of 95 and was obtained as a 
white solid (1.25 g, 2.58 mmol, 82% yield). M.p. 108-109 ºC; Rf = 0.63 (EA:hexane = 1:1); 
[α]D
20
 = +34.4 (c = 2.0, CHCl3); FTIR (film) νmax 3664, 3321, 2973, 1737, 1690, 1646, 1511, 
1244, 1169, 1033; 1H NMR (CDCl3, 400 MHz) δ 7.12 (d, J = 8.6 Hz, H-5 or H-13, 2H), 6.91 
(d, J = 8.6 Hz, H-13 or H-5, 2H), 6.84 (d, J = 8.6 Hz, H-6 or H-14, 2H), 6.78 (d, J = 8.6 Hz, 
H-14 or H-6, 2H), 6.26 (br s, CHCONH, 1H), 4.98 (br s, NHBoc, 1H), 4.75 (dd, J = 12.6, 5.9 
Hz, H-10, 1H), 4.30 (dd, J = 12.6, 6.8 Hz, H-2, 1H), 3.79 (s, H-8 and H-16, 6H), 3.69 (s, H-20, 
3H), 3.07-2.92 (m, H-3 and H-11, 4H), 1.43 (s, H-19, 9H); 13C NMR (CDCl3, 100 MHz) δ 
171.4 (C-9), 170.8 (C-1), 158.7 (C-7 and C-15), 155.3 (C-17), 130.4 (C-5 or C-13), 130.2 (C-
13 or C-5), 128.4 (C-4 or C-12), 127.5 (C-12 or C-4), 114.1 (C-6 or C-14), 113.9 (C-14 or C-
6), 80.2 (C-18), 55.8 (C-2), 55.2 (C-8 and C-16), 53.4 (C-10), 52.2 (C-20), 37.4 (C-3 or C-11), 
37.1 (C-11 or C-3), 28.3 (C-19); HRMS (ESI) calculated for C26H34N2O7Na [M+Na]
+ 





Preparation of DKP 157 
 
A solution of dipeptide derivative 156 (2.40 g, 5.67 mmol) in formic acid (15 mL) was stirred 
at rt for 8 h. The solvent was concentrated under reduced pressure and trace formic acid was 
removed from the dipeptide intermediate by azeotropic distillation with toluene (2×10 mL). 
To the residue was added 3:1 s-butanol:toluene (60 mL) and the resultant mixture was heated 
at reflux for 6 h. The reaction was cooled to rt and filtered. The solid was washed with EtOAc 
(2×5 mL), dried first by suction and subsequently under high vacuum with an oil pump to 
give DKP 157 as a white solid (1.21 g, 69% yield). M.p. 241-243 ºC; Rf = 0.20 
(EtOAc/MeOH 5:1); [α]D
20
 = -109.9 (c = 1.0, DMSO); FTIR (film) νmax 3664, 2988, 2974, 
2904, 1676, 1658, 1246, 1066, 1041; 1H NMR (DMSO-d6, 400 MHz) δ 7.86 (s, NH, 2H), 
6.95 (d, J = 8.6 Hz, ArH, 4H), 6.85 (d, J = 8.6 Hz, ArH, 4H), 3.92 (dd, J = 6.1, 4.7 Hz, CHNH, 
2H), 3.70 (s, OCH3, 6H), 2.55 (dd, J = 13.7, 4.7 Hz, CHaHb, 2H), 2.22 (dd, J = 13.7, 6.1 Hz, 
CHaHb, 2H); 
13C NMR (DMSO-d6, 100 MHz) δ 166.8 (C=O), 158.5 (Ar), 131.3 (Ar), 128.8 
(Ar), 114.1 (Ar), 56.0 (CHNH), 55.5 (OCH3), 38.9 (ArCH2); HRMS (ESI) calculated for 
C20H22N2O4Na [M+Na]
+ 377.1477, found 377.1481. 
 





Piperazine derivative 158 was prepared from DKP 157 (0.97 g, 2.74 mmol) following a 
similar procedure to that for the synthesis of 97 and was obtained as a white solid (0.55 g, 
1.70 mmol, 62% yield). M.p. 169-172 oC; Rf = 0.35 (MeOH:EtOAc = 1:2); [α]D
20
 = +4 (c = 
0.6, CHCl3); FTIR (film) νmax 3343, 2955, 2932, 2835, 1512, 1247, 1033; 
1H NMR (CDCl3, 
300 MHz) δ 7.16 (d, J = 8.6 Hz, ArH, 4H), 6.87 (d, J = 8.6 Hz, ArH, 4H), 3.81 (s, OCH3, 6H), 
2.98 (dt, J = 13.0, 4.8 Hz, CHNH, 2H), 2.89-2.83 (m, CH2, 6H), 2.75 (dd, J = 13.0, 5.5 Hz, 
CH2, 2H), 1.95 (br s, NH, 2H); 
13C NMR (CDCl3, 100 MHz) δ 158.1(Ar), 131.3 (Ar), 130.1 
(Ar), 114.0 (Ar), 55.7 (CHNH), 55.3 (OCH3), 47.9 (CH2NH), 37.6 (ArCH2); HRMS (ESI) 
calculated for C20H27N2O2 [M+H]
+ 327.2073, found 327.2063. 
 
Preparation of piperazine 159 
 
Piperazine 159 was prepared from 158 (1.50 g, 4.60 mmol) following a similar procedure to 
that for the synthesis of 101 and was obtained as a colourless oil (2.30 g, 4.37 mmol, 95% 
yield). Rf = 0.60 (EtOAc/petroleum ether 1:3); [α]D
20
 = +6.7 (c = 1.2, CHCl3); FTIR (film) 
νmax 2973, 2933, 1686, 1511, 1404, 1245, 1152, 1110, 1035; 
1H NMR (CDCl3, 300 MHz) δ 
7.03 (d, J = 8.6 Hz, ArH, 4H), 6.81 (d, J = 8.6 Hz, ArH, 4H), 4.05 (br s, CH, 2H), 3.83 (br s, 
NCHaHb, 2H), 3.81 (s, OCH3, 6H), 2.81 (dd, J = 13.3, 3.8 Hz, ArCHaHb, 2H), 2.73-2.30 (m, 
ArCHaHb and NCHaHb, 4H), 1.46 (s, COOC(CH3)3, 18H); 
13C NMR (CDCl3, 100 MHz) δ 
158.3 (Ar), 155.1 (COOtBu), 130.3 (Ar), 129.2 (Ar), 113.9 (Ar), 80.0 (COOC(CH3)3), 55.3 
(OCH3), 54.5 (CH), 41.1 (NCH2), 37.1 (CH2Ar), 28.3 (COOC(CH3)3); HRMS (ESI) 
calculated for C30H42N2O6Na [M+Na]




Preparation of piperazine 160 
 
To a solution of piperazine derivative 158 (0.13 g, 0.39 mmol) in DCM (15 mL) at 0 oC was 
added PhSO2Cl (0.11 mL, 0.82 mmol), followed by DIPEA (0.15 mL, 0.82 mmol). The 
reaction solution was stirred at 0 oC for 1 h and then at rt for 5 h. The mixture was partitioned 
between brine (20 mL) and DCM (15 mL). The aqueous phase was extracted with DCM 
(2×15 mL). The combined organic fractions were washed with brine (20 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by 
flash column chromatography eluting with 25% EtOAc in petroleum ether to afford the 
protected product 160 as a white solid (0.21 g, 87% yield). M.p. 149-151 oC; Rf = 0.60 
(EA:hexane = 1:4); [α]D
20
 = +10.8 (c = 1.0, CHCl3); FTIR (film) νmax 2999, 2956, 2934, 1512, 
1347, 1248, 1164; 1H NMR (CDCl3, 400 MHz) δ 7.72 (dd, J = 8.3, 1.1 Hz, ArH, 4H), 7.64-
7.58 (m, ArH, 2H), 7.55-7.48 (m, ArH, 4H), 7.06 (d, J = 8.6 Hz, ArH, 4H), 6.85 (d, J = 8.6 
Hz, ArH, 4H), 3.84 (s, OCH3, 6H), 3.77 (td, J = 9.7, 6.0 Hz, NCH, 2H), 3.14 (dd, J = 13.4, 6.0 
Hz, NCHaHb, 2H), 3.13 (dd, J = 13.4, 4.2 Hz, ArCHaHb, 2H), 3.00 (dd, J = 13.4, 4.2 Hz, 
NCHaHb, 2H), 2.95 (dd, J = 13,4, 9.7 Hz, ArCHaHb, 2H); 
13C NMR (CDCl3, 100 MHz) δ 
158.5 (Ar), 138.5 (Ar), 133.0 (Ar), 130.5 (Ar), 129.3 (Ar), 128.8 (Ar), 127.3 (Ar), 114.1 (Ar), 
56.8 (CH), 55.3 (OCH3), 43.5 (NCH2), 38.5 (ArCH2); HRMS (ESI) calculated for 
C32H34N2O6NaS2 [M+Na]







Preparation of piperazine 111 
 
To a solution of piperazine derivative 158 (0.28 g, 0.84 mmol) in THF (10 mL) was added 
paraformaldehyde (0.10 g, 3.33 mmol) and the resulting mixture was stirred at room 
temperature for 1 h. Sodium triacetoxyborohydride (0.75 g, 3.33 mmol) was added and the 
reaction mixture was stirred for 12 h before the addition of another portion of 
paraformaldehyde (0.10 g, 3.33 mmol) followed by sodium triacetoxyborohydride (0.75 g, 
3.33 mmol). After stirring for additional 12 h, water (15 mL) was added to the reaction 
system and the mixture was extracted with DCM (3×15 mL). The combined organic fraction 
was washed with saturated NaHCO3 solution (15 mL), brine (15 mL), dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash 
column chromatography eluting with 40% EtOAc in petroleum ether to yield the final product 
as a white solid (0.24 g, 82% yield). M.p. 117-118 ºC; Rf = 0.45 (MeOH:EtOAc = 1:2); [α]D
20
 
= +89 (c = 2.0, CHCl3); FTIR (film) νmax 2957, 2936, 2424, 1668, 1611, 1512, 1246, 1030, 
820, 731; 1H NMR (CDCl3, 300 MHz) δ 7.13 (d, J = 8.6, ArH, 4H), 6.85 (d, J = 8.6, ArH, 
4H), 3.81 (s, OCH3, 6H), 2.93 (dd, J = 13.0, 3.0 Hz, ArCHaHb, 2H), 2.71 (dd, J = 13.0, 9.6 Hz, 
ArCHaHb, 2H), 2.53 (m, NCH and NCHaHb, 4H), 2.37 (s, NCH3, 6H), 2.24 (dd, J = 10.7, 2.3 
Hz, NCHaHb, 2H); 
13C NMR (CDCl3, 100 MHz) δ 157.8 (Ar), 132.1 (Ar), 130.2 (Ar), 113.8 
(Ar), 62.9 (NCH), 55.4 (NCH2), 55.2 (OCH3), 42.8 (NCH3), 32.0 (ArCH2); HRMS (ESI) 
calculated for C22H31N2O2 [M+H]






Preparation of dipeptide 107 
 
Dipeptide 107 was prepared from acid 351 (1.70 g, 4.57 mmol) and amine 88 (1.30 g, 4.57 
mmol) following a similar procedure to that for the synthesis of 95 and was obtained as a 
white solid (2.18 g, 3.43 mmol, 75% yield). M.p. 128-131 ºC (lit.177 m.p. 163-165 ºC); Rf = 
0.65 (EA:hexane = 1:1); [α]D
20 = +29.2 (c = 1.5, CHCl3); FTIR (film) νmax 3314, 2977, 2930, 
1740, 1706, 1645, 1511, 1240, 1174, 1018; 1H NMR (CDCl3, 300 MHz) δ 7.51-7.31 (m, PhH, 
10H), 7.13 (d, J = 8.6 Hz, H-5 or H-13, 2H), 6.92 (d, J = 8.6 Hz, H-6 or H-14, 2H), 6.91 (d, J 
= 8.6 Hz, H-13 or H-5, 2H), 6.89 (d, J = 8.6 Hz, H-14 or H-6, 2H), 6.29 (d, J = 6.8 Hz, 
CHCONH, 1H), 5.04 (s, C-8 or C-16, 2H), 5.03 (s, C-16 or C-8, 2H), 4.97 (d, J = 5.7 Hz, 
NHBoc, 1H), 4.76 (dd, J = 12.6, 5.7 Hz, H-10, 1H), 4.31 (dd, J = 12.6, 6.8 Hz, H-2, 1H), 3.69 
(s, H-20, 3H), 3.02-3.00 (m, H-3 and H-11, 4H), 1.43 (s, H-19, 9H); 13C NMR (CDCl3, 100 
MHz) δ 171.5 (C-9), 170.8 (C-1), 157.9 (C-7 and C-15), 155.3 (C-17), 137.0 (Ph), 130.5 (C-5 
or C-13), 130.3  (C-13 or C-5), 128.7 (C-4 or C-12), 128.6 (Ph), 128.0 (Ph), 127.9 (C-12 or C-
4), 127.5 (Ph), 127.4 (Ph), 115.0 (C-6 or C-14), 114.9 (C-14 or C-6), 80.2 (C-18), 70.0 (C-8 
and C-16), 55.7 (C-2), 53.4 (C-10), 52.3 (C-20), 37.4 (C-3 or C-11), 37.1 (C-11 or C-3), 28.3 
(C-19); HRMS (ESI) calculated for C38H42N2O7Na [M+Na]
+ 661.2890, found 661.2909. 







Preparation of DKP 89 
 
DKP 89 was prepared from dipeptide 107 (0.55 g, 0.86 mmol) following a similar procedure 
to that for the synthesis of 157 and was obtained as a white solid (0.27 g, 0.54 mmol, 63% 
yield). M.p. 234-237 ºC; Rf = 0.25 (EtOAc/MeOH 5:1); [α]D
20
 = -103.7 (c = 1.0, DMSO); 
FTIR (film) νmax 3671, 2987, 2974, 2901, 1396, 1066, 1057; 
1H NMR (DMSO-d6, 400 MHz) 
δ 7.87 (s, NH, 2H), 7.40-7.26 (m, ArH, 10H), 6.96 (d, J = 9.0 Hz, ArH, 4H), 6.93 (d, J = 9.0 
Hz, ArH, 2H), 5.06 (s, PhCH2, 4H), 3.91 (dd, J = 6.2, 4.8 Hz, CHNH, 2H), 2.55 (d, J = 13.7, 
4.8 Hz, ArCHaHb, 2H), 2.21 (dd, J = 13.7, 6.2 Hz, ArCHaHb, 2H); 
13C NMR (DMSO-d6, 100 
MHz) δ 166.7 (C=O), 157.6 (Ar), 137.6 (Ar), 131.3 (Ar), 129.2 (Ar), 128.8 (Ar), 128.2 (Ar), 
127.9 (Ar), 115.0 (Ar), 69.6 (PhCH2), 56.0 (CHNH), 39.0 (CH2CHNH); HRMS (ESI) 
calculated for C32H30N2O4Na [M+Na]
+ 529.2103, found 529.2098. 
The observed data are in accord with published values.178 
 
Reduction of DKP to piperazine 354 
 
Piperazine 354 was prepared from DKP 89 (0.46 g, 0.91 mmol) following a similar procedure 
to that for the synthesis of 158 and was obtained as a white solid (0.29 g, 0.60 mmol, 66% 
yield). M.p. 111-113 ºC; Rf = 0.40 (MeOH:EtOAc = 1:2); [α]D
20




FTIR (film) νmax 3341, 2926, 2855, 1511, 1242; 
1H NMR (CDCl3, 400 MHz) δ 7.35-7.15 (m, 
ArH, 10H), 7.01 (d, J = 8.5 Hz, ArH, 4H), 6.77 (d, J = 8.5 Hz, ArH, 4H), 4.88 (s, PhCH2, 4H), 
3.15-2.98 (m, CHNH, 2H), 2.78 (m, CH2, 6H), 2.60-2.33 (m, CH2, 2H); 
13C NMR (CDCl3, 
100 MHz) δ 157.7 (Ar), 137.0 (Ar), 130.3 (Ar), 130.2 (Ar), 129.7 (Ar), 128.6 (Ar), 128.0 (Ar), 
127.5 (Ar), 115.1 (Ar), 70.0 (PhCH2), 54.7 (CHNH), 45.4 (CH2NH), 36.3 (ArCH2); HRMS 
(ESI) calculated for C32H35N2O2 [M+H]
+ 479.2699, found 479.2697. 
 
Preparation of piperazine 355 
 
Piperazine 355 was prepared from 354 (0.38 g, 0.79 mmol) following a similar procedure to 
that for the synthesis of 101 and was obtained as a colourless oil (0.44 g, 0.65 mmol, 82% 
yield). Rf = 0.60 (EtOAc/petroleum ether 1:3); [α]D
20
 = +16 (c = 1.0, CHCl3); FTIR (film) νmax 
2973, 2930, 1686, 1511, 1246, 1174; 1H NMR (DMSO-d6, 400 MHz) δ 7.45 (d, J = 7.2 Hz, 
ArH, 4H), 7.39 (t, J = 7.2 Hz, ArH, 4H), 7.35-7.29 (m, ArH, 2H), 7.07 (d, J = 8.5 Hz, ArH, 
4H), 6.95 (d, J = 8.5 Hz, ArH, 4H), 5.08 (s, PhCH2, 4H), 3.91-3.85 (m, NCH, 2H), 3.67-3.61 
(m, NCHaHb, 2H), 2.80 (dd, J = 14.3, 11.3 Hz, NCHaHb, 2H), 2.75 (dd, J = 13.0, 5.1 Hz, 
ArCHaHb, 2H), 2.61 (dd, J = 13.0, 8.4 Hz, ArCHaHb, 2H), 1.31 (s, COOC(CH3)3, 18H); 
13C 
NMR (DMSO-d6, 100 MHz) δ 157.4 (Ar), 154.7 (COO
tBu), 137.7 (Ar), 130.5 (Ar), 130.2 
(Ar), 128.9 (Ar), 128.2 (Ar), 128.0 (Ar), 115.1 (Ar), 79.4 (COOC(CH3)3), 69.6 (PhCH2), 55.2 
(NCH), 40.8 (NCH2), 36.9 (ArCH2), 28.3 (COOC(CH3)3); HRMS (ESI) calculated for 
C42H50N2O6Na [M+Na]





Iodination of DKP 96   
 
To a solution of DKP 96 (0.18 g, 0.50 mmol) in MeOH (30 mL) was added AgOTf (0.27 g, 
1.05 mmol). The mixture was cooled to 0 oC and a solution of I2 (0.27 g, 1.05 mmol) in 
MeOH (10 mL) was slowly added over a period of 15 min. The reaction mixture was stirred 
at 0 oC for 1 h and then at rt for 8 h. Sodium thiosulfate was added to the reaction system to 
consume excess iodine. The mixture was filtered through a layer of Celite pad and the solid 
was washed with DCM (3×10 mL). The filtrate was concentrated under reduced pressure and 
the crude product was purified by column chromatography with 5% methanol in ethyl acetate 
as the eluent to give DKP 356 as an off-white solid (0.21 g, 69% yield). M.p. 183-184 ºC; Rf 
= 0.20 (EtOAc/MeOH 6:1); [α]D
20
 = -118 (c = 1.0, CHCl3); FTIR (film) νmax 3213, 2939, 1680, 
1646, 1490, 1253, 1048; 1H NMR (CDCl3, 400 MHz) δ 7.63 (d, J = 2.1 Hz, H-5, 1H), 7.41 (d, 
J = 2.1 Hz, H-14, 1H), 7.08 (dd, J = 8.4, 2.1 Hz, H-9, 1H), 6.90 (dd, J = 8.4, 2.1 Hz, H-18, 
1H), 6.85 (d, J = 8.4 Hz, H-8, 1H), 6.76 (d, J = 8.4 Hz, H-17, 1H), 5.83 (d, J = 1.9 Hz, NH, 
1H), 4.16 (t, J = 4.0 Hz, H-2, 1H), 3.91 (dd, J = 5.8, 3.2 Hz, H-11, 1H), 3.85 (s, H-19 and H-
20, 6H), 3.17 (dd, J = 14.2, 3.6 Hz, H-3a, 1H), 3.11 (s, H-21, 3H), 3.05 (dd, J = 14.2, 4.4 Hz, 
H-3b, 1H), 2.91 (dd, J = 13.6, 2.7 Hz, H-12a, 1H), 0.92 (dd, J = 13.6, 11.3 Hz, H-12b, 1H); 
13C NMR (CDCl3, 100 MHz) δ 165.5 (C-10), 165.1 (C-1), 157.9 (C-7), 157.4 (C-16), 141.0 
(C-5), 139.8 (C-14), 131.4 (C-9), 130.7 (C-18), 130.0 (C-13), 129.0 (C-4), 111.2 (C-8), 111.1 
(C-17), 86.6 (C-6 and C-15), 63.0 (C-2), 56.7 (C-11), 56.6 (C-19 or C-20), 56.5 (C-20 or C-
19), 39.7 (C-12), 35.3 (C-3), 33.2 (C-21); HRMS (ESI) calculated for C21H22N2O4NaI2 




Preparation of DKP 219 
 
DKP 219 was prepared from 99 (0.31 g, 0.60 mmol) following a similar procedure to that for 
the synthesis of 356 and was obtained as a white solid (0.29 g, 0.38 mmol, 63% yield). M.p. 
95-96 ºC; Rf = 0.25 (EtOAc/MeOH 6:1); [α]D
24
 = -48 (c = 0.9, MeOH); FTIR (film) νmax 3209, 
2972, 2902, 1680, 1653, 1487, 1251, 1046, 734; 1H NMR (CDCl3, 300 MHz) δ 7.65 (d, J = 
2.1 Hz, H-5, 1H), 7.50-7.46 (m, H-14 and PhH, 2H), 7.42-7.30 (m, PhH, 6H), 7.23-7.19 (m, 
PhH, 3H), 6.99 (dd, J = 8.4, 2.1 Hz, H-9, 1H), 6.85-6.77 (m, H-8 and H-17 and H-18, 3H), 
5.57 (d, J = 1.2 Hz, NH, 1H), 5.16 (s, H-19 or H-20, 2H), 5.13 (s, H-20 or H-19, 2H), 4.15 (t, 
J = 3.8 Hz, H-2, 1H), 3.85-3.78 (m, H-11, 1H), 3.18 (dd, J = 14.2, 3.8 Hz, H-3a, 1H), 3.09 (s, 
H-21, 3H), 3.03 (dd, J = 14.2, 3.8 Hz, H-3b, 1H), 2.76 (dd, J = 13.6, 2.8 Hz, H-12a, 1H), 0.72 
(dd, J = 13.6, 11.5 Hz, H-12b, 1H); 13C NMR (CDCl3, 100 MHz) δ 165.3 (C-1 or C-10), 
165.0 (C-10 or C-1), 156.8 (C-7), 156.5 (C-16), 141.1 (C-5), 139.9 (C-14), 136.3 (Ph), 136.0 
(Ph), 131.2 (C-9), 130.5 (C-18), 130.3 (C-13), 129.2 (C-4), 128.6 (Ph), 128.5 (Ph), 128.0 (Ph), 
127.9 (Ph), 127.0 (Ph), 126.8 (Ph), 113.0 (C-8 or C-17), 112.9 (C-17 or C-8), 87.5 (C-6 or C-
15), 87.4 (C-15 or C-6), 71.0 (C-19 or C-20), 70.8 (C-20 or C-19), 62.9 (C-2), 56.8 (C-11), 
39.7 (C-12), 35.2 (C-3), 33.1 (C-21); HRMS (ESI) calculated for C33H31N2O4I2 [M+H]
+ 








Iodination of piperazine 101 
 
Iodination of piperazine 101 (1.30 g, 2.95 mmol) was performed following a similar 
procedure to that for the synthesis of 356 to afford product 171 as a colourless oil (1.16 g, 
1.68 mmol, 57% yield). Rf = 0.60 (EtOAc/petroleum ether 1:1); [α]D
20
 = -7.5 (c = 1.8, MeOH); 
FTIR (film) νmax 2969, 2927, 2792, 1689, 1611, 1520, 1246, 1055, 823; 
 1H NMR (CDCl3, 400 
MHz) δ 7.66 (d, J = 2.0 Hz, H-5 and H-14, 2H), 7.16 (dd, J = 8.4, 2.0 Hz, H-9 and H-18, 2H), 
6.75 (d, J = 8.4 Hz, H-8 and H-17, 2H), 4.12-4.03 (br m, H-2, 1H), 3.87 (s, H-19 or H-20, 3H), 
3.85 (s, H-20 or H-19, 3H), 3.80-3.74 (br m, H-10a, 1H), 3.05 (dd, J = 14.0, 3.9 Hz, H-12a, 
1H), 3.00-2.61 (m, H-3 and H-1a and H-10b, 4H), 2.47 (dd, J = 13.8, 9.0 Hz, H-12b, 1H), 
2.35 (s, H-21, 3H), 2.26-2.07 (m, H-1b and H-11, 2H), 1.33 (s, H-24, 9H); 13C NMR (CDCl3, 
100 MHz) δ 156.7 (C-7 or C-16), 156.6 (C-16 or C-7), 154.3 (C-22), 140.1 (C-5 or C-14), 
140.0 (C-14 or C-5), 133.6 (C-4 or C-13), 132.4 (C-13 or C-4), 130.4 (C-9 and C-18), 110.8 
(C-8 and C-17), 86.0 (C-6 and C-15), 79.7 (C-23), 63.8 (C-11), 57.8 (C-1), 56.4 (C-19 and C-
20), 53.5 (C-2), 43.2 (C-21), 42.9 (C-10), 36.2 (C-12), 34.7 (C-3), 28.3 (C-24); HRMS (ESI) 
calculated for C26H35I2N2O4 [M+H]
+ 693.0686, found 693.0688. 
 





Iodination of piperazine 102 (0.42 g, 0.71 mmol) was performed following a similar 
procedure to that for the synthesis of 356 to afford product 213 as a colourless oil (0.32 g, 
0.38 mmol, 53% yield). Rf = 0.30 (EtOAc/petroleum ether 1:3); [α]D
20
 = -14 (c = 0.7, CHCl3); 
FTIR (film) νmax 2975, 2927, 2793, 1689, 1488, 1249, 1046; 
1H NMR (CDCl3, 300 MHz) δ 
7.69 (d, J = 2.0 Hz, H-5 and H-14, 2H), 7.57-7.29 (m, PhH, 10H), 7.14 (dd, J = 8.6, 2.0 Hz, 
H-9 or H-18, 1H), 7.13 (dd, J = 8.4, 2.0 Hz, H-18 and H-9, 1H), 6.80 (d, J = 8.6 Hz, H-8 or 
H-17 1H), 6.78 (d, J = 8.4 Hz, H-17 or H-8, 1H), 5.14 (s, H-19 and H-20, 4H), 4.16-4.02 (br 
m, H-2, 1H), 3.88-3.70 (br m, H-10a, 1H), 3.06 (dd, J = 14.0, 3.2 Hz, H-12a, 1H), 2.89-2.64 
(m, H-3 and H-1a and H-10b, 4H), 2.51-2.42 (br m, H-12b, 1H), 2.36 (s, H-21, 3H), 2.25-2.07 
(br m, H-1b and H-11, 2H), 1.33 (s, H-24, 9H); 13C NMR (CDCl3, 100 MHz) δ 155.9 (C-7 or 
C-16), 155.8 (C-16 or C-7), 154.3 (COOtBu), 140.2 (C-5 or C-14), 140.0 (C-14 or C-5), 136.6 
(Ph), 134.0 (C-4 or C-13), 132.8 (C-13 or C-4), 130.3 (C-9 and C-18), 128.6 (Ph), 127.9 (Ph), 
127.5 (Ph), 127.0 (Ph), 112.6 (C-8 and C-17), 86.9 (C-6 and C-15), 79.7 (C-23), 71.0 (C-19 
and C-20), 63.7 (C-11), 57.9 (C-1), 53.7 (C-2), 43.2 (C-21), 43.0 (C-10), 36.3 (C-12), 34.8 
(C-3), 28.3 (C-24); HRMS (ESI) calculated for C38H42N2O4I2Na [M+Na]
+ 867.1132, found 
867.1152.  
 
Iodination of piperazine 159 
 
Iodination of piperazine 159 (0.41 g, 0.78 mmol) was performed following a similar 
procedure to that for the synthesis of 356 to afford product 169 as a colourless oil (0.43 g, 
0.55 mmol, 71% yield). Rf = 0.58 (EtOAc/petroleum ether 1:3); [α]D
20
 = +4.6 (c = 1.2, CHCl3); 
FTIR (film) νmax 2973, 2934, 1684, 1391, 1251, 1153; 




J = 2.0 Hz, ArH, 2H), 7.08 (dd, J = 8.4, 2.0 Hz, ArH, 2H), 6.74 (d, J = 8.4 Hz, ArH, 2H), 
4.10-4.00 (br m, NCH, 2H), 3.87 (s, OCH3, 6H), 3.87-3.85 (m, NCHaHb, 2H), 2.81 (dd, J = 
13.3, 4.1 Hz, ArCHaHb, 2H), 2.68-2.62 (m, NCHaHb, 2H), 2.57 (dd, J = 13.3, 8.4 Hz, 
ArCHaHb, 2H), 1.45 (s, COOC(CH3)3, 9H); 
13C NMR (CDCl3, 100 MHz) δ 156.9 (Ar), 155.0 
(COOtBu), 140.0 (Ar), 131.5 (Ar), 130.2 (Ar), 110.9 (Ar), 86.0 (Ar), 80.3 (COOC(CH3)3), 
56.4 (OCH3), 54.6 (NCH), 41.2 (NCH2), 36.7 (ArCH2), 28.4 (COOC(CH3)3); HRMS (ESI) 
calculated for C30H40I2N2O6Na [M+Na]
+ 801.0873, found 801.0867.  
 
Preparation of piperazine 218 
 
Piperazine derivative 218 was prepared from 169 (0.39 g, 0.50 mmol) following a similar 
procedure to that for the synthesis of 94 and was afforded as a yellow oil (0.26 g, 0.46 mmol, 
92% yield). Rf = 0.35 (MeOH:EtOAc = 1:2); [α]D
22
 = +14.5 (c = 0.8, CHCl3); FTIR (film) νmax 
2945, 2935, 2834, 1672, 1600, 1491, 1255, 1048; 1H NMR (CDCl3, 400 MHz) δ 7.57 (d, J = 
2.0 Hz, ArH, 2H), 7.08 (dd, J = 8.3, 2.0 Hz, ArH, 2H), 6.69 (d, J = 8.3 Hz, ArH, 2H), 3.78 (s, 
OCH3, 6H), 2.93-2.87 (m, CHNH, 2H), 2.79-2.65 (m, CH2, 8H), 2.30 (br s, NH, 2H); 
13C 
NMR (CDCl3, 100 MHz) δ 156.7 (Ar), 139.9 (Ar), 133.2 (Ar), 130.2 (Ar), 111.0 (Ar), 86.2 
(Ar), 56.4 (OCH3), 55.5 (CHNH), 47.4 (NCH2), 36.9 (ArCH2); HRMS (ESI) calculated for 
C20H25I2N2O2 [M+H]






Preparation of piperazine 161 
 
N-trifluoroacetyl-protected piperazine derivative 161 was prepared from 218 (0.18 g, 0.31 
mmol) following a similar procedure to that for the synthesis of 103 and was obtained as a 
colourless oil (0.20 g, 0.26 mmol, 85% yield). Rf = 0.50 (EtOAc/petroleum ether 1:3); [α]D
20
 = 
+47 (c = 1.8, CHCl3); FTIR (film) νmax 2970, 2949, 1691, 1492, 1203, 1139; 
1H NMR (CDCl3, 
400 MHz) δ 7.42 (d, J = 1.6 Hz, ArH, 2H), 6.94 (dd, J = 8.4, 1.6 Hz, ArH, 2H), 6.69 (d, J = 
8.4 Hz, ArH, 2H), 4.34 (dd, J = 10.8, 5.0 Hz, NCH, 2H), 3.83 (s, OCH3, 6H), 3.66 (dd, J = 
15.6, 5.0 Hz, NCHaHb, 2H), 2.85 (dd, J = 15.6, 10.8 Hz, NCHaHb, 2H), 2.73-2.68 (m, ArCH2, 
4H); 13C NMR (CDCl3, 100 MHz,) δ 157.5 (Ar), 156.5 (q, 
2JFC = 36 Hz, C=O), 140.0 (Ar), 
130.1 (Ar), 128.7 (Ar), 115.8 (q, 1JFC = 286 Hz, CF3), 111.0 (Ar), 86.2 (Ar), 56.5 (OCH3), 
55.4 (NCH), 42.4 (NCH2), 33.9 (ArCH2); HRMS (ESI) calculated for C24H22I2N2O4F6Na 
[M+Na]+ 792.9471, found 792.9465. 
 
Iodination of piperazine 160 
 
Iodination of piperazine 160 (0.14 g, 0.23 mmol) was performed following a similar 
procedure to that for the synthesis of 356 to afford product 217 as a white solid (0.14 g, 0.16 
mmol, 70% yield). M.p. 161-163 oC; Rf = 0.60 (EA:hexane = 1:4); [α]D
20
 = +14 (c = 0.8, 
CHCl3); FTIR (film) νmax 2927, 2854, 1490, 1345, 1254, 1159, 1048, 629; 




400 MHz) δ 7.71 (dd, J = 7.2, 1.4 Hz, ArH, 4H), 7.63 (dt, J = 2.1, 1.4 Hz, ArH, 2H), 7.58-
7.50 (m, ArH, 6H), 7.14 (dd, J = 8.4, 2.1 Hz, ArH, 2H), 6.77 (d, J = 8.4 Hz, ArH, 2H), 3.90 (s, 
OCH3, 6H), 3.73 (dd, J = 9.9, 4.8 Hz, CH, 2H), 3.15-3.08 (m, ArCHaHb and NCHaHb, 4H), 
3.03 (dd, J = 13.6, 4.8 Hz, NCHaHb, 2H), 2.88 (dd, J = 13.6, 9.9 Hz, ArCHaHb, 2H); 
13C NMR 
(CDCl3, 100 MHz) δ 157.1 (Ar), 139.9 (Ar), 138.4 (Ar), 133.2 (Ar), 130.9 (Ar), 130.8 (Ar), 
129.5 (Ar), 127.2 (Ar), 111.0 (Ar), 86.2 (Ar), 56.5 (CH), 56.4 (OCH3), 43.6 (NCH2), 38.0 
(ArCH2); HRMS (ESI) calculated for C32H32N2O6NaS2
127I2 [M+Na]
+ 880.9689, found 
880.9695. 
 
Preparation of tyrosine derivative 207 
 
The iodination of 91 (1.80 g, 5.82 mmol) was conducted following a similar procedure to that 
for the synthesis of 356 and 207 was obtained as a colourless oil (2.07 g, 4.77 mmol, 82% 
yield). Rf = 0.53 (EtOAc/petroleum ether 1:1); [α]D
20
 = +35.9 (c = 1.2, CHCl3); FTIR (film) 
νmax 3374, 2976, 1743, 1712, 1491, 1253, 1164, 1050, 1018; 
1H NMR (CDCl3, 300 MHz) δ 
7.48 (d, J = 1.5 Hz, ArH, 1H), 7.02 (dd, J = 8.4, 1.5 Hz, ArH, 1H), 6.67 (d, J = 8.4 Hz, ArH, 
1H), 5.07 (d, J = 7.7 Hz, NH, 1H), 4.53 (dd, J = 13.8, 6.0 Hz, CHNH, 1H ), 3.78 (s, ArOCH3, 
3H), 3.67 (s, COOCH3, 3H), 3.18 (dd, J = 14.0, 5.5 Hz, ArCHaHb, 1H), 2.98 (dd, J = 14.0, 
6.0 Hz, ArCHaHb, 1H), 1.37 (s, COOC(CH3)3, 9H); 
13C NMR (CDCl3, 100 MHz) δ 172.1 
(COOMe), 157.2 (Ar), 155.0 (COOtBu), 140.2 (Ar), 130.3 (Ar), 130.2 (Ar), 110.8 (Ar), 85.9 
(Ar), 80.0 (COOC(CH3)3), 56.4 (ArOCH3), 54.5 (CHNH), 52.3 (COOCH3), 36.9 (ArCH2), 
28.3 (COOC(CH3)3). 




Preparation of amine 208 
 
Amine 208 was prepared from 207 (0.80 g, 1.84 mmol) following a similar procedure to that 
for the synthesis of 94 and was obtained as a colourless oil (0.56 g, 1.67 mmol, 91% yield). Rf 
= 0.20 (EtOAc); [α]D
20
 = +32 (c = 0.5, MeOH); FTIR (film) νmax 3377, 2948, 2838, 1733, 
1490, 1252, 1197, 1176, 1048, 811; 1H NMR (CDCl3, 300 MHz) δ 7.63 (d, J = 2.1 Hz, ArH, 
1H), 7.16 (dd, J = 8.4, 2.1 Hz, ArH, 1H), 6.77 (d, J = 8.4 Hz, ArH, 1H), 3.88 (s, ArOCH3, 3H), 
3.74 (s, COOCH3, 3H), 3.68 (dd, J = 7.8, 5.2 Hz, CHNH, 1H), 3.01 (dd, J = 13.7, 5.2 Hz, 
ArCHaHb, 1H), 2.80 (dd, J = 13.7, 7.8 Hz, ArCHaHb, 1H), 1.75 (br s, NH2, 2H); 
13C NMR 
(CDCl3, 100 MHz) δ 175.1 (COOMe), 157.1 (Ar), 140.1 (Ar), 131.3 (Ar), 130.4 (Ar), 110.9 
(Ar), 86.1 (Ar), 56.4 (ArOCH3), 55.8 (CHNH), 52.1 (COOCH3), 39.4 (ArCH2). 
The observed data are in accord with published values.180 
 
Preparation of acid 209 
 
Acid 209 was prepared from 207 (0.98 g, 2.25 mmol) following a similar procedure to that for 
the synthesis of 92 and was obtained as a colourless oil (0.83 g, 1.98 mmol, 88% yield). Rf = 
0.35 (EtOAc/petroleum ether 1:2); [α]D
20
 = +34.4 (c = 1.0, CHCl3); FTIR (film) νmax 3326, 
2978, 1712, 1492, 1254, 1166, 1050; 1H NMR (CDCl3, 300 MHz) (major rotamer) δ 9.99 (s, 
COOH, 1H), 7.59 (d, J = 2.0 Hz, ArH, 1H), 7.14 (dd, J = 8.4, 2.0 Hz, ArH, 1H), 6.75 (d, J = 




(s, OCH3, 3H), 3.17-3.11 (m, ArCH2, 2H), 1.44 (s, COOC(CH3)3, 9H); 
13C NMR (CDCl3, 100 
MHz) (major rotamer) δ 175.5 (COOH), 157.2 (Ar), 155.3 (COOtBu), 140.3 (Ar), 130.4 (Ar), 
130.1 (Ar), 110.9 (Ar), 85.9 (Ar), 80.4 (COOC(CH3)3), 56.4 (OCH3), 54.3 (CHNH), 36.5 
(ArCH2CH), 28.3 (COOC(CH3)3). 
The observed data are in accord with published values.181 
 
Preparation of dipeptide 210 
 
Dipeptide 210 was prepared from acid 209 (0.80 g, 1.90 mmol) and amine 208 (0.63 g, 1.90 
mmol) following a similar procedure to that for the synthesis of 95 and was obtained as a 
colourless oil (1.11 g, 1.50 mmol, 79% yield). Rf = 0.60 (EtOAc:hexane = 1:1); [α]D
20
 = +37.6 
(c = 1.8, CHCl3); FTIR (film) νmax 3309, 2974, 2938, 1742, 1657, 1491, 1253, 1168, 1049; 
1H 
NMR (CDCl3, 400 MHz) δ 7.63 (d, J = 2.0 Hz, H-5 or H-14, 1H), 7.42 (d, J = 2.0 Hz, H-14 or 
H-5, 1H), 7.17 (dd, J = 8.4, 2.0 Hz, H-9 or H-18, 1H), 6.95 (dd, J = 8.4, 2.0 Hz, H-18 or H-9, 
1H), 6.75 (d, J = 8.4 Hz, H-8 or H-17, 1H), 6.71 (d, J = 8.4 Hz, H-17 or H-8, 1H), 6.38 (d, J = 
7.4 Hz, CHCONH, 1H), 5.09 (d, J = 7.1 Hz, NHBoc, 1H), 4.74 (dd, J = 12.7, 7.4 Hz, H-11, 
1H), 4.30 (dd, J = 13.2, 7.1 Hz, H-2, 1H), 3.86 (s, H-20 and H-21, 6H), 3.72 (s, H-19, 3H), 
3.03-2.95 (m, H-3 and H-12, 4H), 1.43 (s, H-24, 9H); 13C NMR (CDCl3, 100 MHz) δ 171.2 
(C-10), 170.7 (C-1), 157.2 (C-7 and C-16), 155.3 (C-22), 140.1 (C-5 and C-14), 130.7 (C-4 or 
C-13), 130.4 (C-9 or C-18), 130.3 (C-18 or C-9), 129.8 (C-13 or C-4), 110.0 (C-8 or C-17), 




56.3 (C-21 or C-20), 55.7 (C-2), 53.3 (C-11), 52.5 (C-19), 36.9 (C-3 or C-12), 36.5 (C-12 or 
C-3), 28.3 (C-24); HRMS (ESI) calculated for C26H32N2O7I2Na [M+Na]
+ 761.0197, found 
761.0194. 
 
Preparation of DKP 211 
 
DKP 211 was prepared from dipeptide 210 (1.51 g, 2.13 mmol) following a similar procedure 
to that for the synthesis of 157 and was obtained as a white solid (0.89 g, 1.47 mmol, 69% 
yield). M.p. 189-190 oC; Rf = 0.20 (EtOAc/MeOH 5:1); [α]D
20
 = -130.2 (c = 0.55, CHCl3); 
FTIR (film) νmax 3192, 2971, 1666, 1492, 1254, 1050, 760; 
1H NMR (DMSO-d6, 300 MHz) δ 
8.07 (s, NH, 2H), 7.44 (d, J = 1.6 Hz, ArH, 2H), 7.00 (dd, J = 8.4, 1.6 Hz, ArH, 2H), 6.87 (d, 
J = 8.4 Hz, ArH, 2H), 3.97 (dd, J = 5.4, 4.7 Hz, CHNH, 2H), 3.79 (s, OCH3, 6H), 2.55 (dd, J 
= 13.7, 4.7 Hz, ArCHaHb, 2H), 2.33 (dd, J = 13.7, 5.4 Hz, ArCHaHb, 2H); 
13C NMR (DMSO-
d6, 100 MHz) δ 166.2 (C=O), 156.4 (Ar), 140.0 (Ar), 131.0 (Ar), 130.6 (Ar), 111.0 (Ar), 85.8 
(Ar), 56.2 (CHNH), 55.2 (OCH3), 37.5 (ArCH2); HRMS (ESI) calculated for C20H21N2O4I2 
[M+H]+ 606.9591, found 606.9598. 
 
Preparation of piperazine 215 
 




that for the synthesis of 111 and was obtained as a colourless oil (0.44 g, 0.58 mmol, 60% 
yield). Rf = 0.50 (MeOH:EtOAc = 1:2); [α]D
20
 = +81 (c = 1.2, CHCl3); FTIR (film) νmax 2925, 
2852, 2792, 1509, 1487, 1453, 1241, 734; 1H NMR (CDCl3, 400 MHz) δ 7.70 (d, J = 2.0 Hz, 
ArH, 2H), 7.53 (d, J = 7.3 Hz, ArH, 4H), 7.42 (t, J = 7.3 Hz, ArH, 4H), 7.36 (d, J = 7.3 Hz, 
ArH, 2H), 7.13 (dd, J = 8.4, 2.0 Hz, ArH, 2H), 6.81 (d, J = 8.4 Hz, ArH, 2H), 5.15 (s, PhCH2, 
4H), 2.87 (dd, J = 13.2, 3.3 Hz, ArCHaHb, 2H), 2.69 (dd, J = 13.2, 10.0 Hz, ArCHaHb, 2H), 
2.58-2.52 (br m, NCH, 2H), 2.46 (dd, J = 11.5, 6.2 Hz, NCHaHb, 2H), 2.37 (s, NCH3, 6H), 
2.25 (dd, J = 11.5, 3.1 Hz, NCHaHb, 2H); 
13C NMR (CDCl3, 100 MHz) δ 155.6 (Ar), 140.1 
(Ar), 136.9 (Ar), 134.8 (Ar), 130.3 (Ar), 128.6 (Ar), 127.9 (Ar), 127.0 (Ar), 112.6 (Ar), 86.8 
(Ar), 70.5 (PhCH2), 62.5 (NCH), 55.3 (ArCH2), 42.7 (NCH3), 31.6 (NCH2); HRMS (ESI) 
calculated for C34H37N2O2I2 [M+H]
+ 759.0944, found 759.0952. 
 
Preparation of piperazine 164 (Li-I exchange approach) 
 
n-Butyllithium (0.23 mL, 0.36 mmol, 1.6 M solution in hexanes) was added dropwise to a 
solution of piperazine derivative 169 (95 mg, 0.12 mmol) in anhydrous THF (6 mL) at -78 oC. 
The mixture was stirred at -78 oC for 1 h before the addition of freshly distilled 
chlorotrimethylsilane (77 μL, 0.60 mmol). The resultant mixture was stirred at -78 oC for 30 




quench the reaction and the mixture was extracted with DCM (3×15 mL). The combined 
organic fractions were washed with brine (15 mL), dried over MgSO4 and concentrated under 
reduced pressure. The residue was purified by flash column chromatography eluting with 15% 
EtOAc in petroleum ether to afford 164 (63% yield) and 163 (12% yield) as colourless oils, 
along with deiodinated material 159 (10% yield). 
Data for 164: Rf = 0.62 (EtOAc/petroleum ether 1:3); [α]D
20
 = +20 (c = 0.2, CHCl3); FTIR 
(film) νmax 2961, 2936, 1693, 1402, 1239, 1157, 838; 
1H NMR (CDCl3, 300 MHz) δ 7.11 (d, J 
= 2.2 Hz, ArH, 2H), 7.08 (dd, J = 8.2, 2.2 Hz, ArH, 2H), 6.73 (d, J = 8.2 Hz, ArH, 2H), 4.12-
4.01 (br m, CH, 2H), 3.97-3.85 (br m, NCHaHb, 2H), 3.79 (s, OCH3, 6H), 2.86 (dd, J = 13.2, 
4.0 Hz, ArCHaHb, 2H), 2.67-2.51 (m, ArCHaHb and NCHaHb, 4H), 1.45 (s, COOC(CH3)3, 
18H), 0.26 (s, Si(CH3)3, 18H); 
13C NMR (CDCl3, 100 MHz) δ 164.1 (Ar), 156.0 (COO
tBu), 
136.6 (Ar), 132.3 (Ar), 129.6 (Ar), 129.0 (Ar), 110.6 (Ar), 80.8 (COOC(CH3)3), 56.1 (OCH3), 
55.6 (CH), 42.1 (NCH2), 38.4 (CH2Ar), 29.4 (COOC(CH3)3), 0.0 (Si(CH3)3); HRMS (ESI) 
calculated for C36H58N2O6
28Si2Na [M+Na]
+ 693.3731, found 693.3738. 
 
Data for 163: Rf = 0.61 (EtOAc/petroleum ether 1:3); [α]D
20
 = +25.6 (c = 0.5, CHCl3); FTIR 
(film) νmax 2970, 2936, 1693, 1404, 1244, 1163, 840; 
1H NMR (CDCl3, 300 MHz) δ 7.09 (d, J 
= 2.1 Hz, H-5, 1H), 7.08 (dd, J = 8.2, 2.1 Hz, H-9, 1H), 7.03 (d, J = 8.6 Hz, H-14, 2H), 6.81 
(d, J = 8.6 Hz, H-15, 2H), 6.72 (d, J = 8.2 Hz, H-8, 1H), 4.14-4.00 (br m, H-2 and H-11, 2H), 




3a and H-12a, 2H), 2.65-2.54 (m, H-1b and H-3b and H-10b and H-12b, 4H), 1.46 (s, H-21 or 
H-24, 9H), 1.45 (s, H-24 or H-21, 9H), 0.27 (s, H-25, 9H); 13C NMR (CDCl3, 100 MHz) δ 
164.1 (C-7), 159.2 (C-16), 156.0 (C-19 and C-22), 136.7 (C-5), 132.4 (C-9), 131.2 (C-14), 
130.1 (C-13), 129.5 (C-4), 129.0 (C-6), 114.9 (C-15), 110.5 (C-8), 80.9 (C-19 and C-22), 56.2 
(C-17 or C-18), 56.1 (C-18 or C-17), 55.4 (C-2 and C-11), 42.1 (C-1 and C-10), 38.1 (C-3 and 
C-12), 29.4 (C-19 and C-22), 0.0 (C-25); HRMS (ESI) calculated for C33H50N2O6
28SiNa 
[M+Na]+ 621.3336, found 621.3337. 
 
General procedure for oxidative cuprate coupling 
Attempted intramolecular oxidative cuprate coupling with piperazine 169: 
 
Oxidation using nitrobenzene: To a solution of piperazine derivative 169 (0.36 g, 0.46 mmol) 
in anhydrous THF (10 mL) was added n-butyllithium (0.63 mL, 1.01 mmol, 1.6 M in hexanes) 
dropwise at -78 oC under N2. The reaction mixture was stirred at the same temperature for 30 
min before being transferred to a pre-cooled flask at -78 oC containing a suspension of CuCN 
(42 mg, 0.46 mmol) in THF (15 mL). The resultant mixture was stirred at -78 oC for 30 min 
and then at -40 oC for 1 h. Upon warming up, the reaction mixture became homogeneous and 
the colour of the system changed from light yellow to light green. The reaction solution was 




resultant mixture was allowed to warm up to rt within 2 h and stirred for 3 h. Upon fully 
consumption of the starting material, the mixture was partitioned between water (20 mL) and 
DCM (20 mL). The aqueous phase was extracted with DCM (3×15 mL). The organic 
fractions were combined, washed with brine (15 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography (gradient eluent: 20% to 35% EtOAc in petroleum ether) to afford 175 (0.12 
g, 0.23 mmol, 50% yield) and 174 (0.05 g, 0.09 mmol, 20% yield) as colourless oils, along 
with deiodinated material 159 (41 mg, 0.078 mmol, 17% yield). 
 
Oxidation using O2: n-Butyllithium (0.31 mL, 0.50 mmol, 1.6 M solution in hexanes) was 
added dropwise to a solution of piperazine derivative (0.18 g, 0.23 mmol) in anhydrous THF 
(8 mL) at -78 oC under N2. The reaction mixture was stirred at the same temperature for 30 
min before being transferred to a pre-cooled flask at -78 oC containing a suspension of CuCN 
(21 mg, 0.23 mmol) in THF (8 mL). The resultant mixture was stirred at -78 oC for 30 min 
and then at -40 oC for 1 h. The reaction solution was then cooled to -78 oC and dry molecular 
oxygen was bubbled through the reaction mixture for 1 h. The mixture was then allowed to 
warm to rt and stirred for 3 h under an atmosphere of O2. The system was cooled to 0 
oC and 
water (5 mL) was added. The mixture was partitioned between water (15 mL) and DCM (20 
mL). The aqueous phase was extracted with DCM (3×10 mL). The combined organic 
fractions were washed with brine (15 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash column chromatography (gradient eluent: 
20% to 35% EtOAc in petroleum ether) to afford 175 (68 mg, 0.12 mmol, 53% yield) and 174 
(32 mg, 0.060 mmol, 26% yield) as colourless oils, along with deiodinated material 159 (17 




Data for 175: Rf = 0.30 (EtOAc/petroleum ether 1:2); [α]D
20
 = +66.4 (c = 0.5, CHCl3); FTIR 
(film) νmax 3670, 2973, 2931, 1685, 1405, 1244, 1153, 1023; 
1H NMR (CDCl3, 300 MHz) δ 
6.76 (d, J = 8.2 Hz, ArH, 2H), 6.70 (d, J = 1.8 Hz, ArH, 2H), 6.60 (dd, J = 8.2, 1.8 Hz, ArH, 
2H), 5.63 (br s, OH, 2H), 4.11-3.98 (br m, CH, 2H), 3.93-3.83 (br m, NCHaHb, 2H), 3.88 (s, 
OCH3, 6H), 2.82 (dd, J = 13.2, 3.9 Hz, ArCHaHb, 2H), 2.62-2.56 (m, ArCHaHb and NCHaHb, 
4H), 1.46 (s, COOC(CH3)3, 18H); 
13C NMR (CDCl3, 100 MHz) δ 155.1 (COO
tBu), 145.5 
(Ar), 145.3 (Ar), 130.4 (Ar), 120.7 (Ar), 115.6 (Ar), 110.8 (Ar), 80.0 (COOC(CH3)3), 56.0 
(OCH3), 54.5 (CH), 41.2 (NCH2), 37.5 (CH2Ar), 28.4 (COOC(CH3)3); HRMS (ESI) 
calculated for C30H42N2O8Na [M+Na]
+ 581.2839, found 581.2834. 
 
Data for 174: Rf = 0.35 (EtOAc/petroleum ether 1:2); [α]D
20
 = +118 (c = 0.2, CHCl3); FTIR 
(film) νmax 3369, 2973, 2930, 1683, 1511, 1406, 1245, 1153, 1121, 734; 
1H NMR (CDCl3, 300 
MHz) δ 7.04 (d, J = 8.6 Hz, H-14, 2H), 6.82 (d, J = 8.6 Hz, H-15, 2H), 6.75 (d, J = 8.2 Hz, H-
8, 1H), 6.70 (d, J = 1.9 Hz, H-5, 1H), 6.59 (dd, J = 8.2, 1.9 Hz, H-9, 1H), 5.60 (br s, OH, 1H), 
4.07-4.03 (br m, H-2 and H-11, 2H), 3.88 (s, H-18, 3H), 3.88-3.80 (br m, H-1a and H-10a, 
2H), 3.81 (s, H-17, 3H), 2.86-2.78 (m, H-3a and H-12a, 2H), 2.66-2.55 (m, H-1b and H-3b 
and H-10b and H-12b, 4H), 1.46 (s, H-21 or H-24, 9H), 1.45 (s, H-24 or H-21, 9H); 13C NMR 
(CDCl3, 100 MHz) δ 158.3 (C-16), 155.1 (C-19 and C-22), 145.5 (C-7), 145.3 (C-6), 130.4 
(C-4), 130.3 (C-14), 129.2 (C-13), 120.7 (C-9), 115.5 (C-5), 113.9 (C-15), 110.7 (C-8), 80.0 




(C-3), 37.1 (C-12), 28.4 (C-21 and C-24); HRMS (ESI) calculated for C30H42N2O7Na 
[M+Na]+ 565.2890, found 565.2892. 
 
Model reactions with 4-iodoanisole: 
 
The reaction with 170 (0.16 g, 0.68 mmol) was conducted following a similar procedure to 
that for the synthesis of 175 and biphenyl 141 was obtained as a colourless crystalline solid in 
79% yield (57 mg, 0.27 mmol, CuCl2 as the oxidant) or 86% yield (63 mg, 0.29 mmol, 
PhNO2 as the oxidant). M.p. 177-178 ºC; Rf = 0.55 (hexane:EtOAc = 15:1); FTIR (film) νmax 
2958, 2840, 1608, 1502, 1276, 1251, 1041, 824, 737; 1H NMR (CDCl3, 300 MHz) δ 7.50 (d, J 
= 8.8 Hz, 4H), 6.98 (d, J = 8.8 Hz, 4H), 3.87 (s, 6H); 13C NMR (CDCl3, 100 MHz) δ 158.7, 
133.5, 127.7, 114.2, 55.4. 
The observed data are in accord with published values.182 
 
General procedure for intramolecular Suzuki-Miyaura coupling 
 
To a mixture of DKP 211 derivative (62 mg, 0.10 mmol), Pd(dppf)Cl2•CH2Cl2 (16 mg, 0.02 
mmol), bis(pinacolato)diboron (28 mg, 0.11 mmol) and K2CO3 (80 mg, 0.60 mmol) was 




argon for 20 h. The mixture was then cooled to rt and partitioned between 5% HCl (30 mL) 
and 3:1 CHCl3/isopropanol (40 mL). The aqueous phase was extracted with 3:1 
CHCl3/isopropanol (2×40 mL). The combined organic fractions were washed with brine (30 
mL), dried over MgSO4, filtered and concentrated under reduced pressure. The crude product 
was purified by flash column chromatography eluting with 5% MeOH in DCM to afford the 
coupling DKP product 212 as a white solid (15 mg, 39% yield). M.p. (dec.) 252-256 ºC; 
[α]D
20
 = +32 (c = 0.2, CHCl3); FTIR (film) νmax 3181, 3041, 2958, 1664, 1512, 1266; 
1H NMR 
(DMSO-d6, 400 MHz) δ 8.00 (s, NH, 2H), 7.02 (dd, J = 8.2, 1.7 Hz, ArH, 2H), 6.84 (d, J = 
8.2 Hz, ArH, 2H), 6.49 (d, J = 1.7 Hz, ArH, 2H), 4.34 (d, J = 5.2 Hz, CHNH, 2H), 3.80 (s, 
OCH3, 6H), 3.55 (d, J = 15.3 Hz, ArCHaHb, 2H), 2.66 (dd, J = 15.3, 5.7 Hz, ArCHaHb, 2H); 
13C NMR (DMSO-d6, 100 MHz) δ 168.2 (C=O), 154.9 (Ar), 141.4 (Ar), 130.5 (Ar), 129.2 
(Ar), 126.9 (Ar), 111.3 (Ar), 56.2 (ArOCH3), 55.5 (CHNH), 33.4 (ArCH2); HRMS (ESI) 
calculated for C20H21N2O4 [M+H]
+ 353.1501, found 353.1499. 
 
Preparation of DKP 114 
 
DKP 114 was prepared from 356 (109 mg, 0.17 mmol) following a similar procedure to that 
for the synthesis of 212 and was obtained as a white solid (29 mg, 0.08 mmol, 48% yield). 
M.p. 118-119 ºC; Rf = 0.25 (MeOH/EtOAc = 1:6); [α]D
20
 = +74 (c = 0.7, MeOH); FTIR (film) 
νmax 3242, 2959, 2929, 1674, 1651, 1510, 1263, 1247; 
1H NMR (CDCl3, 300 MHz) δ 7.06 (dd, 




Hz, H-6 or H-15, 1H), 6.76 (d, J = 8.2 Hz, H-15 or H-6, 1H), 6.53 (d, J = 2.2 Hz, H-9 or H-18, 
1H), 6.45 (d, J = 1.8 Hz, H-18 or H-9, 1H), 5.71 (s, NH, 1H), 4.50 (dd, J = 9.4, 5.8 Hz, H-11, 
1H), 4.35 (dd, J = 9.4, 6.3 Hz, H-2, 1H), 4.07 (dd, J = 15.9, 9.4 Hz, H-12a, 1H), 4.02 (dd, J = 
15.9, 9.4 Hz, H-3a, 1H), 3.93 (s, H-20 or H-21, 3H), 3.91 (s, H-21 or H-20, 3H), 2.98 (dd, J = 
15.9, 6.3 Hz, H-3b, 1H), 2.80 (s, H-19, 3H), 2.65 (dd, J = 15.9, 5.8 Hz, H-12b, 1H); 13C NMR 
(CDCl3, 100 MHz) δ 167.9 (C-10), 166.9 (C-1), 155.7 (C-7 or C-16), 155.5 (C-16 or C-7), 
141.9 (C-9 or C-18), 141.6 (C-18 or C-9), 129.9 (C-5 or C-14), 129.6 (C-14 or C-5), 129.5 
(C-4 or C-13), 129.1 (C-13 or C-4), 125.4 (C-8 or C-17), 125.2 (C-17 or C-8), 112.2 (C-6 or 
C-15), 111.8 (C-15 or C-6), 62.2 (C-2), 56.3 (C-11), 56.1 (C-20 or C-21), 56.0 (C-21 or C-20), 
34.7 (C-12), 34.1 (C-3), 31.7 (C-19); HRMS (ESI) calculated for C21H22N2O4Na [M+Na]
+ 
389.1477, found 389.1471. 
 
Preparation of DKP 220 
 
DKP 220 was prepared from 219 (0.21 g, 0.27 mmol) following a similar procedure to that 
for the synthesis of 212 and was obtained as a white solid (73 mg, 0.14 mmol, 52% yield). 
M.p. 169-172 oC; Rf = 0.22 (EtOAc/MeOH 6:1); [α]D
25
 = +116 (c = 0.4, CHCl3); FTIR (film) 
νmax 3221, 2974, 2901, 1677, 1664, 1507, 1251, 1052, 736; 
1H NMR (CDCl3, 300 MHz) δ 
7.40-7.32 (m, PhH, 4H), 7.31-7.24 (m, PhH, 6H), 7.03 (dd, J = 8.3, 2.3 Hz, H-5 or H-14, 1H), 
6.96 (dd, J = 8.2, 2.1 Hz, H-14 or H-5, 1H), 6.81 (d, J = 8.3 Hz, H-6 or H-15, 1H), 6.75 (d, J 




or H-9, 1H), 5.98 (s, NH, 1H), 5.26 (d, J = 11.8 Hz, PhCHaHb, 1H), 5.19 (d, J = 11.8 Hz, 
PhCHaHb, 1H), 5.13 (s, PhCH2, 2H), 4.50 (d, J = 6.4 Hz, H-11, 1H), 4.35 (d, J = 6.4 Hz, H-2, 
1H), 4.07 (d, J = 5.9 Hz, H-12a, 1H), 4.02 (d, J = 5.9 Hz, H-3a, 1H), 2.98 (dd, J = 15.9, 6.4 
Hz, H-3b, 1H), 2.80 (s, H-19, 3H), 2.67 (dd, J = 15.9, 6.4 Hz, H-12b, 1H); 13C NMR (CDCl3, 
100 MHz) δ 167.8 (C-10), 166.8 (C-1), 154.9 (C-7 or C-16), 154.8 (C-16 or C-7), 141.9 (C-9 
or C-18), 141.6 (C-18 or C-9), 137.4 (Ph), 137.3 (Ph), 130.4 (C-4 or C-13), 129.9 (C-13 or C-
4), 129.7 (C-5 or C-14), 129.4 (C-14 or C-5), 128.4 (Ph), 127.6 (Ph), 127.5 (Ph), 127.4 (Ph), 
125.7 (C-8 or C-17), 125.6 (C-17 or C-8), 114.2 (C-6 or C-15), 113.6 (C-15 or C-6), 70.8 
(PhCH2), 70.7 (PhCH2), 62.2 (C-2), 56.3 (C-11), 34.8 (C-12), 34.1 (C-3), 31.7 (C-19); HRMS 
(ESI) calculated for C33H30N2O4Na [M+Na]
+ 541.2103, found 541.2115. 
 
Intramolecular Suzuki-Miyaura coupling of 169 
 
The coupling reaction of piperazine 169 (0.13 g, 0.17 mmol) was performed following a 
similar procedure to that for the synthesis of 212 and dimeric compound 206 was isolated as a 
white solid (18 mg, 0.015 mmol, 18% yield). M.p. 160-161 ºC; Rf = 0.40 (EtOAc/petroleum 
ether 1:2); [α]D
20
 = +30 (c = 0.2, CHCl3); FTIR (film) νmax 2974, 2930, 1688, 1246, 1153, 




14 and H-18 and H-23 and H-27 and H-32, 7H), 6.89 (d, J = 8.4 Hz, H-17 or H-26, 1H), 6.88 
(d, J = 8.4 Hz, H-26 or H-17, 1H), 6.81 (d, J = 8.6 Hz, H-33, 2H), 6.72 (d, J = 8.4 Hz, H-8, 
1H), 4.18-4.00 (br m, H-2 and H-11 and H-20 and H-29, 4H), 3.99-3.72 (m, H-1a and H-10a 
and H-19a and H-28a, 4H), 3.85 (s, OCH3, 3H), 3.79 (s, OCH3, 3H), 3.76 (s, OCH3, 6H), 
2.94-2.76 (m, H-3a and H-12a and H-21a and H-30a, 4H), 2.72-2.48 (m, H-1b and H-3b and 
H-10b and H-12b and H-19b and H-21b and H-28b and H-30b, 8H), 1.46 (s, COOC(CH3)3, 
9H), 1.45 (s, COOC(CH3)3, 18H), 1.44 (s, COOC(CH3)3, 9H); 
13C NMR (CDCl3, 100 MHz) δ 
158.3 (C-34), 156.9 (C-7), 155.8 (C-16 and C-25), 155.1 (COOtBu), 155.0 (COOtBu), 140.0 
(C-5), 132.5 (C-32), 131.7 (C-13 and C-22), 130.2 (C-9 and C-14 and C-23), 129.3 (C-4 or C-
31), 129.1 (C-18 and C-27), 128.7 (C-31 or C-4), 127.4 (C-15 and C-24), 113.9 (C-33), 111.3 
(C-17 and C-26), 110.9 (C-8), 86.0 (C-6), 80.0 (COOC(CH3)3), 79.9 (COOC(CH3)3), 56.4 
(OCH3), 55.8 (OCH3), 55.3 (OCH3), 54.7 and 54.6 (C-2 and C-11 and C-20 and C-29), 41.1 
(C-1 and C-10 and C-19 and C-28), 37.3 (C-3 and C-12 and C-21 and C-30), 28.4 
(COOC(CH3)3); HRMS (ESI) calculated for C60H82N4O12I [M+H]
+ 1177.4974, found 
1177.4980. 
 





The coupling reaction of piperazine 161 (96 mg, 0.12 mmol) was performed following a 
similar procedure to that for the synthesis of 212 and dimeric compound 358 was isolated as a 
colourless viscous oil (8 mg, 0.007 mmol, 12% yield). Rf = 0.45 (EtOAc/petroleum ether 1:2); 
[α]D
20
 = +43 (c = 0.3, CHCl3); FTIR (film) νmax 2924, 2854, 1690, 1444, 1240, 1204, 1138; 
1H 
NMR (CDCl3, 300 MHz) δ 7.44 (d, J = 1.0 Hz, H-5, 1H), 7.04-6.79 (m, H-9 and H-14 and H-
17 and H-18 and H-23 and H-26 and H-27 and H-32, 9H), 6.72 (d, J = 8.4 Hz, H-33, 2H), 
6.64 (d, J = 8.4 Hz, H-8, 1H), 4.45-4.28 (m, H-2 and H-11 and H-20 and H-29, 4H), 3.78 (s, 
OCH3, 3H), 3.71 (s, OCH3, 3H), 3.70 (s, OCH3, 3H), 3.70 (s, OCH3, 3H), 3.80-3.59 (m, H-1a 
and H-10a and H-19a and H-28a, 4H), 3.07-2.54 (m, H-1b and H-3 and H-10b and H-12 and 
H-19b and H-21 and H-28b and H-30, 12H); HRMS (ESI) calculated for C48H46N4O8IF12 
[M+H]+ 1161.2169, found 1161.2220. 
Due to the small quantity of material, 13C NMR spectrum was not obtained. The 1H NMR 
signals of 358 were assigned by referring to the cases of dimeric product 206 and piperazine 
161. 
 
Preparation of piperazine 214 
 
Piperazine 214 was prepared from 213 (0.12 g, 0.14 mmol) following a similar procedure to 
that for the synthesis of 212 and was obtained as a colourless oil (5 mg, 0.008 mmol, 6% 
yield). Rf = 0.65 (EA/hexane = 1:5); [α]D
20
 = -83.2 (c = 0.5, MeOH); FTIR (film) νmax 2961, 




(m, ArH, 6H), 6.86-6.78 (m, ArH, 2H), 6.74 (dd, J = 8.2, 2.4 Hz, ArH, 2H), 5.25 (br s, PhCH2, 
4H), 4.18-4.03 (m, NCH, 1H), 3.50-3.37 (m, CH2, 1H), 3.30-3.09 (m, CH2, 2H), 2.58-2.39 (m, 
CH2, 2H), 2.34-2.08 (m, NCH and CH2, 4H), 1.94 (s, NCH3, 3H), 1.37 (s, COOC(CH3)3, 9H); 
13C NMR (DMSO-d6, 100 MHz) δ 154.3 (Ar), 154.0 (Ar), 153.0 (Ar), 142.9 (Ar), 137.5 (Ar), 
137.4 (Ar), 129.7 (Ar), 129.3 (Ar), 129.0 (Ar), 128.5 (Ar), 128.2 (Ar), 127.5 (Ar), 127.4 (Ar), 
113.6 (Ar), 79.0 (COOC(CH3)3), 70.3 (PhCH2), 70.0 (PhCH2), 61.9 (CH), 50.6 (CH and 
NCH2), 45.1 (NCH2), 42.5 (NCH3), 36.0 (ArCH2), 33.3 (ArCH2), 28.0 (COOC(CH3)3); 
HRMS (ESI) calculated for C38H43N2O4 [M+H]
+ 591.3223, found 591.3231. 
Due to the small quantity of material, suitable 2D NMR spectra were not obtained. 
 
Preparation of piperazine 173 
 
Piperazine 173 was prepared from precursor 171 (0.13 g, 0.19 mmol) following a similar 
procedure to that for the synthesis of 212 and was obtained as a colourless oil (3 mg, 0.008 
mmol, 4% yield). Rf = 0.60 (EA/hexane = 1:4); FTIR (film) νmax 3230, 2957, 2927, 2850, 
1673, 1651, 1509, 1263; 1H NMR (CDCl3, 300 MHz) δ 7.39 (br s, 2H), 6.97-6.88 (m, 2H), 
6.77 (dd, J = 7.6, 6.3 Hz, 2H), 4.27-4.14 (m, 1H), 3.99 (s, 2×OCH3, 6H), 3.59-3.43 (m, 1H), 
3.39-3.17 (m, 2H), 2.70-2.49 (m, 2H), 2.46-2.16 (m, 4H), 2.03 (s, NCH3, 3H), 1.45 (s, 
COOC(CH3)3, 9H); HRMS (ESI) calculated for C26H35N2O4 [M+H]
+ 439.2597, found 
439.2593. 




Preparation of piperazine 216 
 
Piperazine 216 was prepared from precursor 215 (101 mg, 0.13 mmol) following a similar 
procedure to that for the synthesis of 212 and was obtained as a white solid (3 mg, 0.005 
mmol, 4% yield). M.p. 149-150 ºC; Rf = 0.30 (EA:Hexane = 2:3); FTIR (film) νmax 2963, 
2922, 1685, 1673, 1507, 1455, 1380, 1263, 1057; 1H NMR (CDCl3, 400 MHz) δ 8.20 (d, J = 
2.2 Hz, 2H), 7.42 (dd, J = 7.3, 2.0 Hz, 4H), 7.27-7.20 (m, 6H), 6.95 (dd, J = 8.1, 2.2 Hz, 2H), 
6.73 (d, J = 8.1 Hz, 2H), 5.21 (s, PhCH2, 4H), 3.11-2.90 (m, 4H), 2.83-2.73 (m, 2H), 2.73-
2.66 (m, 2H), 2.65-2.55 (m, 2H), 1.80 (s, NCH3, 6H); HRMS (ESI) calculated for C34H37N2O2 
[M+H]+ 505.2855, found 505.2844. 
Due to the small quantity of material, 13C NMR spectrum was not obtained. 
 
Preparation of piperazine 259 
 
The methylation of 114 (0.19 g, 0.52 mmol) was performed following a similar procedure to 
that for the synthesis of 93 (Method A) and DKP 259 was obtained as a white solid (0.14 g, 
0.38 mmol, 73% yield). M.p. 180-182 oC; Rf = 0.30 (MeOH:EtOAc = 1:6); [α]D
20
 = +101 (c = 
0.5, CHCl3); FTIR (film) νmax 2956, 2929, 2851, 1655, 1648, 1508, 1255; 




400 MHz) δ 7.05 (dd, J = 8.3, 2.0 Hz, ArH, 2H), 6.77 (d, J = 8.3 Hz, ArH, 2H), 6.46 (d, J = 
2.0 Hz, ArH, 2H), 4.34 (d, J = 6.4 Hz, CH, 2H), 4.10 (d, J = 16.0 Hz, CHaHb, 2H), 3.92 (s, 
OCH3, 6H), 2.94 (dd, J = 16.0, 6.4 Hz, CHaHb, 2H), 2.80 (s, NCH3, 6H); 
13C NMR (CDCl3, 
100 MHz) δ 166.6 (C=O), 155.5 (Ar), 141.9 (Ar), 129.4 (Ar), 129.1 (Ar), 125.3 (Ar), 111.9 
(Ar), 62.1 (CH), 56.0 (OCH3), 33.8 (CH2), 31.5 (NCH3); HRMS (ESI) calculated for 
C22H24N2O4Na [M+Na]
+ 403.1634, found 403.1635. 
 
General procedure for directed ortho lithiation 
Model reaction with 1,2-dimethoxybenzene: 
 
n-Butyllithium (1.42 mL, 2.28 mmol, 1.6 M solution in hexanes) was added dropwise to a 
solution of 1,2-dimethoxybenzene (0.21 g, 1.52 mmol) and freshly distilled TMEDA (0.45 
mL, 4.56 mmol) in anhydrous THF (10 mL) at -78 oC. The mixture was warmed up to rt and 
stirred for 3 h. The system was then cooled to -78 oC and freshly distilled 
chlorotrimethylsilane (0.58 mL, 4.56 mmol) was added to the reaction mixture. The resultant 
mixture was stirred at -78 oC for 30 min and then at rt for 5 h. Saturated NaHCO3 aqueous 
solution (15 mL) was added slowly to quench the reaction and the mixture was extracted with 
Et2O (3×15 mL). The combined organic fractions were washed with brine (15 mL), dried over 
MgSO4 and concentrated under reduced pressure. The residue was purified by flash column 
chromatography eluting with 10% EtOAc in petroleum ether to afford 168 (0.27 g, 85% yield) 
as a colourless oil. Rf = 0.60 (EA:hexane = 1:10); FTIR (film) νmax 2954, 2901, 2835, 1457, 




Hz, 1H), 6.99 (dd, J = 7.5, 1.7 Hz, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 0.34 (s, 9H); 13C NMR 
(CDCl3, 100 MHz) δ 154.2, 152.4, 133.8, 126.7, 124.4, 114.4, 61.0, 56.0, 0.0.  
The observed data are in accord with published values.95 
 
Model reactions with anisole: 
 
Anisole derivative 166 was prepared from anisole 165 (62 mg, 0.57 mmol) following a 
similar procedure to that for the synthesis of 168 and was obtained as a colourless oil (75 mg, 
0.42 mmol, 73% yield). Rf = 0.55 (EA:hexane = 1:30); FTIR (film) νmax 2955, 2930, 2838, 
1732, 1513, 1248; 1H NMR (CDCl3, 300 MHz) δ 7.45-7.32 (m, 2H), 6.98 (td, J = 7.3, 0.8 Hz, 
1H), 6.86 (d, J = 8.2 Hz, 1H), 3.83 (s, 3H), 0.29 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ 165.3, 
135.9, 131.7, 128.9, 121.3, 110.5, 56.0, 0.0.  
The observed data are in accord with published values.183 
 
General procedure for direct ortho cupration 
Preparation of the solution of amidocuprate (TMP)2Cu(CN)Li2 in THF: 
 
At -78 oC, to a solution of TMP (1.15 mL, 6.78 mmol) in THF (5 mL) was added n-
butyllithium (4.85 mL, 6.78 mmol, 1.4 M solution in hexanes) dropwise over a period of 15 




slowly transferred to a pre-cooled flask containing a suspension of CuCN (0.31 g, 3.39 mmol) 
in THF (3 mL). The resultant mixture was allowed to warm to 0 oC within 20 min and stirred 
for further 30 min at 0 oC to give a solution of (TMP)2Cu(CN)Li2 in THF (0.26 mol/L). 
 
Direct ortho cupration of 1,2-dimethoxybenzene (Preparation of silane 168): 
 
At -78 oC, to a stirred solution of 1,2-dimethoxybenzene (69 mg, 0.50 mmol) in anhydrous 
THF (3 mL) was added dropwise a solution of (TMP)2Cu(CN)Li2 (5.75 mL, 1.50 mmol, 0.26 
mol/L) in THF. The reaction solution was warmed to rt and stirred for 3 h at the same 
temperature. The system was then cooled to -78 oC and freshly distilled TMSCl (0.25 mL, 2.0 
mmol) was added. After the reaction mixture being warmed up and stirred for 10 h at rt, 
saturated NaHCO3 aqueous solution (15 mL) was added slowly to quench the reaction and the 
mixture was extracted with Et2O (3×15 mL). The combined organic fractions were washed 
with brine (15 mL), dried over MgSO4 and concentrated under reduced pressure. The residue 
was purified by flash column chromatography eluting with 10% EtOAc in petroleum ether to 
afford 168 (69 mg, 66% yield). 
 





At -78 oC, to a stirred solution of 1,2-dimethoxybenzene (69 mg, 0.50 mmol) in anhydrous 
THF (3 mL) was added dropwise a solution of (TMP)2Cu(CN)Li2 (5.75 mL, 1.50 mmol, 0.26 
mol/L) in THF. The reaction solution was warmed to rt and stirred for 3 h at the same 
temperature. The system was then cooled to -78 oC and PhNO2 (0.31 mL, 3.0 mmol) was 
added. After the reaction mixture being stirred for 8 h at rt, saturated NaHCO3 aqueous 
solution (15 mL) was added slowly to quench the reaction and the mixture was extracted with 
Et2O (3×15 mL). The combined organic fractions were washed with brine (15 mL), dried over 
MgSO4 and concentrated under reduced pressure. The residue was purified by flash column 
chromatography eluting with 20% EtOAc in petroleum ether to afford 183 (50 mg, 73% yield) 
as a white crystalline solid. M.p. 105-106 ºC; Rf = 0.50 (EA:hexane = 1:10); FTIR (film) νmax 
2996, 2938, 2835, 1465, 1261, 1031; 1H NMR (CDCl3, 300 MHz) δ 7.10 (dd, J = 8.2, 7.6 Hz, 
2H), 6.96 (dd, J = 8.2, 1.6 Hz, 2H), 6.89 (dd, J = 7.6, 1.6 Hz, 2H), 3.93 (s, 6H), 3.68 (s, 6H); 
13C NMR (CDCl3, 100 MHz) δ 152.8, 146.8, 132.9, 123.3, 111.7, 60.6, 55.8; HRMS (ESI) 
calculated for C16H19O4 [M+H]
+ 275.1283, found 275.1280.  
The observed data are in accord with published values.184 
 
Preparation of telluride 224 
 
A mixture of Te powder (0.10 g, 0.80 mmol) and NaH (71 mg, 1.76 mmol, 60% dispersion in 
mineral oil) in anhydrous DMF (6 mL) was stirred at 140 oC for 1.5 h under Ar to give a 
purple suspension. The system was cooled to rt and a solution of 4-iodoanisole (0.37 g, 1.60 




stirred for 15 h before being cooled to rt. Saturated NH4Cl (aq) (10 mL) was added to the 
reaction mixture and the system was extracted with Et2O (3×15 mL). The combined organic 
phases were washed with brine (10 mL), dried over MgSO4 and concentrated under reduced 
pressure. The residue was purified by flash column chromatography eluting with 2% EtOAc 
in petroleum ether to afford 224 (97 mg, 65% yield) as a yellow solid. M.p. 50-52 oC (lit.115 
m.p. 51-52 oC); Rf = 0.45 (EA:hexane = 1:15); FTIR (film) νmax 3408, 1587, 1493, 1253, 1178; 
1H NMR (CDCl3, 300 MHz) δ 7.65 (d, J = 8.8 Hz, 1H), 6.78 (d, J = 8.8 Hz, 1H), 3.80 (s, 2H); 
13C NMR (CDCl3, 100 MHz) δ 159.7, 139.7, 115.4, 104.3, 55.2. 
The observed data are in accord with published values.115 
 
Preparation of sulfide 251 
 
To a solution of 4-chloroanisole (0.13 mL, 1.04 mmol) in DCM (5 mL) at 0 oC was added 
AlCl3 (70 mg, 0.52 mmol), followed by S2Cl2 (42 μL, 0.52 mmol). The reaction mixture was 
stirred at 0 oC for 1 h and then warmed up to rt for 2 h. Upon completion, water (15 mL) was 
added to the system and the mixture was extracted with DCM (3×15 mL). The combined 
organic phases were washed with brine (10 mL), dried over MgSO4 and concentrated under 
reduced pressure. The crude product was purified by flash column chromatography eluting 
with 5% EtOAc in petroleum ether to afford 251 (0.13 g, 81% yield) as a yellow crystalline 
solid. M.p. 107-108 ºC; Rf = 0.45 (EA:hexane = 1:4); FTIR (film) νmax 3008, 2965, 2937, 
2838, 1474, 1462, 1241; 1H NMR (CDCl3, 300 MHz) δ 7.25 (dd, J = 8.7, 2.6 Hz, H-6, 2H), 





(CDCl3, 100 MHz) δ 156.4 (C-4), 131.2 (C-2), 128.5 (C-6), 126.0 (C-1), 123.7 (C-3), 111.9 
(C-5), 56.2 (OCH3); HRMS (ESI) calculated for C14H12O2SCl2 [M+H]
+ 313.9935, found 
313.9922. 
Although 251 was mentioned in the literature,185 no characterization has been reported. 
 
Preparation of biphenyl 141 from telluride 224 
 
Under Ar, Et3N (57 μL, 0.42 mmol) was added to a mixture of telluride 224 (70 mg, 0.21 
mmol) and Pd(OAc)2 (46 mg, 0.21 mmol) in MeCN (10 mL). The resultant mixture was 
stirred at 65 oC for 6 h. Upon completion, the reaction system was cooled to rt and filtered 
through a layer of Celite pad. The solid was washed with Et2O (2×5 mL). The filtrate was 
concentrated under reduced pressure and the residue was purified by flash column 
chromatography eluting with petroleum ether to afford 141 (37 mg, 68% yield) as a white 
solid. 
 
6.4 Preparative Procedures for Chapter 4 
Catalytic hydrogenation of bis-phenol 105 to bis-alcohol 306 
 
A mixture of compound 105 (0.21 g, 0.51 mmol) and 5% Rh/C (0.10 g) in ethyl acetate (15 




of Celite pad and the filtrate was concentrated under reduced pressure. The crude product was 
purified by column chromatography using MeOH/EtOAc (1:6) as the eluent to afford the 
desired compound 306 (colourless oil, 70 mg, 32% yield) as a mixture of diastereoisomers. Rf 
= 0.45 (MeOH:EA = 1:2); FTIR (film) νmax 3662, 2988, 2905, 1691, 1407, 1243, 1168, 1056, 
879, 730; 1H NMR (300 MHz, CDCl3) δ 4.15-3.79 (m, CHNBoc and CHaHbNBoc, 2H), 3.66-
3.35 (m, CHOH, 2H), 2.73-2.48 (m, CHaHbNBoc and CHaHbNMe, 2H), 2.42-2.22 (m, 
CHaHbNMe and CHNMe, 2H), 2.20 (s, NCH3, 3H), 2.01-1.61 (m, CH2, 9H), 1.62-1.47 (m, 
CH2, 3H), 1.44 (s, COOC(CH3)3, 9H), 1.33-0.80 (m, CH and CH2, 10H); 
13C NMR (CDCl3, 
100 MHz) δ 154.5 (COOtBu), 79.7 (COOC(CH3)3), 70.8 (CHOH), 66.9 (CHOH), 61.3 (NCH), 
59.8 (NCH2), 49.1 (NCH), 48.9 (CH2), 43.1 (NCH3), 42.9 (CH2), 38.1 (CH2), 35.5 (CH2), 
35.4 (CH2), 35.3 (CH2), 33.7 (CH2), 32.3 (CH), 32.1 (CH), 28.5 (COOC(CH3)3); HRMS (ESI) 
calculated for C24H44N2NaO4 [M+Na]
+ 447.3199, found 447.3204. 
 
Oxidation of piperazine 306 to bis-ketone 266 
 
To a solution of diol 306 (45 mg, 0.11 mmol) in DCM (10 mL) was slowly added Dess-
Martin periodinane (110 mg, 0.27 mmol) at 0 ºC, followed by NaHCO3 (45 mg, 0.27 mmol). 
The mixture was allowed to warm to rt and stirred for 6 h. To the reaction system was added 
DCM (10 mL) and the mixture was filtered through a layer of Celite pad. The Celite pad was 
washed with DCM (2×10 mL). The filtrate was concentrated and the crude product was 




diketone 266 (35 mg, 79% yield) as a colourless oil. Rf = 0.45 (MeOH:EA = 1:2); [α]D
20
 = -28 
(c = 0.2, CHCl3); FTIR (film) νmax 2972, 2927, 2868, 1690, 1417, 1248, 1162, 764; 
1H NMR 
(CDCl3, 300 MHz) δ 4.14-3.97 (m, H-2 and H-8a, 2H), 2.68-2.53 (m, H-1 and H-8b, 3H), 
2.40-2.20 (m, H-6 and H-9 and H-13, 9H), 2.19 (s, H-15, 3H), 2.01-1.69 (m, H-5 and H-12 
8H), 1.67-1.51 (m, H-3 and H-4 and H-10 and H-11, 6H), 1.43 (s, H-18, 9H); 13C NMR 
(CDCl3, 100 MHz) δ 211.7 (C-7 or C-14), 211.2 (C-14 or C-7), 154.5 (C-16), 80.0 (C-17), 
61.2 (C-9), 59.8 (C-1), 49.2 (C-2), 43.1 (C-15), 42.9 (C-8), 40.8 (C-6 or C-13), 40.5 (C-13 or 
C-6), 35.6 (C-3 or C-10), 34.2 (C-10 or C-3), 33.1 (C-5 or C-12), 32.7 (C-4 and C-11), 32.4 




General procedure for the preparation of bis-silyl enol ether 315 
 
To a suspension of (-)-bis[(R)-1-phenylethyl]amine hydrochloride (0.19 g, 0.73 mmol) in 
anhydrous THF (4.0 mL) at -78 oC was added n-butyllithium (1.18 mL, 1.54 mmol, 1.3 M 
solution in hexanes) over a period of 10 min. The mixture was stirred at -78 oC for 20 min and 
then 0 oC for 30 min before being cooled to -78 oC. To the lithium amide base solution was 
added slowly a solution of bis-ketone 266 (77 mg, 0.18 mmol) in THF (3 mL). The resulting 
mixture was stirred for 1 h at -78 oC and TBSOTf (0.34 mL, 1.46 mmol) was added to the 
reaction system. After being stirred for 30 min at -78 oC, the mixture was warmed to 0 oC and 




reaction solution slowly and the mixture was extracted with DCM (3×15 mL). The combined 
organic fractions were washed with brine (15 mL), dried over MgSO4 and concentrated under 
reduced pressure. The residue was purified by flash column chromatography eluting with 25% 
EtOAc in petroleum ether to afford 315 (colourless oil, 55 mg, 45% yield) as a mixture of 
diastereoisomers. Rf = 0.60 (EA:hexane = 1:3); 
1H NMR (CDCl3, 300 MHz) δ 4.83 (br s, 
C=CH, 2H), 4.33-3.83 (m, CHNBoc and CHaHbNBoc, 2H), 2.73-2.57 (m, 2H), 2.35-2.18 (m, 
2H), 2.23 (s, NCH3, 3H), 2.16-1.96 (m, 4H), 1.92-1.80 (m, 2H), 1.78-1.57 (m, 8H), 1.47 (br s, 
COOC(CH3)3, 9H), 1.34-1.12 (m, 4H), 0.94 (2s, (CH3)2SiC(CH3)3, 18H), 0.14 (2s, 
(CH3)2SiC(CH3)3, 12H); HRMS (ESI) calculated for C36H69N2O4Si2 [M+H]
+ 649.4796, found 
649.4798. 
 
Reduction of DKP 353 to piperazine 310 
 
Piperazine derivative 310 was prepared from the reduction of 353 (0.57 g, 1.55 mmol) 
following a similar procedure to that for the synthesis of 97 and was obtained as a white solid 
(0.35 g, 1.02 mmol, 66% yield). M.p. 164-166 ºC; Rf = 0.35 (EtOAc/MeOH 3:1); [α]D
20
 = -
25.6 (c = 0.25, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 7.09 (d, J = 8.6 Hz, H-5 or H-12, 2H), 
7.05 (d, J = 8.6 Hz, H-12 or H-5, 2H), 6.83 (d, J = 8.6 Hz, H-6 or H-13, 2H), 6.79 (d, J = 8.6 
Hz, H-13 or H-6, 2H), 3.78 (s, H-15 or H-16, 3H), 3.77 (s, H-16 or H-15, 3H), 3.11 (dd, J = 
13.5, 4.1 Hz, H-3a, 1H), 3.01-2.91 (m, H-9, 1H), 2.85 (dd, J = 11.2, 2.5 Hz, H-8a, 1H), 2.72 




8.7 Hz, H-10b, 1H), 2.41 (s, H-17, 3H), 2.36 (dd, J = 11.8, 1.7 Hz, H-1b, 1H), 2.31 (dd, J = 
13.5, 9.5 Hz, H-3b, 1H), 2.23-2.13 (m, H-2, 1H), 2.00 (t, J = 10.8 Hz, H-8b, 1H), 1.81 (s, NH, 
1H); 13C NMR (CDCl3, 100 MHz) δ 157.2 (C-7 or C-14), 157.0 (C-14 or C-7), 129.8 (C-4 or 
C-11), 129.2 (C-11 or C-4), 129.1 (C-5 and C-12), 112.9 (C-6 or C-13), 112.7 (C-13 or C-6), 
63.7 (C-2), 61.8 (C-8), 55.6 (C-9), 54.2 (C-15 and C-16), 50.0 (C-1), 42.2 (C-17), 38.9 (C-10), 
36.0 (C-3); HRMS (ESI) calculated for C21H29N2O2 [M+H]
+ 341.2229, found 341.2237. 
 
Demethylation of 310 to bis-phenol 311 
 
To a solution of 310 (0.13 g, 0.38 mmol) in DCM (5 mL) was slowly added BBr3 (1.0 M in 
DCM, 3.82 mL, 3.82 mmol) over 10 min at 0 ºC. The system was allowed to warm to rt and 
the mixture was stirred for 20 h. Upon completion, MeOH (10 mL) was slowly added to 
quench the reaction, followed by water (10 mL). The product started to precipitate from the 
solution. The solid was collected by filtration, washed with water (3×3 mL) and thoroughly 
dried under high vacuum to afford piperazine 311 (0.10 g, 85%) as an off-white solid. M.p 
(dec) 250-260 ºC; Rf = 0.30 (EtOAc/MeOH 2:1); [α]D
20
 = -33 (c = 0.20, MeOH); FTIR (film) 
νmax 3525, 3230, 2807, 2586, 1612, 1514, 1468, 1247, 819; 
1H NMR (acetic acid-d4, 300 MHz) 
δ 7.09 (d, J = 8.4 Hz, H-5 or H-12, 2H), 7.07 (d, J = 8.4 Hz, H-12 or H-5, 2H), 6.83 (d, J = 
8.4 Hz, H-6 or H-13, 2H), 6.80 (d, J = 8.4 Hz, H-13 or H-6, 2H), 4.18-4.00 (br m, H-2 and H-
9, 2H), 3.83-3.66 (m, H-8, 2H), 3.60-3.50 (m, H-1a, 1H), 3.44 (dd, J = 13.6, 4.1 Hz, H-3a, 
1H), 3.34 (dd, J = 13.9, 2.5 Hz, H-1b, 1H), 3.08 (s, H-15, 3H), 2.98 (d, J = 6.9 Hz, H-10, 2H), 




C-14), 155.9 (C-14 or C-7), 130.5 (C-5 or C-12), 130.1 (C-12 or C-5), 125.3 (C-4 or C-11), 
124.5 (C-11 or C-4), 115.8 (C-6 or C-13), 115.7 (C-13 or C-6), 60.9 (C-2), 54.9 (C-8), 53.9 
(C-9), 44.3 (C-1), 39.9 (C-15), 35.0 (C-10), 32.7 (C-3); HRMS (ESI) calculated for 
C19H25N2O2 [M+H]
+ 313.1916, found 313.1918. 
 
Catalytic hydrogenation of 311 
 
The hydrogenation of piperazine 311 (0.22 g, 0.71 mmol) was performed in HOAc/MeOH 
(1:4, v/v) following a similar procedure to that for the synthesis of 306. After 5 days, TLC 
indicated a low conversion of bis-phenol. From the mixture recovered most of the starting 
material and 46 mg (0.14 mmol, 20% yield) of the desired bis-alcohol 312 as a mixture of 
diastereoisomers as a colourless oil. Rf = 0.35 (EtOAc/MeOH 2:1); 
1H NMR (CDCl3, 300 
MHz) δ 3.21-2.97 (br m, CHOH, 2H), 2.49-1.90 (m, NCH and NCH2, 6H), 2.07 (s, NCH3, 
3H), 1.80-1.00 (m, CH and CH2, 22H); HRMS (ESI) calculated for C19H36N2NaO2 [M+Na]
+ 
347.2674, found 347.2676. 
 
Catalytic hydrogenation of tyrosine derivative 90 to alcohol 307 
 
The hydrogenation reaction of 90 was performed following a similar procedure to that for the 




colourless oil (gram scale, 76-84% yield). Rf = 0.30 (EtOAc/petroleum ether 1:1); 
1H NMR 
(CDCl3, 300 MHz) δ 4.98 (d, J = 8.6 Hz, NH, 1H), 4.37-4.30 (m, CHNH, 1H), 3.97-3.95 (m, 
CHOH, 1H), 3.72 (s, OCH3, 3H), 1.79-1.37 (m, CH and CH2, 11H), 1.43 (s, COOC(CH3)3, 
9H); ESI-MS calculated for C15H27NO5Na [M+Na]
+ 324.1, found 324.1. 
The observed data are in accord with published values.186 
 
Swern oxidation of alcohol 307 to ketone 313 
 
To a stirred solution of oxalyl chloride (0.14 mL, 1.59 mmol) in DCM (10 mL) was added 
anhydrous DMSO (0.23 mL, 3.18 mmol) dropwise at -78 oC over a period of 15 min. After 
stirring the reaction mixture for an additional 15 min, a solution of alcohol 307 (0.32 g, 1.06 
mmol) in DCM (3 mL) was added and the resultant mixture was stirred at -78 oC for 40 min. 
Et3N (0.45 mL, 3.12 mmol) was added and the reaction system was allowed to warm to rt 
over a period of 30 min. After being stirred for 40 min at rt, the reaction mixture was 
quenched with saturated NaHCO3 (aq) (15 mL) and the mixture was extracted with DCM 
(3×15 mL). The combined organic phases were washed with brine (10 mL), dried over 
MgSO4 and concentrated under reduced pressure. The crude product was purified by flash 
column chromatography eluting with 30% EtOAc in petroleum ether to afford ketone 313 
(0.28 g, 88% yield) as a colourless oil. Rf = 0.35 (EtOAc/petroleum ether 1:1); [α]D
20
 = +4 (c 
= 1.5, CHCl3); FTIR (film) νmax 3356, 2957, 2933, 1705, 1515, 1163; 
1H NMR (CDCl3, 300 
MHz) δ 5.09 (d, J = 8.6 Hz, NH, 1H), 4.36 (td, J = 9.0, 5.0 Hz, CHNH, 1H), 3.72 (s, OCH3, 
3H), 2.43-2.26 (m, CO(CH2)2, 4H), 2.24-2.10 (m, 1H), 2.06-1.94 (m, 1H), 1.91-1.66 (m, 2H), 
1.64-1.55 (m, 1H), 1.48-1.33 (m, 2H), 1.42 (s, COOC(CH3)3, 9H); 




MHz) δ 211.5 (CO(CH2)2), 173.4 (COOMe), 155.5 (COO
tBu), 80.0 (COOC(CH3)3), 52.3 
(COOCH3), 51.6 (CHNH), 40.6 (CO(CH2)2), 38.8 (CH2), 32.9 (CH2), 32.6 (CH), 28.3 
(COOC(CH3)3); HRMS (ESI) calculated for C15H25NO5Na [M+Na]
+ 322.1630, found 
322.1629. 
The observed data are in accord with published values.186 
 
Catalytic hydrogenation of tyrosine derivative 91 
 
The hydrogenation of 91 (1.68 g, 5.44 mmol) was performed following a similar procedure to 
that for the synthesis of 306 and the desired product 308 was obtained as mixture of 
diastereoisomers (colourless oil, 1.34 g, 4.24 mmol, 78% yield), accompanied by 309 (0.26 g, 
0.92 mmol, 17%).  
Data for 308: Rf = 0.45 (EtOAc/petroleum ether 1:1); 
1H NMR (CDCl3, 300 MHz) δ 4.96 (d, 
J = 8.4 Hz, NH, 1H), 4.34-4.26 (m, CHNH, 1H), 3.69 (s, COOCH3, 3H), 3.37 (br s, CHOCH3, 
1H), 3.26 (s, CHOCH3, 3H), 1.91-1.75 (m, 2H), 1.68-1.62 (m, 1H), 1.56-1.27 (m, 8H), 1.41 (s, 
COOC(CH3)3, 9H); ESI-MS calculated for C16H30NO5 [M+H]
+ 316.2, found 316.2. 
Data for 309: Rf = 0.65 (EtOAc/petroleum ether 1:1); 
1H NMR (CDCl3, 300 MHz) δ 4.89 (d, 
J = 8.4 Hz, NH, 1H), 4.35 (td, J = 8.9, 5.2 Hz, CHNH, 1H), 3.74 (s, OCH3, 3H), 1.83 (d, J = 
12.6 Hz, CH2CHNH, 1H), 1.74-1.60 (m, 6H), 1.46 (s, COOC(CH3)3, 9H), 1.27-1.16 (m, 4H), 
0.98-0.88 (m, 2H); ESI-MS calculated for C15H28NO4 [M+H]
+ 286.2, found 286.2. 




Preparation of amine 318 
 
Amine 318 was prepared from 307 (0.41 g, 1.36 mmol) following a similar procedure to that 
for the synthesis of 94 and was obtained as a mixture of diastereoisomers (colourless oil, 0.22 
g, 1.10 mmol, 81% yield). Rf = 0.65 (EtOAc/MeOH 8:1); 
1H NMR (CDCl3, 400 MHz) δ 6.94 
(d, J = 7.6 Hz, NH2, 2H), 4.79-4.62 (m, CHNH2, 1H), 4.04-3.95 (m, CHOH, 1H), 3.80 (s, 
OCH3, 3H), 2.48 (br s, OH, 1H), 1.99 (dd, J = 11.0, 2.2 Hz, CHaHbCHNH2, 1H), 1.93-0.94 (m, 
10H); ESI-MS calculated for C10H19NO3Na [M+Na]
+ 224.1, found 224.1. 
 
Preparation of acid 319 
 
Acid 319 was prepared from 307 (0.56 g, 1.86 mmol) following a similar procedure to that for 
the synthesis of 92 and was obtained as a mixture of diastereoisomers (colourless oil, 0.47 g, 
1.64 mmol, 88% yield). Rf = 0.50 (EtOAc/MeOH 10:1); 
1H NMR (CDCl3, 400 MHz) δ 6.63 
(br s, COOH, 1H), 5.09 (d, J = 8.3 Hz, NH, 1H), 4.38-4.29 (m, CHNH, 1H), 4.00 (s, OH, 1H), 
1.99 (d, J = 10.6 Hz, CHaHbCHNH, 1H), 1.92-0.91 (m, 10H), 1.45 (s, COOC(CH3)3, 9H); 
ESI-MS calculated for C14H25NO5Na [M+Na]







Preparation of dipeptide 320 
 
Dipeptide 320 was synthesised from acid 319 (0.24 g, 0.84 mmol) and amine 318 (0.17 g, 
0.84 mmol) following a similar procedure to that for the synthesis of 95 and was obtained as a 
mixture of diastereoisomers (colourless oil, 0.31 g, 0.65 mmol, 78% yield). Rf = 0.30 (EtOAc); 
1H NMR (CDCl3, 300 MHz) δ 7.02 (d, J = 7.8 Hz, NH, 1H), 4.96 (d, J = 8.5 Hz, NH, 1H), 
4.77-4.61 (m, CHNH, 1H), 4.42-4.27 (m, CHNH, 1H), 3.99-3.97 (m, CHOH, 2H), 3.74 (s, 
COOCH3, 3H), 2.03-0.92 (m, 22H), 1.44 (s, COOC(CH3)3, 9H); ESI-MS calculated for 
C24H42N2O7Na [M+Na]
+ 493.3, found 493.3. 
 
General procedure for oxidative coupling of enolate (Model reaction with cyclohexanone) 
 
To a solution of diisopropylamine (0.20 mL, 1.43 mmol) at -78 oC was added n-butyllithium 
(1.02 mL, 1.43 mmol, 1.4 M solution in toluene) over a period of 10 min and the mixture was 
stirred at the same temperature for 30 min. The reaction solution was warmed to 0 oC and 
stirred for further 30 min before being cooled to -78 oC. To the reaction system was added a 
solution of cyclohexanone (0.12 mL, 1.19 mmol) in THF (2 mL) and the resulting mixture 




transferred to a pre-cooled flask containing CuCl2 (0.17 g, 1.26 mmol) at -78 
oC and the 
reaction system was stirred for 30 min before being warmed up to rt. After 4 h, H2O (10 mL) 
was added to quench the reaction and the mixture was extracted with Et2O (3×15 mL). The 
combined organic fractions were washed with brine (15 mL), dried over MgSO4 and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography eluting with 2% EtOAc in petroleum ether to afford 279a (71 mg, 65% yield) 
and 279b (5 mg, 5%) as colourless oils. 
Data for 279a: M.p. 70-71 ºC; Rf = 0.30 (EA:hexane = 1:8); FTIR (film) νmax 2957, 2869, 
1707, 1468, 1366, 1228; 1H NMR (CDCl3, 300 MHz) δ 2.92 (m, H-2, 2H), 2.46-2.38 (m, H-6, 
4H), 2.17-2.01 (m, H-5, 4H), 1.97-1.85 (m, H-3a, 2H), 1.78-1.58 (m, H-4, 4H), 1.43-1.22 (m, 
H-3b, 2H); 13C NMR (CDCl3, 100 MHz) δ 211.8 (C-1), 49.0 (C-2), 42.3 (C-6), 30.1 (C-3), 
28.1 (C-5), 25.4 (C-4); HRMS (EI) calculated for C12H18O2 [M]
+ 194.1307, found 194.1305. 
The observed data are in accord with published values.160,161 
Data for 279b: Rf = 0.31 (EA:hexane = 1:8); FTIR (film) νmax 2946, 2868, 1707, 1461, 1357, 
1218; 1H NMR (CDCl3, 300 MHz) δ 2.69-2.60 (m, H-2, 2H), 2.44-2.27 (m, H-6, 4H), 2.08-
1.85 (m, H-3a and H-5, 6H), 1.77-1.62 (m, H-3b and H-4, 6H); 13C NMR (CDCl3, 100 MHz) 
δ 210.7 (C-1), 50.3 (C-2), 41.8 (C-6), 29.1 (C-3), 26.5 (C-5), 25.0 (C-4); HRMS (EI) 
calculated for C12H18O2 [M]
+ 194.1307, found 194.1310. 
The observed data are in accord with published values.161 
 





Preparation of 336: At -78 oC, to a solution of LDA in THF prepared from diisopropylamine 
(0.41 mL, 2.93 mmol) and n-butyllithium (1.94 mL, 2.70 mmol, 1.4 M solution in toluene) 
was added a solution of cyclohexanone (0.23 mL, 2.27 mmol) in THF (2 mL) and the mixture 
was stirred for 30 min before being warmed up to 0 oC. The reaction mixture was stirred for 
another 30 min at 0 oC and TBSCl (0.78 mL, 4.55 mol, 50 wt.% in toluene) was added over a 
period of 5 min. The resulting solution was stirred for 10 min at 0 oC and 2 h at rt before the 
addition of triethylamine (1.0 mL) followed by saturated NaHCO3 (aq) (15 mL). The mixture 
was extracted with Et2O (3×15 mL) and the combined organic fractions were washed with 
brine (15 mL), dried over MgSO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography eluting with petroleum ether to afford 336 (0.39 g, 
83% yield) as a colourless oil. Rf = 0.65 (Hexane:EtOAc = 20:1); FTIR (film) νmax 2929, 2858, 
1670, 1194, 1182, 891, 837, 776; 1H NMR (CDCl3, 400 MHz) δ 4.74 (ddd, J = 3.8, 2.6, 1.3 
Hz, H-2, 1H), 1.92-1.84 (m, H-3 and H-6, 4H), 1.57-1.49 (m, H-5, 2H), 1.41-1.35 (m, H-4, 
2H), 0.79 (s, SiC(CH3)3, 9H), 0.00 (s, SiCH3, 6H); 
13C NMR (CDCl3, 100 MHz) δ 150.5 (C-
1), 104.4 (C-2), 29.9 (C-6 and SiC(CH3)3), 25.7 (SiC(CH3)3), 23.8 (C-3), 23.2 (C-5), 22.4 (C-
4), -4.4 (SiCH3). 
The observed data are in accord with published values.188 
 
Oxidative coupling of 336: A solution of silyl enol ether (96 mg, 0.45 mmol) in MeCN (2.0 
mL) was slowly added to a mixture of CAN (0.27 g, 0.54 mmol) and NaHCO3 (76 mg, 0.90 
mmol) in MeCN (4.0 mL). The resulting mixture was stirred for 1 h at rt. Upon complete 
consumption of the starting material, H2O (15 mL) was added and the mixture was extracted 
with Et2O (3×15 mL). The combined organic fractions were washed with brine (15 mL), dried 




column chromatography eluting with 2% EtOAc in petroleum ether to afford 279a (53 mg, 60% 
yield) and a trace amount of 279b. 
 
Preparation of piperazine 328 
 
Birch reduction of piperazine 158: Liquid ammonia (30 mL) was collected by condensing 
ammonia into a three-neck flask at -78 oC. Sodium (0.10 g, 4.34 mmol) was added and the 
mixture was stirred for 20 min to give a deep-blue solution. A solution of piperazine 158 
(0.25 g, 0.77 mmol) and EtOH (0.5 mL) in THF (8 mL) was added to the liquid ammonia 
solution over a period of 1 h. More sodium was added when necessary to maintain a blue 
colour of the system. The reaction mixture was stirred at -78 oC for 5 h before being quenched 
with EtOH (5 mL). The ammonia was allowed to evaporate overnight and the residue was 
partitioned between water (20 mL) and DCM (20 mL). The organic phase was separated and 
the aqueous phase was extracted with DCM (3×15 mL). The combined organic fractions were 
washed with brine (20 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure. The crude product 327 was used directly in the next step to avoid rearomatisation 
during the purification process. 
 
Preparation of piperazine 328: The crude piperazine substrate 327 from the Birch reduction 




0 oC, followed by DIPEA (0.34 mL, 1.96 mmol). The reaction solution was allowed to warm 
to rt and stirred for 6 h. Upon completion, the mixture was diluted with DCM (20 mL) and the 
mixture was washed with NaHCO3 (aq) (15 mL) and brine (15 mL) successively. The organic 
phase was separated, dried over MgSO4, filtered and concentrated under reduced pressure. 
The crude product was purified by flash column chromatography eluting with 20% EtOAc in 
hexane to afford bis-enol ether 328 as a colourless oil (0.19 g, 43% yield). Rf = 0.60 
(EA:hexane = 1:4); [α]D
20 = +24 (c = 0.5, CHCl3); FTIR (film) νmax 2932, 1513, 1343, 1164, 
730; 1H NMR (CDCl3, 300 MHz) δ 7.80-7.73 (m, ArH, 4H), 7.65-7.48 (m, ArH, 6H), 5.34 (br 
s, H-5, 2H), 4.63 (s, H-8, 2H), 3.74 (dt, J = 10.0, 5.7 Hz, H-2, 2H), 3.58 (s, OCH3, 6H), 3.27-
3.22 (m, H-1, 4H), 2.82-2.62 (m, H-6 and H-9, 8H), 2.52 (dd, J = 13.6, 3.3 Hz, H-3a, 2H), 
2.35 (dd, J = 13.6, 10.2 Hz, H-3b, 2H); 13C NMR (CDCl3, 300 MHz) δ 152.7 (C-7), 132.9 (C-
4), 130.8 (Ar), 129.3 (Ar), 127.2 (Ar), 125.0 (Ar), 122.7 (C-5), 90.2 (C-8), 54.6 (OCH3), 54.0 
(C-2), 44.8 (C-1), 39.9 (C-3), 29.2 (C-6 and C-9); HRMS (ESI) calculated for 
C32H38N2O6NaS2 [M+Na]
+ 633.2069, found 633.2063. 
 
Preparation of bis-ketone 329 
 
To a solution of piperazine 328 (66 mg, 0.11 mmol) in MeOH (10 mL) and THF (5 mL) was 
added a solution of oxalic acid (24 mg, 0.26 mmol) in water (1.0 mL). The resulting system 
was stirred at rt for 10 h. Upon completion, the mixture was partitioned between water (15 
mL) and DCM (20 mL). The organic phase was separated and the aqueous phase was 




mL), dried over MgSO4, filtered and concentrated under reduced pressure. The crude product 
was purified by flash column chromatography eluting with 40% EtOAc in hexane to afford 
bis-ketone 329 as a white foam (0.16 g, 35% yield). M.p. 75-77 ºC; Rf = 0.25 (EA:hexane = 
1:1); [α]D
20
 = +50.0 (c = 0.4, CHCl3); FTIR (film) νmax 2925, 2867, 1714, 1342, 1163, 735; 
1H 
NMR (CDCl3, 300 MHz) δ 7.77-7.69 (m, ArH, 4H), 7.64-7.46 (m, ArH, 6H), 5.43 (br s, H-5, 
2H), 3.68 (td, J = 9.9, 4.6 Hz, H-2, 2H), 3.26 (dd, J = 13.6, 9.9 Hz, H-1a, 2H), 3.15 (dd, J = 
13.6, 4.6 Hz, H-1b, 2H), 2.81 (br s, H-6, 4H), 2.66-2.57 (dd, J = 13.6, 1.6 Hz, H-3a, 2H), 
2.54-2.28 (m, H-3b and H-8 and H-9, 10H); 13C NMR (CDCl3, 100 MHz) δ 209.6 (C-7), 
138.6 (Ar), 134.0 (C-4), 133.2 (Ar), 129.4 (Ar), 127.2 (Ar), 122.8 (C-5), 53.4 (C-2), 44.6 (C-
1), 40.4 (C-3), 39.6 (C-6), 38.5 (C-8), 28.3 (C-9); HRMS (ESI) calculated for 
C30H34N2O6NaS2 [M+Na]
+ 605.1756, found 605.1755. 
 
Piperazine 330 was also isolated from the reaction mixture as an off-white film (0.09 g, 19% 
yield), possibly arising from the rearomatisation of bis-dienes. Rf = 0.25 (EA:hexane = 1:1); 
[α]D
20
 = +31 (c = 0.6, CHCl3); FTIR (film) νmax 2932, 1715, 1513, 1346, 1249, 1166; 
1H NMR 
(CDCl3, 400 MHz) δ 7.80-7.74 (m, PhH, 2H), 7.71-7.66 (m, PhH, 2H), 7.65-7.58 (m, PhH, 
2H), 7.56-7.48 (m, PhH, 4H), 7.03 (d, J = 8.6 Hz, H-5, 2H), 6.84 (d, J = 8.6 Hz, H-6, 2H), 
5.45 (br s, H-12, 1H), 3.82 (s, H-17, 1H), 3.77 (dd, J = 9.9, 5.0 Hz, H-9, 1H), 3.70 (dd, J = 
10.1, 5.5 Hz, H-2, 1H), 3.28-3.02 (m, H-1 and H-3a and H-8, 5H), 2.89 (dd, J = 13.8, 10.3 Hz, 
H-3b, 1H), 2.85 (br s, H-13, 2H), 2.65 (dd, J = 13.5, 1.7 Hz, H-10a, 1H), 2.55-2.38 (m, H-10b 
and H-15 and H-16, 5H); 13C NMR (CDCl3, 100 MHz) δ 209.8 (C-14), 158.6 (C-7), 138.7 




127.3 (Ph), 127.2 (Ph), 122.7 (C-12), 114.1 (C-6), 56.7 (C-2), 55.3 (C-17), 53.5 (C-9), 44.5 
(C-8), 43.8 (C-1), 40.6 (C-10), 39.6 (C-13), 38.5 (C-15), 38.1 (C-3), 28.4 (C-16); HRMS (ESI) 
calculated for C31H34N2O6NaS2 [M+Na]
+ 617.1756, found 617.1766. 
 
Preparation of dienol silane 339 
 
Silyl enol ether 339 was synthesised from 330 (83 mg, 0.14 mmol) following a similar 
procedure to that for the synthesis of 336 and was obtained as a colourless oil (87 mg, 0.12 
mmol, 88% yield). Rf = 0.65 (EA:hexane = 1:4); [α]D
20
 = +43 (c = 0.5, MeOH); FTIR (film) 
νmax 2957, 2929, 2857, 1513, 1349, 1249, 1166; 
1H NMR (MeOD-d4, 300 MHz) δ 8.11-7.71 
(m, PhH, 2H), 7.81-7.48 (m, PhH, 8H), 7.07 (d, J = 8.7 Hz, H-5, 2H), 6.87 (d, J = 8.7 Hz, H-6, 
2H), 5.52 (d, J = 5.9 Hz, H-13, 1H), 5.06 (d, J = 5.9 Hz, H-12, 1H), 3.81 (s, H-17, 3H), 3.76-
3.62 (m, H-2 and H-9, 2H), 3.29-3.01 (m, H-1 and H-3a and H-8, 5H), 2.84 (dd, J = 13.4, 9.8 
Hz, H-3b, 1H), 2.54 (dd, J = 13.4, 3.7 Hz, H-10a, 1H), 2.34 (dd, J = 13.4, 9.8 Hz, H-10b, 1H), 
2.26-2.14 (m, H-15 and H-16, 4H); 13C NMR (MeOD-d4, 100 MHz) δ 158.7 (C-7), 152.6 (C-
14), 139.1 (Ph), 132.8 (Ph), 130.2 (C-5 or Ph), 130.1 (Ph or C-5), 129.2 (Ph), 128.7 (C-4), 
127.0 (Ph), 126.9 (Ph), 125.6 (C-11 or Ph), 122.6 (Ph or C-11), 119.9 (C-12), 113.7 (C-6), 
102.0 (C-13), 56.4 (C-2), 54.3 (C-17), 53.6 (C-9), 44.1 (C-8), 43.6 (C-1), 39.6 (C-10), 37.7 
(C-3), 28.8 (C-19), 27.1 (C-15), 24.8 (C-16), 24.7 (C-20), -5.7 (C-18); HRMS (ESI) 
calculated for C37H48N2O6NaS2Si [M+Na]






Preparation of piperazine 331 
 
Piperazine 331 was obtained from the Birch reduction of 159 (0.33 g, 0.63 mmol) as a white 
solid (0.23 g, 0.43 mmol, 68% yield) and tended to rearomatise upon heating or standing in 
the air. M.p. 148-149 ºC; Rf = 0.60 (EtOAc/petroleum ether 1:3); [α]D
20
 = +6.8 (c = 1.0, 
CHCl3); FTIR (film) νmax 2972, 2926, 2831, 1690, 1415, 1170, 1106; 
1H NMR (CDCl3, 400 
MHz) δ 5.43 (br s, H-5, 2H), 4.61 (br s, H-8, 2H), 4.14-3.97 (br m, H-2 and H-1a, 4H), 3.56 (s, 
H-13, 6H), 2.91-2.58 (m, H-1b and H-6 and H-9, 10H), 2.33 (dd, J = 13.2, 2.9 Hz, H-3a, 2H), 
2.02 (dd, J = 13.2, 8.6 Hz, H-3b, 2H), 1.46 (s, H-12, 18H); 13C NMR (CDCl3, 100 MHz) δ 
155.2 (C-10), 152.7 (C-7), 131.3 (C-4), 120.6 (C-5), 90.4 (C-8), 80.0 (C-11), 53.9 (C-13), 
51.6 (C-2), 41.4 (C-1), 39.5 (C-3), 29.4 (C-9), 29.2 (C-6), 28.4 (C-12); HRMS (ESI) 
calculated for C30H46N2O6Na [M+Na]
+ 553.3254, found 553.3258. 
 
Preparation of bis-ketone 333 
 
Bis-ketone 333 was prepared from the hydrolysis of 331 (0.18 g, 0.34 mmol) with aqueous 






 = +21.6 (c = 1.0, CHCl3); FTIR (film) νmax 2973, 2925, 1689, 1417, 1366, 
1168; 1H NMR (CDCl3, 300 MHz) δ 5.53 (t, J = 3.3 Hz, H-5, 2H), 4.20-3.93 (br m, H-1a and 
H-2, 4H), 2.86 (br s, H-6, 4H), 2.70 (dd, J = 14.0, 10.4 Hz, H-1b, 2H), 2.56-2.45 (br m, H-8 
and H-9, 8H), 2.42 (dd, J = 14.0, 4.3 Hz, H-3a, 2H), 2.12 (dd, J = 13.2, 8.3 Hz, H-3b, 2H), 
1.47 (s, H-12, 18H); 13C NMR (CDCl3, 100 MHz) δ 238.1 (C-7), 155.0 (C-10), 134.8 (C-4), 
121.2 (C-5), 80.3 (C-11), 51.6 (C-2), 41.7 (C-1), 41.2 (C-6), 39.6 (C-3), 38.6 (C-8), 28.4 (C-
12), 28.3 (C-9); HRMS (ESI) calculated for C28H42N2O6Na [M+Na]
+ 525.2941, found 
525.2944. 
 
Preparation of bis-ketone 334 
 
Bis-ketone 334 was prepared from the Birch reduction of 101 (0.48 g, 1.09 mmol) followed 
by hydrolysis of the crude bis-diene intermediate with aqueous oxalic acid and was obtained 
as a colourless oil (0.11 g, 0.27 mmol, 25% yield over two steps). Rf = 0.45 (MeOH:EtOAc = 
1:3); [α]D
20
 = -32 (c = 0.3, CHCl3); FTIR (film) νmax 2976, 2925, 1687, 1417, 1166; 
1H NMR 
(CDCl3, 300 MHz) δ 5.59 (br s, H-5 and H-14, 2H), 4.42-4.23 (br m, H-2, 1H), 4.17-3.99 (br 
m, H-10a, 1H), 3.95-3.70 (br m, H-1a and H-10b, 2H), 3.02-2.78 (m, H-6 and H-15, 4H), 
2.79-2.34 (m, H-1b and H-3a and H-8 and H-9 and H-11 and H-12a and H-17 and H-18, 12H), 
2.28 (s, H-22, 3H), 2.09-1.95 (m, H-3b and H-12b, 2H), 1.45 (s, H-21, 9H); 13C NMR (CDCl3, 
100 MHz) δ 211.1 (C-7 or C-16), 210.0 (C-16 or C-7), 154.2 (C-19), 135.9 (C-4 or C-13), 




(C-1), 50.0 (C-2), 44.0 (C-10), 43.0 (C-22), 40.8 (C-6 or C-15), 40.6 (C-15 or C-6), 39.7 (C-3 
or C-12), 39.6 (C-12 or C-3), 38.7 (C-8 or C-17), 38.6 (C-17 or C-8), 28.6 (C-9 and C-18), 
28.4 (C-21); HRMS (ESI) calculated for C28H42N2O6Na [M+Na]
+ 439.2573, found 439.2563. 
 
Oxidative enolate coupling with bis-ketone 329 
 
To a solution of LHMDS (0.45 mL, 0.45 mmol, 1.0 M in THF) in anhydrous THF (15 mL) at 
-78 oC was added a solution of bis-ketone 329 (0.12 g, 0.21 mmol) in anhydrous THF (5 mL) 
over a period of 10 min. The resulting mixture was stirred at -78 oC for 30 min and then at -10 
oC for 10 min. At -10 oC, to the enolate solution was added a solution of CuBr2 (0.12 g, 0.53 
mmol) in anhydrous DMF (2 mL) and the reaction system was warmed up to rt. After stirring 
for 3 h, saturated NH4Cl solution (20 mL) was added to the reaction solution and the mixture 
was extracted with DCM (3×15 mL). The organic fractions were combined, washed with 
brine (15 mL), dried over MgSO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography eluting with 15% EtOAc in petroleum ether to 
afford a trace amount of 338 (4 mg, 3% yield) as a yellow oil. The molecular formula was 
determined by HRMS (ESI): calculated for C30H32N2O6S2Na [M+Na]







Preparation of DKP 347 
 
A mixture of DKP derivative 112 (0.29 g, 0.86 mmol), TBSCl (0.32 g, 2.16 mmol) and 
imidazole (0.15 g, 2.16 mmol) in DCM (20 mL) was stirred at rt for 8 h. Upon completion, 
the mixture was transferred to a separating funnel and partitioned between brine (20 mL) and 
DCM (15 mL). The aqueous phase was extracted with DCM (2×15 mL). The combined 
organic fractions were washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography eluting with EtOAc to afford 347 as a colourless wax (0.37 g, 76% yield). Rf 
= 0.30 (EtOAc/MeOH 6:1); [α]D
24
 = -77 (c = 1.0, CHCl3); FTIR (film) νmax 2957, 2930, 2861, 
1682, 1661, 1511, 1263, 916; 1H NMR (CDCl3, 300 MHz) δ 7.05 (d, J = 8.6 Hz, H-5 or H-12, 
2H), 6.85 (d, J = 8.4 Hz, H-12 or H-5, 2H), 6.82 (d, J = 8.4 Hz, H-6 or H-13, 2H), 6.74 (d, J = 
8.6 Hz, H-13 or H-6, 2H), 5.72 (d, J = 1.9 Hz, NH, 1H), 4.17 (t, J = 3.9 Hz, H-2, 1H), 3.84 (dt, 
J = 11.4, 2.4 Hz, H-9, 1H), 3.22 (dd, J = 14.2, 3.9 Hz, H-3a, 1H), 3.11 (s, H-15, 3H), 3.10 (dd, 
J = 14.2, 3.9 Hz, H-3b, 1H), 2.89 (dd, J = 13.6, 2.4 Hz, H-10a, 1H), 0.97 (s, H-18 or H-21, 
9H), 0.92 (dd, J = 13.6, 11.4 Hz, H-10b, 1H), 0.91 (s, H-21 or H-18, 9H), 0.18 (s, H-19, 6H), 
0.09 (s, H-16a, 3H), 0.06 (s, H-16b, 3H); 13C NMR (CDCl3, 100 MHz) δ 165.9 (C-1 or C-8), 
165.5 (C-8 or C-1), 155.4 (C-7 or C-14), 154.8 (C-14 or C-7), 131.4 (C-5 or C-12), 130.3 (C-




(C-9), 40.1 (C-10), 35.9 (C-3), 33.1 (C-15), 25.7 (C-18 or C-21), 25.6 (C-21 or C-18), 18.2 
(C-17 or C-20), 18.1 (C-20 or C-17), -4.4 (C-19), -4.5 (C-16a and C-16b); HRMS (ESI) 
calculated for C19H20N2O4Na [M+Na]


















Appendix A - X-ray Crystal Structure Data for Compound 108. 
 
Table 1: Crystal data and structure refinement. 
 
Empirical formula  C33H32N2O4 
Formula weight  520.61 
Temperature  120(2) K 
Wavelength  1.54184 Å 
Crystal system  Monoclinic 
Space group  P 21 
Unit cell dimensions a = 15.1004(4) Å α = 90°. 
 b = 10.4371(3) Å β = 103.269(2)°. 
 c = 17.2617(5) Å γ = 90°. 
Volume 2647.89(13) Å3 
Z 4 
Density (calculated) 1.306 Mg/m3 
Absorption coefficient 0.687 mm-1 
F(000) 1104 
Crystal size 0.29 x 0.11 x 0.02 mm3 
Theta range for data collection 2.63 to 71.01°. 
Index ranges -18<=h<=18, -12<=k<=12, -20<=l<=21 
Reflections collected 25298 




Completeness to theta = 71.01° 98.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9864 and 0.8256 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9750/13/713 
Goodness-of-fit on F2 1.041 
Final R indices [I>2sigma(I)] R1 = 0.0380, wR2 = 0.0933 
R indices (all data) R1 = 0.0439, wR2 = 0.0982 
Absolute structure parameter 0.04(14) 





















Appendix B - X-ray Crystal Structure Data for Compound 102. 
 
Table 1: Crystal data and structure refinement. 
 
Empirical formula  C38H44N2O4 
Formula weight  592.75 
Temperature  100.01(10) K 
Wavelength  1.54184 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 5.68231(6) Å α = 90°. 
 b = 15.67459(18) Å β = 90°. 
 c = 36.2806(4) Å γ = 90°. 
Volume 3231.44(6) Å3 
Z 4 
Density (calculated) 1.218 Mg/m3 
Absorption coefficient 0.620 mm-1 
F(000) 1272.0 
Crystal size 0.187 × 0.1404 × 0.0836 mm3 
Theta range for data collection 13.446 to 148.97°. 




Reflections collected 30250 
Independent reflections 6488 [Rint = 0.0246, Rsigma = 0.0169] 
Completeness to theta = 66.97° 99.94 %  
Absorption correction Semi-empirical from equivalents 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6488/0/401 
Goodness-of-fit on F2 1.037 
Final R indices [I>2sigma(I)] R1 = 0.0282, wR2 = 0.0701 
R indices (all data) R1 = 0.0298, wR2 = 0.0714 




















Appendix C - X-ray Crystal Structure Data for Compound 160. 
 
 Table 1: Crystal data and structure refinement. 
 
Empirical formula  C32H34N2O6S2 
Formula weight  606.73 
Temperature  99.95(19) K 
Wavelength  1.54184 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 15.5497(2) Å α = 90°. 
 b = 11.38339(15) Å β = 91.5569(13)°. 
 c = 16.2563(2) Å γ = 90°. 
Volume 2876.43(7) Å3 
Z 4 
Density (calculated) 1.401 Mg/m3 
Absorption coefficient 2.087 mm-1 
F(000) 1280.0 
Crystal size 0.2094 × 0.1624 × 0.0455 mm3 
Theta range for data collection 5.438 to 138.262°. 




Reflections collected 27559 
Independent reflections 10440 [Rint = 0.0372, Rsigma = 0.0374] 
Absorption correction Semi-empirical from equivalents 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10440/1/761 
Goodness-of-fit on F2 1.060 
Final R indices [I>2sigma(I)] R1 = 0.0534, wR2 = 0.1424 
R indices (all data) R1 = 0.0560, wR2 = 0.1454 






















Appendix D - Selected NMR Spectra. 
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